

# The importance of volume overload, hemodialysis access and duration of time on effective therapy during renal replacement modalities

PhD Thesis

**Tibor Fülöp, M.D.**

Semmelweis University  
Basic Medicine Doctoral School



Consultant: László Rosivall, M.D., D.Sc.  
Official reviewers: Orsolya Cseprekál, M.D., Ph.D.  
Szilveszter Dolgos, M.D., Ph.D.

Head of Final Examination Committee: Dr. György Reusz, D.Sc.  
Members of the Final Examination Committee:  
Csaba Ambrus, M.D., Ph.D.  
Kálmán Tory, M.D., Ph.D.

Budapest

2017

**Table of Contents**

<b>Table of Contents</b> .....	2
<b>Abbreviations</b> .....	5
<b>1. Introduction</b> .....	8
1.1 Preamble: the burden of end-stage renal disease world-wide .....	8
1.2 Importance of time during renal replacement therapy .....	8
1.3 Blood pressure control in hemodialysis patients .....	9
1.4 Dry weight determination in hemodialysis patients .....	11
1.5 The interaction between volume status and blood pressure: limitations of physical exam to assess volume status .....	12
1.6 Inflammation and C-reactive protein .....	12
1.7 The importance of vascular access catheters .....	13
1.8 Adherence .....	14
1.9 Definition of Acute Kidney Injury: limitations of serum creatinine .....	15
1.10 Fluid therapy in critically ill .....	16
1.11 Renal replacement therapy in Intensive Care Units .....	17
<b>2. Objectives</b> .....	20
2.1 Volume-related weight gain in the Intensive Care Units study .....	20
2.2 Dialysis prescription and inflammatory markers on hemodialysis study .....	21
2.3 Bedside removal of permanent hemodialysis access catheters studies .....	21
<b>3. Methods</b> .....	23
3.1 Volume-related weight gain study .....	23
3.1.1 Study population .....	23
3.1.2 Definitions and variables of interest .....	24
3.1.3 Statistical methods .....	26
3.2 Dialysis prescription and inflammatory markers on dialysis study .....	26
3.2.1 Study population .....	26
3.2.2 Definitions and variables of interest .....	27
3.2.3 Statistical methods .....	27

3.3	Vascular catheter access removal studies .....	30
3.3.1	Study population .....	30
3.3.2	Definitions and variables of interest .....	31
3.3.3	Statistical methods .....	32
3.3.4	Procedure description for Tunneled Dialysis Catheter removal .....	32
<b>4.</b>	<b>Results</b> .....	<b>34</b>
4.1	Volume-related weight gain in critically ill patients with AKI and subsequent mortality .....	34
4.2	Dialysis prescription and inflammatory markers during conventional hemodialysis .....	40
4.3	Tunneled Dialysis Catheter removal success rate and biomarkers .....	46
4.3.1	Results of the inpatient cohort .....	46
4.3.2	Results of the mixed inpatient-outpatient cohort .....	47
<b>5.</b>	<b>Discussion</b> .....	<b>50</b>
5.1	Volume-related weight gains in critically ill patients with AKI .....	50
5.1.1	Literature on the importance of volume overload in critically ill patients with AKI .....	52
5.1.2	Fluid composition and AKI .....	53
5.1.3	Renal replacement therapy choices – intermittent vs continuous .....	53
5.1.4	Assessment of volume overload .....	54
5.1.5	Potential role of peritoneal dialysis in volume overloaded subjects .....	55
5.1.6	Alternatives to serum creatinine to assess renal function; biomarkers in AKI? .....	55
5.1.7	Oliguria .....	56
5.2	Time on hemodialysis .....	57
5.2.1	Recent literature of treatment time, survival and BP control .....	59
5.2.2	Recent literature on interdialytic weight gain .....	60
5.2.3	Dialysis nonadherence .....	60

5.2.4	Shortcomings of Kt/V based dialysis clearance .....	62
5.2.5	Overnight modalities – the future? .....	62
5.2.6	The paradigm of pregnancy .....	63
5.3	Transitioning between acute and chronic renal replacement therapy: the importance of access choice .....	63
5.3.1	Peritoneal dialysis .....	64
5.3.2	Impact of access choice on morbidity and mortality .....	65
5.3.3	Timely removal of vascular access devices .....	65
5.3.4	Complications during Tunneled Dialysis Catheter removal .....	66
5.4	Emerging concepts and future directions .....	68
5.4.1	Optimized start for renal replacement therapy .....	68
5.4.2	Convective clearance .....	68
5.4.3	Frequency is not replacing effective time on renal replacement therapy.....	69
5.4.4	Gradual escalation of treatment time .....	69
5.4.5	Ensuring lack of constipation and accelerating gastrointestinal transit time .....	70
<b>6.</b>	<b>Conclusions</b> .....	<b>71</b>
<b>7.</b>	<b>Summary</b> .....	<b>73</b>
<b>8.</b>	<b>Összefoglalás</b> .....	<b>74</b>
<b>9.</b>	<b>References</b> .....	<b>75</b>
<b>10.</b>	<b>Bibliography of the candidate</b> .....	<b>110</b>
10.1	Original publications utilized to develop the Thesis .....	110
10.2	Additional publications .....	111
<b>11.</b>	<b>Acknowledgements</b> .....	<b>120</b>

**Abbreviations:**

**aHR** = adjusted hazard ratio

**AV** = arteriovenous (fistula or graft)

**ABPM** = ambulatory blood pressure monitoring

**AKI** = acute kidney injury

**AKIN** = acute kidney injury network

**ANCOVA** = analysis of covariance

**AN-69** = a type of polyacrylonitrile dialysis membranes

**Apache II** = "Acute Physiology and Chronic Health Evaluation II": a severity-of-disease scoring system specific for Intensive Care Units

**aPTT** = activated partial thromboplastin time

**ARF** = acute renal failure

**BIA** = bioimpedance analysis (a.k.a. Bioimpedance Spectroscopy, BIS; or Body Composition Monitoring, BCM)

**BMI** = body mass index

**BNP** = brain-type natriuretic peptide

**BP** = blood pressure

**BSA** = body surface area

**BUN** = blood nitrogen

**CBC** = complete blood count

**CHF** = congestive heart failure

**CKD** = chronic kidney disease

**CKD-EPI** = Chronic Kidney Disease Epidemiology (formula to calculate estimated glomerular filtration rate)

**CRP** = C-reactive protein

**CRRT** = continuous renal replacement therapy

**CV** = cardiovascular

**DOPPS** = Dialysis Outcomes Practice Pattern Study

**ED** = Emergency Department

**EDW** = estimated dry weight

**ESRD** = end-stage renal disease

**GI** = gastrointestinal

**GFR** = glomerular filtration rate

**HD** = hemodialysis

**HIV** = human immunodeficiency-virus

**ICU** = Intensive Care Unit

**IDWG** = interdialytic weight gain

**INR** = international normalized ratio (of prothrombin time)

**IV** = intravenous

**IQR** = 25-75% interquartile range

**KDIGO** = Kidney Disease Improving Global Outcomes

**KDQOI** = Kidney Disease Outcomes Quality Initiative

**Kt/V** = single-pool urea clearance; dimensionless expression of dialysis adequacy

**NKF** = National Kidney Foundation (of the United States)

**OR** = Odds Ratio

**PT** = prothrombin time

**RIFLE** = risk/injury/failure/loss/end-stage (classification stages of Acute Kidney Injury)

**RRF** = residual renal function

**RRT** = renal replacement therapy

**TDC** = tunneled dialysis catheter

**PD** = peritoneal dialysis

**UF** = ultrafiltration

**UFR** = ultrafiltration rate

**UMMC** = University of Mississippi Medical Center

**US** = United States (of America)

**VRWG** = volume-related weight gain

**WBC** = white blood cell count

**95% CI** = 95% confidence intervals

## **1. Introduction**

### **1.1. Preamble: the burden of end-stage renal disease world-wide**

Survival for end-stage renal disease (ESRD) patients remains dismal and much below of their age-adjusted peers. We are far from being able to deliver true cure for chronic renal failure and our technology to replace the functions of the native kidneys is imperfect at best. During the care of these patients many issues remain insufficiently addressed and likely to contribute to adverse outcomes. At a time of increasing burden of chronic kidney disease (CKD) in the aging population and escalating load of prevalent ESRD patients, our specialty is under siege by shrinking reimbursement in the industrialized part of the world, inadequate resources and limitations of trained manpower in most places of the globe. Clinical nephrology training is demanding, requiring excellent cognitive skills and years of dedicated training to deliver optimal care; a competent nephrologist is much more than a “dialysis doctor”. Yet, at the same time, interest in nephrology has reached an all-time low, a phenomenon observed world-wide (1, 2). Under such circumstances, we should judiciously re-assess the available resources, both societal and of the health care practitioners’, to ensure the best possible care for our patients. Further, we should scrutinize existing knowledge and stimulate interest among trainees, both in research and clinical care, to maintain attraction for the specialty and seek new solutions for our ever-changing clinical problems. There is yet much to be learned about the care of these patients; call for action for all of us.

### **1.2 Importance of time during renal replacement therapy**

Relying predominantly on small solute clearance (3), including single-pool urea clearance ( $Kt/V$ ) and creatinine removal to define adequacy of renal dialysis constitutes perhaps the “original sin” of clinical nephrology. Historically, an adequate  $Kt/V$  was mediated by the combination of filter clearance and time spent on renal replacement therapy. With evolving technology, using larger surface area filters and higher flow rates, identical  $Kt/V$ s have been re-created but within a much shorter time, leading to a potential deterioration of overall well-being and hemodynamical stability. In the largest dialysis trial to date, participants assigned to higher  $Kt/V$  with high-flux dialysis were more likely



to experience hypotension (4). Progressive decline of hemodialysis (HD) time was indeed the rule in the U.S. for most of the late 90s and the early 2000s; many limitations of reduced time with such approach were not sufficiently appreciated until the current decade. Among these are that Kt/Vs are not normalized for the body surface area (BSA), may impact smaller subjects differently (including women) (5) and do not account for differences in body compositions (6). It is virtually impossible to deliver identical clearance characteristics during an inherently discontinuous therapy (4 hours, three times a week) to replace the smooth 24-hour function of the native kidneys. The clearance of large-size uremic toxins will be primarily a matter of time spent on renal replacement therapy (RRT) (7-10). Several markers of uremia (phenylacetylglutamine, hippurate, indoxyl sulfate) maintain a markedly elevated level on chronic hemodialysis (x40-120) despite receiving what appears to be an adequate RRT (11, 12). During the care ESRD patients, the last 2 decades have witnessed an evolving shift from purely biochemical determinants of outcome (e.g. urea clearance, hemoglobin, phosphate and parathyroid hormone control) to a broader view emphasizing the use of fistulas, pre-dialysis nephrology care, and maneuvers to preserve residual renal function (13). Additional considerations are the length of effective dialysis received, the presence of inflammation with vascular access catheters and suboptimal compliance with dietary and fluid restrictions (14). As volume removal and ultrafiltration rates are almost impossible to disengage from dialysis duration in chronic outpatient dialysis, excess fluid gains and/or insufficient time on dialysis will result volume overload and worsening blood pressure (BP) control. Since the publication of our original publication on the importance of time during renal hemodialysis (13), significant advancement and new knowledge has accumulated on the subject and will be discussed in this current thesis.

### **1.3 Blood pressure control in hemodialysis patients**

The current approach of excessive reliance on BP measurement at and around the time of the dialysis procedure to assess overall BP control is difficult to support (15). BP monitoring during HD is done primarily to ensure the safety of renal dialysis. Extreme caution should be exercised to extrapolate HD-associated BP to judge the efficacy of BP control in the outpatient setting (16). Optimal BP targets in dialysis patients are subjects

to debate (16) and the link between hypertension and poor cardiovascular outcomes is less clear than in the case of the general population. The assessment of BP for these patients comprises multiple limitations: the functioning arterio-venous (AV) grafts and fistulas in the upper extremities, the presence of peripheral vascular disease (17-19), inappropriately small BP cuffs in the obese (20) and misleadingly high BP immediately after clinic arrival pressure (21). Abrupt changes in fluid volume and plasma ion concentration during HD treatment will frequently predispose patients to erratic BP changes. In the largest controlled trial to date, those assigned to higher Kt/V were more likely to have hypotensive episodes (equilibrated Kt/V of 1.45 vs 1.05, 18.3% versus 16.8%;  $p < 0.001$ ) (4). On the other hand, BP stability at and around the time of hemodialysis confers a lower risk of mortality independent of the actual BP values and persisting through a 2-year follow-up period (22). Climatic circumstances may influence blood pressure but so may the interdialytic weight gain (IDWG): e.g., in one study, cooler temperatures were associated with higher systolic blood pressure, IDWG, and serum potassium values across the United States (23). Similarly, in a cohort of 100 ESRD subjects we also observed some influence of “hot and dry” environmental temperatures on IDWG (24).

Ambulatory blood pressure monitoring (ABPM) circumvents many problems of unit-derived BP measurements. It relieves the provider from the burden of making BP management decisions based on HD unit-based measurements, known to be highly inaccurate and heterogeneous across the population (25). It poses minimal inconvenience to the patients (26) and has better long-term reproducibility than casual blood pressure measurement in hemodialysis patients (27, 28). Abbreviated ABPM monitoring or a limited number of BP readings in the outpatient setting convey prognostic information similar to more extensive monitoring (29). Home BP self-recording assesses out-of-unit BP burden well (28), is easy to repeat and represents a simple and low-cost alternative to ABPM (16). Similarly to past studies, we also have demonstrated that the post-dialytic BP had a better association with 48-hour BP burden during ABPM than the predialysis BP (30). A recent paper by Agarwal et al. has explored the clinical utility of intra-dialytic BP recording in estimating the out-of-the-dialysis-unit BP load (31), conferring to the usual clinical practice of nephrologists to review intra-dialytic BP fluctuations when establishing the patients’ ideal target weights. Significant practice variation exists across

countries with regard to the nephrologists being present during dialysis, conceivably compromising the practicability of this approach in many places (32).

#### **1.4 Dry weight determination in hemodialysis patients**

Defining the ideal volume status and weight continues to be a challenge in clinical practice dialysis (33-35). Elevated BP may or may not equate with hypervolemia. In brief, one needs to find a target or “ideal” weight where both symptomatic fluid overload before dialysis and hypotensive episodes during and after treatments are minimized to as little as possible. There have been many attempts to define such an optimal volume status via scientific, objective and reproducible means (36). The historical practice pattern (37) has been to “challenge” the patients’ target weight by gradual escalation of ultrafiltration goals during renal dialysis and, as needed, re-administer IV fluids for hypotensive events and/or symptomatic hypovolemia. As crude as this practice pattern appears, little has changed in clinical practice over the last three decades and the concept of “physician-estimated dry weight” or “physician-declared dry weight” remained well-entrenched in textbooks. These maneuvers, however, can be very distressing to patients and create extra labor and alarm for the dialysis unit care staff (38). Dry weight, probed to a symptomatic threshold (37) causes not only hypotension but also sympathetic activation, potentially triggering acute cardiovascular and vascular access events (39). Repetitive end-dialytic weight below estimated dry weight (EDW) is associated with worsened survival (40). Additional concerns for such an approach are ischemia in the mesenteric (41) or peripheral vascular supply territories (42), both of which could carry a high mortality rate. Further complicating care is the fact that in certain countries (e.g. U.S.), shortage of physicians and the reimbursement paradigm do not provide an incentive for clinicians to be present during RRT and assess intra-dialytic BP changes during the sessions (32). Hence, variation of ultrafiltration goals will be determined by mid-level providers or worse, the dialysis nurse on site. Physicians may have limited time, if some, to review care charts of RRT sessions.

### **1.5 The interaction between volume status and blood pressure: limitations of physical examination to assess volume status**

Establishing the optimal volume status is exceedingly difficult in the multiple comorbid ESRD cohort. The physical examination may have severe limitations in assessing the necessary or, more importantly, the possible tolerated amount of ultrafiltration (43). Similarly to time on hemodialysis, volume management has not received sufficient attention by decision-maker parties of ESRD-care until very recently (44). Fluid overload is associated with a graded elevation of blood pressure before dialysis (45) and excessive interdialytic fluid gains are associated with worsened survival (46, 47). Clearly, escalating anti-hypertensive therapy alone is insufficient (48-50) without addressing the extracellular fluid space expansion (6, 51, 52), the root cause of hypertension among these subjects. On the other hand, aggressive volume control may accelerate the development of full anuria (53), further compromising downstream management for these patients. At both two extremes, in volume depletion-related hypotension and hypotension induced by excessive ultrafiltration with large IDWGs, physicians may respond by increasing the estimated dry weight; however, in the latter case this would only escalate the volume-overloaded state further (54). Accordingly, it is critical to be able to determine the relative contribution of volume overload to elevated blood pressure in a reproducible, observer independent, standardized manner. The judicious challenge of the target weight remains an important element of blood pressure management in daily practice of nephrology at present time (52, 55). Clearly, a subset of patients have volume-independent hypertension (56) and these subjects need to be identified, as well. Available tools include imaging procedures (chest ultrasonography, inferior vena cava diameter assessment, echocardiography), biomarkers such as atrial and B-natriuretic peptides (38) and, more recently, bioimpedance analysis (BIA) (6, 38, 57, 58) and blood volume monitoring (59, 60).

### **1.6 Inflammation and C-reactive protein**

C-reactive protein (CRP) is an acute phase protein, clinically attractive as an *in vivo* bioassay to gauge the overall degree of inflammation (61). Elevated CRP has also emerged as a non-traditional risk factor for adverse cardiovascular outcomes in the

general population, potentially adding to conventional vascular risk assessment for non-renal patients (62, 63). The relationship between CRP and hypertension is directional: hypertension is not only associated with elevated CRP in non-renal patients (64), but among normotensive subjects, elevated CRP increases the future risk of hypertension (65). Elevated CRP levels are associated with cardiovascular (CV) disease and mortality (66-68), sudden cardiac death (67) and stroke (69), possibly mediated through an association with preclinical (70) or manifest atherosclerosis (71). The presence of access type has a profound impact on the CRP level in dialysis patients (72). Albumin - historically viewed as a purely “nutritional” marker - is perhaps better viewed as a “negative acute phase” protein and known to correlate inversely with CRP (73, 74). Low albumin is associated with increased mortality (75-77) and serum albumin is low in about half of the hemodialysis patients (78-80) despite what one would consider an “adequate” dialysis by Kt/V-based criteria. A substantial number of these patients have elevated CRP (81). In summary, both serum albumin (82-85) and CRP (86-89) are known to correlate with inflammation and mortality in ESRD patients. Unlike in the case of CRP, the implication of elevated cardiac troponins in this population is not well understood (88). Subtle troponin-I elevation has been associated with worse CV outcomes in ESRD and occasionally has been ascribed to the ESRD status alone. Many of these patients with clinical symptoms (e.g., chest pains, shortness of breath or fever) will also receive measurements of commonly utilized biomarkers looking for myocardial damage and inflammation during Emergency Department (ED) evaluation. To what degree elevated troponin-I may reflect true myocardial damage or being a sign of an underlying infection is not well-defined to date.

### **1.7 The importance of vascular access catheters**

Vascular access dialysis catheters are life-saving during the care of dialysis patients when urgent RRT is needed and an arterio-venous (AV) fistula is not immediately available (90). While regular (non-tunneled) dual-lumen catheters can be used for the hospitalized patients, tunneled (occasionally referred to as “tunneled-cuffed”) dialysis catheters (TDC) are preferentially utilized in ambulatory settings (91). These catheters have the advantage of securing themselves into the subcutaneous tissue with a specific

type of polyethylene “cuff,” eliciting soft tissue growth and scarring while increasing the exit site’s resilience to infections (92). Nonetheless, they represent an inferior access modality (72, 93-96) and are linked to increased mortality (97-100) when compared with traditional AV fistulas or even AV grafts. The Dialysis Outcomes and Practice Patterns Study (DOPPS) II has demonstrated that a 20% increase in the use of a dialysis unit catheter was associated with a 16% increase in mortality risk (101). A later study confirmed that less frequent catheter and graft use is associated with improved patient survival (102). Bacterial colonization of these catheters is in fact common (103) and may adversely impact residual renal function (104) and sooner or later lead to manifest infectious events (105-107). In practical effect, the cumulative duration of the catheter itself represents the largest risk factor for a catheter infection (108, 109) and limiting the catheters’ presence to the shortest time possible requires the care provider’s vigilance and commitment. Up until now, the literature on long-term dialysis catheters was focused on circumstances of placement (110-112), optimizing patency and function (107, 113, 114), as well as prevention of infections (115-118). On the other hand, circumstances and indications of TDC removal were less well understood or studied. Historically, the removal of these catheters was felt to be a surgical or an interventionalist’s task and, up until recently, very little has been published on bedside removal of TDCs by non-interventional nephrologists.

## **1.8 Adherence**

Adherence (compliance) is a critical issue for successful care in dialysis patients. Adherence to dietary salt and water restrictions will influence weight gains and the stability of blood pressure, both during and off renal replacement therapy. Compliance with dietary restrictions would translate into IDWG, determining the ultrafiltration rate and, to large degree, the expected hemodynamic burden of the next hemodialysis session. Major variations exist among dialysis cohorts regarding adherence, perhaps best documented through the DOPPS (119), an international collaboration collecting data on care and practice patterns among Japanese, European and American dialysis patients. The DOPPS collected data on adverse prognostic markers (120), including phosphate control, IDWG and the number of unattended or significantly ( $\geq 10$  minutes) shortened dialysis

sessions per month (119). In clinical practice, one has to realize that the relationship between mortality, morbidity and behavior is more closely related to shortened and non-attended sessions than to the achieved control of phosphate and potassium (120, 121). Short but repetitive early terminations of HD sessions are not innocent events and can lead to adverse clinical outcomes (120, 122). Of concern are the Southern dialysis networks in the United States, having higher degrees of adverse outcomes despite improvements in overall healthcare delivery. Our own published experience from the Northwestern Louisiana found striking nonadherence the rule, rather than the exception: 85.9% of patients shortened at least one hemodialysis session and 29% skipped at least one hemodialysis session per month (123). Repetitive volume overload will be associated with increased mortality and will lead to large changes in BP during dialysis sessions (124, 125). BP variability is known to be the highest on the first day of the week after the long, three-day period off RRT (126). Dialysis alone may not be the only answer and, perhaps not surprisingly, in the largest controlled trial to date (HEMO trial), those assigned to higher Kt/V (1.45 vs. 1.05) experienced more hypotensive episodes (18.3% versus 16.8%;  $p < 0.001$ ) (4). Compliance with the prescribed loop diuretic regimen helps to reduce IDWG between sessions (127, 128), further reducing the expected hemodynamic burden of net ultrafiltration during the following dialysis session. Additional potential maneuvers to decrease hemodynamic fluctuations include decreasing dialysis temperature (129) or, alternatively, increasing session lengths during RRTs (13). We could not gather affirmative evidence for anecdotal claims of excessive fluid intake precipitated by hot or humid weather in a relatively small, single-center study of 100 patients from Central Europe (24). In summary, conclusions from large-scale studies may not be uniformly applicable to select subpopulations of patients (94, 102, 119, 130) and thus, local patterns of suboptimal treatment compliance impact hemodynamic stability and ultrafiltration (UF) burden during dialysis sessions.

### **1.9 Definition of Acute Kidney Injury: limitations of serum creatinine**

The current classification theme of the acute impairment of renal function is heavily dependent on assessment of serum creatinine [Table 1]. However, the practical value of creatinine is much limited in the setting of positive fluid balances and dilutional

effects on creatinine (131-133) and different cut-off values may apply to start renal replacement technologies in critically ill. Volume overload, when massive, may completely mask the rise of serum creatinine and markedly underestimate the degree of renal functional impairment. Chronically ill, wasted patients may have a low muscle mass and creatinine generation rate (134); on the other hand, muscle injury and rhabdomyolysis may lead to disproportionate creatinine elevation in anuric subjects. Accordingly, interpretation of serum creatinine in critically ill may be markedly different from outpatients. As we stated in our recent review paper highlighting limitations of measured serum creatinine in acute kidney injury (AKI), along with calculated glomerular filtration rate (GFR):

“To some degree, the current thinking is captive to an era, viewing integrity of renal homeostasis as “kidney function percent”, a conceptual thought further reinforced by the emergence of automated glomerular filtration calculations (e.g., Modification of Diet in Renal Disease and CKD-EPI formula-based equations). When calculating fractional decline of renal function, only filtration is considered, assuming that decline of all other functions of the human kidney would be parallel to the decline of GFR - an assumption obviously not always taking place in terms of other indices, for instance, volume overload and hemodynamic status. Such thinking, however, applies even less to the setting of AKI in critically ill patients. As reasonable as progressive decline of GFR can be described in gradual CKD progression between the 15-60 mL/min/1.73 m<sup>2</sup> GFR range, clinical experience shows it to be inadequate when trying to define trigger points for clinical uremia in a catabolic state or need for RRT for volume-related indications. Such thinking applies even less to the setting of AKI in volume overloaded or critically ill patients. An observed serum creatinine may have little relevance in a wasted subject with low muscle mass, generalized edema and prolonged respiratory failure with difficulty in weaning (134) Volume overload, when massive, may completely mask the rise of serum creatinine and/or markedly underestimates the degree of renal functional impairment.”(135)

### **1.10 Fluid therapy in critically ill**

Since the early 2000s, early goal-directed therapy in sepsis has been the general rule (136), creating a practice pattern of aggressive volume resuscitation in Intensive Care Units (ICU) (137). However, an early study of successful goal-directed therapy to optimize mixed venous O<sub>2</sub> saturation by Rivers et al. (138) was not replicated in



subsequent large, multi-center trials (139, 140). Volume load with isotonic saline promotes a non-anion gap metabolic acidosis, potentially contributing to increased mortality (141). Additionally, neither the use of albumin (142, 143), nor hydroxyethyl starch preparations (144-146) appear to be more effective than isotonic saline expansion alone. If anything, there is a potential for harm, including more RRT needed in hydroxyethyl starch recipients (147, 148). In comparison with historical approaches - which avoided bicarbonate administration - recent trends favor administering bicarbonate-containing fluids (149). Indeed, volume replacement with bicarbonate-containing solutions resulted in a decreased occurrence of elevated creatinine and Risk-Injury-Failure-Loss-End-Stage (RIFLE) staging “injury” or “failure” stage in a prospective, in a prospective, open-label, sequential period pilot study from Australia (149), further supported by a systemic network meta-analysis in 2013 (148). All these studies are raising the possibility that that fluid composition itself is less important than the degree of volume overload developing during a critical illness, especially in those with renal failure.

### **1.11 Renal replacement therapy in Intensive Care Units**

Renal replacement therapy in ICUs continues to represent an ongoing clinical challenge, including the inherent difficulties identifying the “optimal” filling pressures for these patients. They represent an especially vulnerable group of patients with a high mortality rate, where AKI is particularly harmful when occurring as part of multi-organ failure (151, 152). In those with volume-depleted state, early administration of sufficient IV volume replacement is critical to reverse tissue hypoperfusion and impact subsequent prognosis (138). Standard operating practice involves the administration of 20–30 mL/body weight kg IV crystalloids over a 30-minute period, further repeated as necessary. However, over-aggressive volume resuscitation is also harmful and fluid overload has been associated with increased morbidity and mortality in patients with acute respiratory distress syndrome (153, 154), sepsis (155), in surgical ICU patients (156, 157) and those with abdominal compartment syndrome (158, 159). In a large observational clinical trial, persistently negative fluid balance was associated with improved outcomes during critical illness (mean daily fluid balance: -234 mL/day vs +560 mL/day among

non-survivors vs. survivors,  $p < 0.0001$ ) (160). Among children with renal failure, initial pediatric studies established that fluid overload at the initiation of continuous renal replacement therapy (CRRT) was associated with increased mortality (161-163). Among

Table 1. Kidney Disease Improving Global Outcomes (KDIGO) definition and classification of Acute Kidney Injury (AKI)(150)

<b>KDIGO Stage<sup>a</sup></b>	<b>Serum Creatinine Increase</b>	<b>Urine Output Criteria<sup>d</sup></b>
1	1.5–1.9 times baseline <sup>a</sup> or $\geq 0.3$ mg/dl ( $\geq 26.5$ mmol/L) increase <sup>b</sup>	$< 0.5$ ml/kg per hour for 6–12 h
2	2–2.9 times baseline	$\leq 0.5$ ml/kg per hour for $\geq 12$ h
3	3 times baseline or increase in serum creatinine $\geq 4$ mg/dl ( $\geq 353.6$ mmol/L) or initiation of renal replacement therapy <sup>c</sup> [in patients aged $\leq 18$ years, decrease in estimated glomerular filtration rate to $\leq 35$ mL/min per $1.73$ m <sup>2</sup> ]	$\leq 0.3$ ml/kg per hour for $\geq 24$ h or anuria $\geq 12$ h

<sup>a</sup>Serum creatinine increase is known or presumed to have occurred within the prior 7 days.

<sup>b</sup>Serum creatinine to have occurred within any 48-hour period.

<sup>c</sup>For patients reaching stage 3 by serum creatinine  $> 4$  mg/dl, rather than require an acute rise  $\geq 0.5$  mg/dl over an unspecified time-period, KDIGO requires that the patient first achieve the creatinine-based change specified in the KDIGO AKI definition (either  $\geq 0.3$  mg/dl within a 48-hour time window or an increase of  $\geq 1.5$  times baseline within 7 days).

<sup>d</sup>Urine output criteria are identical to the corresponding risk/injury/failure/loss/end-stage (RIFLE) and Acute Kidney Injury Network (AKIN) stages.

(Republished modified from Reference #150; Copyright has been obtained from American Journal of Kidney Disease and publisher Elsevier)

children with renal failure, initial pediatric studies established that fluid overload at the initiation of CRRT was associated with increased mortality (161-163). In adult ICU cohorts, AKI non-survivors had a more positive fluid balance than the non-survivors (164, 165). On the other hand, the impact of the RRT in this context was not well studied until recently and it remains uncertain whether CRRT can meaningfully influence prognosis. In our former paper, we observed better outcomes in those with shorter wait-time before CRRT and in those with impaired baseline creatinine (166). Further, the change in creatinine between admission and the initiation of CRRT (but not creatinine at initiation) was statistically different between survivors and non-survivors (1.6 vs. 2.6 mg/dL,  $p=0.023$ ) (166). Unlike chronic RRT patients, critically ill renal patients are much more heterogeneous with an acute component of renal dysfunction, further complicating the interpretation of serum creatinine. The presence of an indwelling vascular catheter (rather than an AV fistula) is the rule, rather than an exception in these patients. In addition to the importance of time on RRT and hemodialysis access issues, the presence of comorbid fluid overload is another difficult clinical issue to address. Considering the above, there is a critical need to re-assess the impact of volume overload in critically ill patients, especially as it pertains to the trigger point of initiating RRT.

## **2. Objectives**

Certain clinical problems are both unique and pervasive in patients receiving RRT. These include volume overload, a frequent problem in ESRD patients on maintenance dialysis and a potential acute complication of AKI. Time is of the essence both during CRRT (maintaining integrity and patency of extracorporeal circuit) and during maintenance dialysis (prescription of appropriate duration of therapy to provide both uremic control and volume control) to minimize hemodynamic stress in these patients. Catheter use has remained prevalent and in fact escalated in dialysis patients over the last several years. Finally, the patients' willingness to adopt the appropriate lifestyle as well as the dietary and time-commitment limitations remains the ultimate limiting factor for any prescribed medical regimen in ESRD. These clinical concerns are not entirely independent of each other, but rather represent interrelated issues: e.g., dietary non-compliance leads to fluid overload and excessive UF during dialysis; the presence of a catheter leads to elevated inflammatory markers and poses the risk of infection, which in turn may lead to hypotension and excessive fluid resuscitation. My subsequent Ph.D. thesis examines my clinical research on several of these clinical concerns.

### **2.1 Volume-related weight gain in the Intensive Care Units study**

Literature emerging around the middle of the first decade of the 21<sup>st</sup> century strongly suggested an adverse impact of volume overload in surgical settings for adults and in critically ill children with AKI. On the other hand, the impact of volume overload in adults with AKI was little explored at that time. Since fluid overload is associated with decreased survival in non-renal patients, we hypothesized that larger volume-related weight gain (VRWG) prior to RRT may be associated with higher mortality in critically ill AKI patients treated with CRRT (167).

Specific research goals:

1. To determine the degree of volume overload experienced in a cohort of critically ill patients before being started on CRRT.
2. To examine the association of VRWG with subsequent outcomes in these critically ill patients.

## **2.2 Dialysis prescription and inflammatory markers on chronic hemodialysis study**

Unlike in AKI patients, the source of fluid overload in ESRD patients is not exogenous IV fluid but represents the dietary intake of both salt (sodium-chloride) and water. Time spent on maintenance dialysis, both for the patients and providers' convenience, became progressively reduced in the era of high-flux dialyzers by the early 2000s and time itself turned into a relatively neglected clinical parameter. Large and indiscriminate salt and water intake would lead to large IDWG, especially when time available for treatment is reduced. Under these circumstances, IDWG, hourly UF rate and time spent on renal dialysis represent a triangle of interconnected parameters, further determined by the patients' compliance. Our initial review on the subjects suggested a potential adverse effect of reduced time in ESRD patients receiving maintenance RRT, including an impact on markers of inflammation, such as CRP and albumin (13). Since treatment time and ultrafiltration-rate (UFR) both correlate with patient survival (168), we hypothesized that long treatments with a slow UFR may also influence the control of inflammation on dialysis (169).

Specific research goals:

1. To examine the association of time on chronic hemodialysis on serum CRP and albumin.
2. To examine the association of hourly UF rate on chronic hemodialysis with serum CRP and albumin levels.

## **2.3 Bedside removal of permanent hemodialysis access catheters studies**

Permanent or semi-permanent (long-term) intravascular access catheters became routine from 1990 on and escalated in the last two decades in dialysis patients. These foreign materials create a state of low-degree inflammation and contribute to excess infectious risk and mortality in ESRD patients (97-100). Since prolonged duration of TDCs represent profound risk factors for adverse outcomes, we wished to examine the circumstances, indications and clinical success rate of an emerging nephrology procedure, the bedside removal of these catheters. Our study hypothesis was that bedside removal of TDC by a nephrologist is safe and effective, both for in- and outpatients and when

performed by physicians during graduate medical education training (114, 170). Our secondary objective was to examine the associations between select biomarkers (CRP, troponin-I) and clinical indications for TDC removals in our inpatient cohort (114).

Specific research goals:

1. To determine success rate with bedside removal of TDCs, including the safety and efficacy and complication rates of such procedure in both inpatient and outpatient settings.
2. To examine the impact of vascular access catheters on certain serum biomarkers (CRP, troponin-I) in patients undergoing removal of these semi-permanent vascular access catheters.

### 3. Methods

My proposed thesis will be supported by my existing publications on the subject (114, 167, 169, 170). Herewith, I would like to review the Materials and Methods of the studies I have utilized to develop this thesis, including one study examining the importance of volume-related weight gain before CRRT (*Volume-Related Weight Gain and Subsequent Mortality in Acute Renal Failure Patients Treated with Continuous Renal Replacement Therapy*. ASAIO Journal 2010 (Jul-Aug); 56(4): 333-7) (167), an another study examining the cross-sectional associations of inflammatory markers with treatment time during conventional hemodialysis (*Correlation of Treatment Time and Ultrafiltration Rate with Serum Albumin and C-reactive Protein Levels in Patients with End Stage Kidney Disease Receiving Chronic Maintenance Hemodialysis: A Cross-Sectional Study*. Blood Purification 2010 (July); 30:8-15) (169) and two studies on TDC removal (*The Safety and Efficacy of Bedside Removal of Tunneled Hemodialysis Catheters by Nephrology Trainees*. Renal Failure 2013 (October); 35 (9): 1264-1268; *Tunneled Hemodialysis Catheter Removals by Non-Interventional Nephrologists: the University of Mississippi Experience*. Seminars in Dialysis 2015 (Sept-Oct); 28(5): E48–E52) (114, 170). The right to re-publish has been obtained from the journals and the publishers. Additionally, several other publications from our research groups will be reviewed or discussed, when appropriate.

#### 3.1 Volume-related weight gain study

##### 3.1.1 Study population

We analyzed demographic, clinical and survival data from an observational, single-center registry of 81 patients treated with CRRT at the University of Mississippi Medical Center (UMMC), Jackson, MS (United States of America) over an 18-month period from January 2003 to June 2004. The study population consisted of all adult patients (age 18 or greater) with AKI admitted to the medical, cardiac, surgical, and cardiothoracic ICU of UMMC and treated with CRRT during the study's period. After obtaining Institutional Review Board approval, the patients were prospectively enrolled into the study during or shortly after an initial nephrology consultation. A written consent

of participation was obtained from the patients or their immediate family. Indications for initiating CRRT included fluid overload and metabolic derangements refractory to conservative management, usually with associated hemodynamic instability. The timing and decision to initiate CRRT as well as the prescribed dose and modality of CRRT were at the discretion of the faculty attending nephrologist and the majority of the subjects received continuous veno-venous hemodiafiltration. All CRRT sessions were performed using Gambro Prisma (Gambro AB, Stockholm, Sweden) CRRT machines using AN-69 polyacrylonitrile dialysis membranes. Patients were excluded if they had preexisting ESRD or if the time from the onset of AKI to the initiation of CRRT was two weeks or greater. The general characteristics of our study cohort and their association with mortality are shown in Table 2. and described in detail in our previous study (166). The principal outcome was mortality on day 30 (167).

### ***3.1.2 Definitions and variables of interest***

The patients were considered to have AKI if their serum creatinine increased by 0.5 mg/dL (44.2  $\mu$ mol/L) or greater from baseline or if they had an abnormal serum creatinine at the presentation with no known baseline value. Data on the patients' creatinine level were collected at the initiation of CRRT. We also recorded the change in creatinine level from hospital admission to the initiation of CRRT and the dose of CRRT. The days waited were the number of days from the diagnosis of AKI to the initiation of CRRT (167). The patients' weights were documented in a variety of settings: ED, regular nursing floors, and the ICUs; in all cases, the first documented weight available on the hospital record was taken as the initial weight; the majority of these was registered only in the ICUs. Standard hospital scales were used for the ambulatory patients and bed scales for the non-ambulatory or ICU patients. Subsequent daily weights in ICUs were monitored with bed scales by the nursing staff of the unit and recorded on daily care charts. In our study, we have defined VRWG as the difference between the initial (first available) weight and the weight at the initiation of CRRT. Weight gain percentage (%) was interpreted as a difference in percentage between the initial weight and weight obtained at the initiation of CRRT. Oliguria was not defined according to the current weight-based Acute Kidney Injury Network (AKIN) standard; instead, by an average urine output of less than 20 mL/hour for at least 12 hours before study enrollment.



**Table 2.** Baseline Characteristics of the University of Mississippi CRRT Cohort Stratified by Mortality (N = 81) (166)

Baseline Characteristics means (SD) or %	Survivors	Death	<i>p</i>
<b>Sample size</b>			
All patients, <i>n</i>	40	41	
Baseline creatinine established, <i>n</i>	27	33	
<b>Demographics</b>			
Age, <i>years</i>	49.4 (16.7)	53.4 (16.6)	0.287
Gender, <i>female</i>	12 (30.0%)	12 (29.3%)	0.943
Apache II <sup>a</sup>	26.7 (7.2)	28.4 (6.5)	0.271
<b>Creatinine (mg/dL)</b>			
Baseline	1.4 (0.8)	1.1 (0.3)	0.088
Admission	3.8 (3.5)	2.1 (1.9)	0.011
CRRT initiation (InitCr)	5.3 (2.5)	4.8 (1.8)	0.304
<b>Change in creatinine (mg/dL)</b>			
InitCr – Admission Cr	1.6 (1.9)	2.6 (1.9)	<b>0.023</b>
InitCr – Baseline Cr	3.0 (2.0)	3.6 (1.6)	0.207
<b>% change in creatinine<sup>b</sup></b>			
InitCr – Admission Cr	165% (209)	223% (197)	0.214
InitCr - Baseline Cr	291% (243)	340% (174)	0.379
CRRT dose (mL/kg/hour) <sup>c</sup>	21.1 (10.2)	24.5 (12.6)	0.187
Days waited <sup>d</sup>	3.2 (2.7)	4.2 (3.2)	0.137
Sepsis	25 (61.0%)	23 (56.1%)	0.558
<b>ARF type</b>			
Inpatient ARF	14 (43.8%)	18 (56.3%)	
Outpatient ARF	2 (16.7%)	10 (83.3%)	
ARF on Chronic Kidney Disease	11 (68.8%)	5 (31.3%)	
<b>ICU service type</b>			0.205
Surgical ICU	9 (22.5%)	7 (17.1%)	
Cardiothoracic ICU	10 (25%)	4 (9.8%)	
Cardiology ICU	3 (7.5%)	6 (14.6%)	
Medical ICU	18 (45%)	24 (58.8%)	

The conversion factor for serum creatinine in mg/dL to  $\mu\text{mol/L}$  is 88.4. Abbreviations: ARF, acute renal failure; Cr, creatinine; CRRT, continuous renal replacement therapy; ICU, Intensive Care Unit; InitCr, creatinine at CRRT initiation

<sup>a</sup>Apache II scores were calculated at time of renal consult.

<sup>b</sup>Percent change in creatinine was computed by either  $100\% \times (\text{InitCr} - \text{AdmCr})/\text{AdmCr}$  or  $100\% \times (\text{InitCr} - \text{BLCr})/\text{BLCr}$ .

<sup>c</sup>CRRT was the prescribed CRRT dose in mL/kg/hour. Continuous veno-venous hemofiltration was prescribed pre-filter dosing.

<sup>d</sup>Days waited was the number of days from first 0.5 mg/dL elevation in serum creatinine to initiation of CRRT.

The diagnosis of sepsis was a clinical diagnosis as stated on the medical record and Acute Physiology and Chronic Health Evaluation Apache II scores were calculated at the time of the renal consult was obtained (167).

### 3.1.3 *Statistical methods*

Data on patient characteristics are shown as mean  $\pm$  standard deviation (SD) for continuous variables or percentages for categorical variables. The primary goal of the study was to examine the effect of various cut-off net fluid accumulations, that is VRWG  $\geq 10\%$  or  $\geq 20\%$  and oliguria as variables associated with mortality. VRWG  $\geq 10\%$  patients were compared to those that gained  $< 10\%$ . In a separate analysis, those who gained  $\geq 20\%$  were compared to those gaining  $< 20\%$ ,  $< 10\%$  or between  $\geq 10$  and  $< 20\%$ . Additional variables included age, sex, chart diagnosis of sepsis, Apache II scores, CRRT dose, creatinine level at the initiation of CRRT, absolute change form of creatinine, days waited and ICU location. A cross-sectional analysis of selected variables was conducted to identify correlates with mortality. Chi-square tests were used for bivariate analyses of correlations between selected variables and mortality. Independent *t*-tests were performed to assess the correlations of continuous variables with mortality. Multivariate logistic analyses were conducted for more complex correlations. The data were analyzed using SPSS version 16 (SPSS Inc., Chicago, IL) and Minitab (version 13; Minitab Inc., State College, PA) (167).

## 3.2 **Dialysis prescription and inflammatory markers on dialysis study**

### 3.2.1 *Study population*

We have undertaken a cross-sectional study in a network of 12 hemodialysis centers including all Diaverum Hemodialysis Units in Hungary and the University of

Mississippi Medical Center outpatient hemodialysis unit in Jackson, Mississippi, USA. All patients receiving in-center maintenance hemodialysis three times a week were recruited for the study. Dialysis centers collected data from patient charts and local databases originally established for purposes of quality control. Patient- and dialysis-related characteristics, comorbidity diagnoses, acute events, medication use, and other covariates were extracted in July, 2007. The study was approved by the UMMC Human Research Office and the Office of Scientific Officer of Diaverum, Inc (169).

### ***3.2.2 Definitions and variables of interest***

Age was the number of full calendar years completed since birth. Sex was self-reported and either male or female. Ethnicity was either Caucasian or African American. Comorbid conditions, such as diabetes mellitus, coronary artery disease, congestive heart failure (CHF) and human immunodeficiency-virus (HIV) positive state were recorded if listed in the medical records. Medical records were updated within the month of data collection. The dialysis vintage was the number of completed months since starting renal replacement therapy on dialysis. EDW was the physician-prescribed ideal weight. Kt/V was defined as the single-pool urea clearance reported by the dialysis provider health information network. An acute infectious or coronary event was acknowledged based on the medical record during the index month. The presence of residual renal function (RRF) was defined as evidence of at least 200 mL urinary output in a 24-hour urine collection within 3 months of July, 2007. Treatment time was defined as the average length of dialysis sessions in minutes recorded during the index month. The UF rate was defined as the hourly volume removed in mL per kg of body weight (mL/kg/hour) according to the DOPPS (168) and averaged over the index month. Serum albumin and CRP were measured as part of the routine care. Albumin was measured by Bromocresol green methods (Diagnosticum Zrt., Hungary; Spectra Laboratories, USA) and reported in gm/L or gm/dL. CRP was measured by immunoturbidimetric assay and reported as either < 5 mg/L, any numerical value above 5 mg/L (Spectra Laboratories, USA) or numerical values both below and above 5 mg/L (APTEC, Belgium) (169).

### ***3.2.3 Statistical methods***

Data on patient characteristics are shown as mean  $\pm$ SD for continuous variables or percentages for categorical variables. Serum albumin and CRP were used as continuous

variables in the analysis of covariance (ANCOVA) models and categorized as bivariate during logistic regression. In our study, we dichotomized *a priori* albumin values at 40 gm/L (approximate mid-normal range value) with albumin > 40 gm/L designated as a favorable outcome for purposes of logistic regression analysis; conversely, albumin  $\leq$  40 gm/L was designated as low albumin or failure to reach normal albumin levels. Similarly, CRP was dichotomized at 5 mg/L, with CRP  $\leq$  5 mg/L being designated as a favorable outcome, CRP > 5 mg/L as failure. Potential factors associated with inflammation were tested in Analysis of Covariance (ANCOVA) models. An initial model of 23 variables included age, sex, ethnicity, vascular access, dialysis vintage, RRF, dry weight, comorbidities, medications (statins, aspirin, vitamin-D analogues, phosphate binders, calcimimetic), Kt/V, type of dialyzer, treatment time and UF rate. These parameters are otherwise identical to the ones listed in Table 3. (169). In a subsequent analysis, the initial set has been narrowed down to 15 variables as follows: age, sex, ethnicity, vascular access type, dialysis vintage, dry weight, diabetes mellitus, coronary artery disease, CHF, HIV infection, acute coronary event, acute infectious event, Kt/V, treatment time and UF rate. Logistic regression models were constructed to calculate Odds Ratio (OR) with 95% confidence intervals (CI) predicting favorable outcomes of CRP and albumin. Treatment time was dichotomized at four hours and entered into logistic regression modeling as a categorical variable of > 4 hours for “long” treatment time and  $\leq$  4 hours for “short” treatment time. The initial logistic regression model operated with the same 15 independent variables as the second ANCOVA model. Stepwise selection was applied in logistic regression modeling to assess the individual contribution of major predictors. As neither of the dependent parameters were found to be normally distributed, the non-parametric Mann-Whitney test was also utilized to establish ranks between longer than 4-hour treatment time and less than 10 mL/kg/h UF rate with favorable outcome in serum albumin and CRP levels. All statistical analyses were performed using SPSS 16 (SPSS Inc., Chicago, IL) (169).

**Table 3.** Population and treatment characteristics (169)

<b>Demographic characteristics:</b>	
<u>All data/partial missing data:</u>	616 / 103
Age (years):	60.9 ±14.4
Gender (M/F) %	52.1% / 47.9%
Ethnicity (African-American/Caucasian) %	18.2% / 81.8%
Vascular Access (NF/TDC/TC/AVG)* %	67.0% / 19.3% / 7.6% / 6.0%
Dialysis Vintage (months):	46.2 ±44.8
Residual Renal Function (≥ 200 mL) %:	57.6%
Estimated Dry Weight (kg):	72.3 ±17.3
<b>Comorbidities:</b>	
<u>Percent of patients having comorbidity (n=616)</u>	
Diabetes Mellitus	35.2%
Coronary Artery Disease	19.3%
Congestive Heart Failure	43.7%
HIV** Infection	1.3%
Active Smoking	24.5%
Acute Coronary Event	4.7%
Acute Infectious Event	12.9%
<b>Dialysis treatment characteristics:</b>	
Treatment Time (min)	237.3 ±23.8
Ultrafiltration Rate (mL/kg/hour)	7.05 ±4.05
Kt/V:	1.50 ±0.34
Dialyzer***:	F-180NR or F200NR in 1 center vs. Polyflux 17 or Polyflux 21 in 11 centers
***Choice of dialyzer and ethnicity almost completely overlapped	
<b>Medications:</b>	
<u>Percent of patients taking medication (n=616):</u>	
Statins (HMG-CoA reductase inhibitors)	26.3%
Aspirin	40.2%
Calcitriol or Vitamin-D analogues	46.8%
Phosphate binders	69.0%
Calcimimetic	5.1%

**Table 3.** Population and treatment characteristics – continued**Clinical outcomes: serum albumin and CRP:**Mean values:

Serum albumin (gm/L):	39.8 ±4.6
C-reactive protein (mg/L):	12.7 ±18.2
<u>Favorable outcomes observed (%):</u>	
Serum albumin ≥ 40 gm/L:	57.7%
C-reactive protein ≤ 5 mg/L:	40.9%

\*Abbreviations: NF/TDC/TC/AVG= native fistula/tunneled dialysis catheter/temporary catheter/synthetic graft; \*\*HIV=Human immunodeficiency virus.

**3.3 Vascular catheter access removal studies****3.3.1 Study population**

Our catheter removal experience consisted of two studies, Study A (114) and Study B (170). Study A consisted of a retrospective cohort of a consecutive 3-year bedside TDC removal experience among hospitalized subjects at the University of Mississippi Medical Center performed via the Nephrology Consult Service (January 01, 2007 to December 31, 2009) (114). Study B consisted of a review of mixed inpatient and outpatient bedside TDC removals from January 1, 2010 to June 30, 2013, over a 3 ½ year period at the Nephrology Division of the University of Mississippi Medical Center (170). In study A, patients had been referred to the procedure team by nephrology consulting teams whenever TDC removal became medically necessary in the team’s clinical judgment. In Study B, subjects had been referred to the author of the present thesis via nephrology providers from a variety of settings: ED, general inpatient floor, ICUs or ambulatory outpatient sections. In both studies, the decision to remove the TDC was made solely by the patients’ nephrology attending physician for a variety of reasons, including proven bacteremia, fever or clinical septic state, catheter malfunction or recovery of renal function. Additionally, in study B, access maturation was also considered as a reason for TDC removal. The basis of data recovery was the procedure teaching and procedure log of the author of the present thesis, which included all inpatient TDC removals by the Nephrology Division for study A and most of the outpatient removal at bedside for study B. In the cases of inpatient TDC removals, these took place in the patients’ room on the nursing floor; for outpatient removals, we utilized rooms specifically reserved for

procedures in the outpatient dialysis unit. Some but not all procedures involved renal trainees, as well. For inpatient procedures, the TDC removal always took place on the same day when the decision to remove the catheter was made (114, 170).

### 3.3.2 *Definitions and variables of interest*

For study A (114), we reviewed and collected data on multiple patient-related variables: age, ethnicity, sex and highest blood urea nitrogen, creatinine and blood coagulation tests within 24 hours of the procedure. Age was the number of full calendar years completed since birth. Sex was self-reported as either male or female. Ethnicity was either Caucasian or African American. Additionally, we collected data on certain other peri-procedure parameters up to three days before and after the procedure which consisted of peak and nadir white blood cell count (WBC); nadir hemoglobin, nadir platelet count and vital signs (temperature, heart rate, blood pressure). Two additional biochemical parameters associated with inflammation and myocardial stress, CRP and troponin-I were searched for and recovered from medical records, if available within 48 hours of TDC removal. Procedure-related variables, which included the indication for the procedure, the site and location of removal and any complications or difficulties during the procedure were recorded from the teaching log of the author of the present thesis (114). For study B (170), we collected data on similar variables, but within three days before and after the procedure: highest blood urea nitrogen, creatinine, and blood coagulation tests; peak WBC count; nadir hemoglobin and platelet count (when available). Demographic definitions (age, sex and ethnicity) were identical to study A. As a rule, we did not require a complete blood count (CBC) or standard tests of blood coagulation with prothrombin time (PT) and activated partial thromboplastin time (aPTT) before outpatient removals. However, we routinely obtained PT/aPTT among inpatients if not already available within 3 days (170).

Full technical details of the procedure are discussed in the following section as described in our original publications (114, 170, 171), our recent review (172) and can be viewed on YouTube video link (173). Contraindications for the procedure included abnormal coagulation results, including prothrombin time PT International Normalized Ratio (INR) >1.5 and markedly decreased platelet count (<60,000/mm<sup>3</sup>), when otherwise correctable. No further selection criteria were applied beyond the above-mentioned

exclusion criteria. All patients provided written consents before the procedure. Both Study A and Study B were reviewed and approved by the UMMC Human Research Office (Institutional Review Board) (114, 170).

### 3.3.3 *Statistical methods*


Upon review of both electronic and paper-based medical records, pre-defined information was collected in Microsoft Excel data sheets. Data were analyzed using SPSS Statistics 19 (IBM Corporation, Armonk, NY) and reported with means  $\pm$ SD or medians 25-75% interquartile range (IQR) for descriptive data; Pearson's correlation and chi-square as well as independent-samples *t*-test were utilized for statistical comparisons (114, 170).

### 3.3.4 *Procedure description for Tunneled Dialysis Catheter removal*

“Preparation for the procedure included obtaining informed consent in writing from the patient or next-of-kin and gathering the limited supplies needed in the patient's care room or the dialysis clinic procedure room: suture removal kit, syringes, needles, 1% lidocaine, face mask, sterile gown, sterile gloves, sterile gauze dressing, vascular clamp, chlorhexidine cleaning swabs and dressing tape. Examples of preparation tray are shown in Photo 1. Before starting the procedure, we carefully ascertain the exact location of the retaining subcutaneous “cuff”, both by visual inspection and gentle palpation over the subcutaneous tract of the of hardware. If uncertainty about the cuff location persisted, one could also apply a “twist” along the axis of the catheter to identify the retention point of the cuff. Sutures if present were removed after cleaning. Subsequently the catheter exit area, the surrounding skin and the catheter proximal to the hub (including the buried, but mobile portion distal to the Dacron cuff) are carefully cleaned with chlorhexidine-based cleaning solution [...] Local anesthesia is achieved with subcutaneous infiltration of 10-15 mL of 1% lidocaine hydrochloride of the surrounding tissues. Afterwards, the cleaned area is draped to create a sterile field for dissection, with additional sterile towel used to wrap around and cover the extracorporeal parts of the catheter. Thereafter, the subcutaneous tissues around the catheter up to the cuff, as well as an additional 2-3 cm proximally are bluntly dissected with a hemostat clamp, to achieve mobilization of the catheter from the surrounding soft tissues. Ideal dissection is achieved by repeatedly inserting the sterile hemostat in all four quadrants around the catheter - that is, above, below, to the right and to the left to it - and opening up the clamp's tip to a width of at least 2 cm. The minimal length of vascular clamp necessary for the procedure would be 15-20 cm, preferentially a straight one. Once the cuff and the catheter are free from all connective tissue, the TDC could be pulled with



a controlled amount of force. During removal, the exit site is covered with sterile gauze and gentle hand pressure is applied to prevent aerosolizing of blood during removal. Hemostasis is obtained by the application of direct pressure on the tract and the exit site with a sterile gauze for 5 minutes or until no bleeding was detectable, whichever is longer; thereafter, a fairly tight dressing is placed until the next morning. [...] The total procedure time is usually between 15-20 minutes and we also routinely ask outpatients to stay in the clinic waiting area for at least 30 min after the end of the procedure. For the newly placed catheters (<7-10 days), usually no dissection is needed and most of the catheters can be smoothly pulled after removing of the sutures.”(172)



**Photo 1.:** Sample TDC removal preparation tray at UMMC

## 4. Results

### 4.1 Volume-related weight gain in critically ill patients with AKI and subsequent mortality

For our study, the mean age of the 81 patients meeting the inclusion criteria was  $51.4 \pm 16.7$  years (range: 23-85), 24 of which were female (30%). The overall raw mortality rate for the cohort was 50.6%. Mean VRWG was  $8.3 \pm 9.6$  kg but with a wide range of variation observed in the cohort (range: -10.5 to +45.9 kg). The mean percent weight gain was  $10.2 \pm 13.5\%$  (range: -11 to +81%). Oliguria was present in 53 patients before RRT commenced (65.4%). We have not observed significant associations between Apache II scores and weight changes ( $p=0.368$ ), chart diagnosis of sepsis and death ( $p=0.653$ ), or sex and death ( $p=1.00$ ) in the course of the univariate analysis. Thirty-eight patients (46.9%) had VRWG  $\geq 10\%$  and thirteen patients (16%) had  $\geq 20\%$  VRWG. VRWG  $\geq 10\%$  ( $p=0.046$ ) and oliguria ( $p=0.020$ ) were significantly associated with death. The basic cohort demographics stratified by the two major cut-off categories are presented in two separate Tables: VRWG of  $<10\%$  and  $\geq 10\%$  are presented in Table 4, while VRWG  $>20\%$  and  $\geq 20\%$  are presented in Table 5. (167). Differences have been observed between the groups with VRWG  $<10\%$  and  $\geq 10\%$  (creatinine at CRRT initiation, CRRT dose and days waited for CRRT) but these did not persist when the cohort was separated according to VRWG  $>20\%$  and  $\geq 20\%$ . Female subjects were less likely to experience VRWG  $\geq 20\%$  (167).

We observed that patients with a VRWG  $\geq 10\%$  had a significantly higher risk of dying than the reference group of  $<10\%$  (OR 2.62, 95% CI: 1.07-6.44;  $p=0.046$ ) (Figure 1.1). When the patients were stratified using 20% VRWG as the cut-off point, the odds ratio for death in the patients with VRWG  $\geq 20\%$  was even higher, compared with the patients with VRWG  $<20\%$  (OR 3.98, 95% CI: 1.01-15.75) albeit nominal significance was lost ( $p=0.067$ ) (Figure 1.2) (167). As shown in Figure 2, separating the cohort into three categories of VRWG ( $<10\%$ ;  $\geq 10$  but  $<20\%$ ;  $\geq 20\%$ ) was associated with a stepwise progressive increase of mortality: 39.5% (17 of 43), 56% (14 of 25) and 76.9% (10 of 13). Accordingly, against a reference group of VRWG  $<10\%$ , OR for death was increased to 1.95 (95% CI: 0.72–5.28;  $p = 0.191$ ) in the group with intermediate weight gains ( $\geq 10$  but  $<20\%$ ) and to 5.10 (95% CI: 1.22–21.25;  $p = 0.025$ ) in the group with

**Table 4.** Clinical Variables and Outcomes in Patients  
with VRWGs of <10% vs. ≥10% (167)

<b>Clinical Variables</b>	<b>All</b>	<b>VRWG&lt;10%</b>	<b>VRWG≥10%</b>	<b>p</b>
Number	81	43	38	N/A
Average weight gain (%)		1.4 ±4.6	20.3 ±13.3	
Age (years)		50.4 ±16.5	52.6 ±17	0.547
Female Sex		27.9%	31.5%	0.718
Apache II scores		27.2 ±6.9	27.9 ±6.8	0.657
Creatinine at CRRT initiation		5.5 ±2.4	4.5 ±1.8	<b>0.039</b>
Change in creatinine (mg/dL)		1.8 ±2.2	2.4 ±1.7	0.167
Days elapsed until CRRT		3.1 ±2.9	4.4 ±3	0.061
Sepsis		55.8%	63.1%	0.500
Oliguria		62.8%	68.4%	0.593
ICU Service				0.192
Cardiology ICU (n=9)		16.3%	5.3%	
Cardiac ICU-Surgery (n=14)		11.7%	23.7%	
Medical ICU (n=42)		55.8%	47.4%	
Surgical ICU (n=16)		16.3%	23.7%	
<b>Mortality</b>	<b>50.6%</b>	<b>39.5%</b>	<b>63.2%</b>	<b>0.029</b>

Abbreviations: CRRT = continuous renal replacement therapy; ICU = intensive care unit; VRWG = volume-related weight gain

Apache II scores were calculated at time of renal consult. The conversion factor for serum creatinine in mg/dL to  $\mu\text{mol/L}$  is 88.4

severe ( $\geq 20\%$ ) weight gains. Of the forty-one deceased patients 32 had oliguria with an unadjusted OR of death 3.22 (95% CI: 1.23-8.45,  $p=0.02$ ) for oliguria (167). Finally, we performed a multivariate modeling to assess the correlations of other potential risk factors for death in these patients. When analyzed together, both oliguria ( $p=0.021$ ) and  $\geq 10\%$  weight gain ( $p=0.042$ ) maintained independent significance. When sepsis and Apache II scores were included in the modeling, once again, oliguria (OR 3.04,  $p=0.032$ ) and  $\geq 10\%$  weight gain (OR 2.71,  $p=0.040$ ) maintained significance in the more complex modeling [Table 6.1-2.].


**Table 5.** Clinical Variables and Outcomes in Patientswith VRWG of <20% vs.  $\geq$ 20% (167)

Clinical Variables	All	VRWG<20%	VRWG $\geq$ 20%	<i>p</i>
Number	81	68	13	n/a
Average VRWG (%)		6.0 $\pm$ 7.4	32.2 $\pm$ 17.1	
Age (years)		51.9 $\pm$ 16.7	49.2 $\pm$ 17	0.61
Female Sex		23.5%	61.5%	<b>0.00</b>
Apache II scores		27.3 $\pm$ 6.8	28.8 $\pm$ 7.2	0.48
Creatinine at CRRT initiation		5.2 $\pm$ 2.2	4.2 $\pm$ 1.6	0.05
Change in creatinine (mg/dL)		2.0 $\pm$ 2.0	2.5 $\pm$ 1.5	0.33
Days elapsed until CRRT		3.5 $\pm$ 2.9	4.7 $\pm$ 3.1	0.24
Sepsis		57.4%	69.2%	0.40
Oliguria		63.2%	76.9%	0.29
ICU Service				0.54
Cardiology ICU (n=9)		10.3%	15.4%	
Cardiac ICU-Surgery (n=14)		19.1%	7.7%	
Medical ICU (n=42)		52.9%	46.2%	
Surgical ICU (n=16)		17.6%	30.8%	
<b>Mortality</b>	<b>50.6</b>	<b>45.6%</b>	<b>76.9%</b>	<b>0.01</b>

Abbreviations: CRRT = continuous renal replacement therapy; ICU = intensive care unit; VRWG = volume-related weight gain


Apache II scores were calculated at time of renal consult. The conversion factor for serum creatinine in mg/dL to mmol/L is 88.4

The effect of sepsis and Apache II scores remained non-significant on multivariate analysis. Altogether, the combined presence of oliguria and  $\geq$ 10% weight gain explained approximately 12% of the observed mortality. Including into the logistic regression model creatinine level at CRRT initiation, CRRT dose and days waited for CRRT abolished the association of mortality with VRWG  $\geq$ 10% ( $p=0.196$ ; OR 0.71-5.29), but not with oliguria (OR 3.94; 95% CI 1.37-11.37;  $p=0.011$ ), with minimal improvement of the model's overall predictability ( $R^2$  0.16) (167). Analyzing our data through a three-way separation of the cohort (VRWG < 10%;  $\geq$ 10 but <20%;  $\geq$ 20%) in logistic regression, the OR of mortality increased 2.17 (95% CI: 1.11-4.26;  $p=0.024$ ) for each categorical change of VRWG.



**Figure 1.1 and 1.2.** Association between VRWG and Mortality at different cut-offs of VRWG

Abbreviations: VRWG = volume-related weight gain; Wt gain: weight gain



**Figure 2.** Association between progressive increases in VRWG and Mortality (167)

Asterisk (\*) indicating statistical significance ( $p < 0.05$ )

Abbreviations: VRWG = volume-related weight gain; Wt gain: weight gain

The effect of oliguria also remained significant: OR 2.17 (1.06-8.11;  $p=0.038$ ); however, Apache II ( $p=0.239$ ) and sepsis ( $p=0.352$ ) did not. Including creatinine in the logistic regression model at CRRT initiation, CRRT dose, and days waited did not show an independent association with death for either one ( $p=0.322$ , 0.584, 0.163, respectively), but abolished the association of VRWG with death ( $p=0.125$ ; OR 0.86-3.51), while the association with oliguria persisted (OR 3.80; 95% CI 1.31-11.01;  $p=0.014$ ) (167). As larger VRWG was also associated with lower serum creatinine ( $5.5 \pm 2.4$  mg/dL vs.  $4.5 \pm 1.8$  mg/dL with lower creatinine in  $VRWG \geq 10\%$ ;  $p=0.039$ ), adjusting for creatinine at CRRT start may have resulted in simultaneous adjustment for larger fluid gains, as well, in those with larger fluid gains and dilution of serum creatinine. With the inclusion of multiple covariates (all the above), the results remained virtually unchanged. Finally, we analyzed the OR between the two extreme ends of our cohort: those gaining VRWG  $<10\%$  vs. those with  $VRWG \geq 20\%$  (a total of 56 subjects) excluding the “intermediate” cohort ( $VRWG \geq 10\%$  but  $<20\%$ ) in multiple logistic regression models. With the inclusion of oliguria, CRRT dose, creatinine at CRRT initiation, and days waited, the OR for death ( $\geq 20\%$  vs.  $<10\%$  VRWG) was 4.34 and now approached significance:  $p=0.069$  (OR 0.89 – 21.16). Further, results with the inclusion of multiple covariate results were similar, as shown in Table 7. (167).

**Table 6.1** The Combined Effect of Oliguria and VRWG  
During Multivariate Modeling (167)

Clinical Variable	<b>exp (B) <math>\pm</math>95% Confidence Intervals</b>	<b>p-value</b>	<b>R<sup>2</sup></b>
<b>Oliguria and <math>\geq 10\%</math> Volume-Related Weight Gain</b>			
Oliguria	3.23 (1.19-8.73)	0.021	0.12
$\geq 10\%$ VRWG	2.64 (1.04-6.70)	0.042	

**Table 6.2.** The Effect of Oliguria, VRWG, Sepsis, and Apache II Scores on Mortality During Multivariate Modeling

<b>Oliguria, <math>\geq 10\%</math> Volume-Related Weight Gain, Sepsis and Apache II scores</b>			
Oliguria	3.04 (1.10-8.36)	0.032	
$\geq 10\%$ VRWG	2.71 (1.05-6.99)	0.040	0.13
Sepsis	0.63 (0.22-1.78)	0.379	
Apache II scores	0.96 (0.89-1.03)	0.219	

Abbreviations: VRWG = volume-related weight gain

**Table 7.** The Effect of VRWGs (<10% vs.  $\geq 20\%$ ) on Mortality During Multivariate Modeling (167)

<b>Clinical Variable</b>	<b>exp (B) <math>\pm 95\%</math> Confidence Intervals</b>	<b>p-value</b>
Oliguria	1.90 (0.53-6.80)	0.325
VRWGs (<10% vs. $\geq 20\%$ )	4.03 (0.88-18.38)	<b>0.072</b>
Sepsis	0.64 (0.18-2.27)	0.490
Apache II scores	1.02 (0.94-1.12)	0.605
Creatinine at CRRT initiation (mg/dL)	0.92 (0.71-1.20)	0.553
Days elapsed until CRRT	1.10 (0.90-1.36)	0.353

Overall  $R^2 = 0.147$ .

Abbreviations: VRWG = volume-related weight gain


## 4.2 Dialysis prescription and inflammatory markers during conventional hemodialysis

Of the 626 reviewed patients, 616 (98.4%) met our inclusion criteria for undergoing maintenance hemodialysis three times a week in the 12 participating centers and having at least one of the critical data (albumin or CRP) obtained during the data collection period available for further analysis. Patient- and treatment-specific characteristics of these 616 participants are summarized in Table 3. (169). Mean age for the cohort was  $60.9 \pm 14.4$  years with an overall dialysis vintage of  $46.16 \pm 44.8$  months. Racial distribution of patients was 408 (79%) Caucasian and 105 (21%) African American and there was a large burden of diabetes mellitus (35%), congestive heart failure (44%) and coronary artery disease (19%) among the participants. Significant RRF ( $\geq 200$  mL) was present in over half (58%) of the population. The average treatment time ( $237.3 \pm 23.8$  minutes) was comparable to the European average at the time the research was taking place and about 16 minutes longer than the US average reported by DOPPS (168). Altogether, 122 (19.8%) patients were dialyzed for longer than 4 hours and 494 (80.2%) for less than or equal to 4 hours; mean treatment time for these was  $269.7 \pm 14$  and  $229.3 \pm 18$  minutes, respectively. However, mean treatment time did not significantly differ between the European ( $237.6 \pm 24$  minutes) and the US arm ( $236.4 \pm 21.6$  minutes) of the cohort. Mean UF rate ( $7.05 \pm 4.05$  mL/kg/h) was the lowest in all DOPPS regions (168). There was no statistically significant univariate association between treatment time and UF rate (Pearson  $r$ : -0.042;  $p=0.222$ ). Both CRP and serum albumin were distributed non-normally. CRP was available for 616 (100%) participants but albumin for only 522 (84.7%). Mean serum albumin was close to 40 gm/L with 301 (57.7 %) patients exceeding this level (169). The distribution of serum albumin values by treatment time and UF rate is shown in Figure 3. and Figure 4., respectively (169).

CRP was highly variable with a wide range (undetectable to 146.8 mg/L) and  $\leq 5$  mg/L in 252 (41%) of the cohort. The covariates of the initial ANCOVA model were the same as the patient- and treatment-specific characteristics in Table 3. However, the type of the dialyzer could not be analyzed separately due to an almost complete overlap of the choice of the dialyzer and African American ethnicity. In the initial screening ANCOVA model, only ethnicity ( $p=0.0036$ ) and acute infection ( $p=0.0002$ ) were significantly associated with serum albumin, and only vascular access type ( $p=0.009$ ), acute coronary




event ( $p=0.0459$ ) and acute infection ( $p<0.0001$ ) were associated with CRP. Analyzing the set of 15 variables [Table 8.1], serum albumin as a continuous variable was significantly associated with ethnicity, dry weight, HIV status, acute infection and treatment time. In the case of CRP [Table 8.2], a significant association was found with vascular access type, dialysis vintage and acute infection while associations with acute coronary events were no longer significant (169).



**Figure 3.** Distribution of serum albumin by treatment time (169)

Abbreviation: HD= hemodialysis

Mean albumin levels were  $39.4 \pm 4.69$  g/L among subjects receiving “short” ( $\leq 4$  hours) treatment and  $41.62 \pm 3.39$  gm/L among those receiving “long” treatment ( $>4$  hours). Stepwise selection was applied in logistic regression modeling to assess the individual



**Figure 4.** Distribution of serum albumin by ultrafiltration rate (UFR) (169)

Abbreviations: UFR = ultrafiltration rate

contribution of major predictors. For albumin, failure to reach more than 40 g/L in Step 1 correlated with short treatment time, Caucasian ethnicity, lower dry weight and the presence of an acute infection [Table 9.] (169). On the other hand, UF rate was not found to be a significant correlate of failure to reach > 40 gm/L albumin.

After Step 4, a treatment time of longer than 4 hours was associated with decreased odds of low albumin (OR 0.397, 95% CI: 0.235-0.672;  $p < 0.001$ ). Being Caucasian increased the likelihood of failing to reach the albumin target (OR 2.304, 95% CI: 1.462-3.630;  $p < 0.0001$ ), as did acute infection (OR 2.240, 95% CI: 1.327-3.780;  $p = 0.003$ ). Dialysis vintage had only borderline significance (OR 0.995, 95% CI: 0.991-1.000;  $p = 0.041$ ) while dry weight was not significant (169). When additional subcohort analysis was performed according to ethnicity (Caucasian vs. African American), treatment time greater than 4 hours once again reduced the risk of having low albumin (OR 0.385, 95% CI: 0.197-0.683,  $p = 0.002$ ) among the 408 Caucasians. However, the

effect of treatment time among African Americans was no longer significant ( $p=0.105$ ), likely due to the limited number of these subjects ( $n=105$ ) (169). Separating CRP according to treatment time, mean CRP in the short-treatment cohort was  $12.05 \pm 18.78$  mg/L and  $11.23 \pm 15.62$  mg/L in the long-treatment-time subgroup. Logistic regression demonstrated that factors correlating with high CRP were age, congestive heart failure (CHF), lower dry weight and vascular access type [Table 10.] (169). During stepwise selection, only the presence of CHF (OR 1.634, 95% CI: 1.154-2.312;  $p=0.006$ ) and acute infection (OR 1.799, 95% CI: 1.059-3.056,  $p=0.03$ ) remained positive correlates of a high CRP level. The significance of age decreased (OR 1.014, 95% CI 1.002-1.026;  $p=0.02$ ) while dry weight and vascular access type lost significance. UF rate was not found to be a significant correlate of either main outcomes (169).

**Table 8.1 – 8.2.** (169)

<b>Table 8.1.</b> ANCOVA analysis for serum albumin		<b>Table 8.2.</b> ANCOVA analysis for C-reactive protein	
<b>Predictor variable</b>	<b>Significance (<math>p</math>)</b>	<b>Predictor variable</b>	<b>Significance (<math>p</math>)</b>
Age	0.292	Age	0.126
Gender	0.512	Gender	0.215
Ethnicity	0.001	Ethnicity	0.973
Vascular Access	0.085	Vascular Access	0.002
Dialysis Vintage	0.759	Dialysis Vintage	0.017
Dry Weight	0.034	Dry Weight	0.239
Diabetes Mellitus	0.108	Diabetes Mellitus	0.190
Coronary Artery Disease	0.266	Coronary Artery Disease	0.410
Congestive Heart Failure	0.169	Congestive Heart Failure	0.260
HIV Infection	0.028	HIV Infection	0.833
Acute Coronary Event	0.468	Acute Coronary Event	0.059
Acute Infectious Event	0.000	Acute Infectious Event	0.000
Kt/V	0.410	KT/V	0.372
Treatment Time	0.016	Treatment Time	0.663
Ultrafiltration Rate	0.053	Ultrafiltration Rate	0.392

$R^2 = 0.122$  (Adjusted  $R^2 = 0.092$ )

$R^2 = 0.151$  (Adjusted  $R^2 = 0.127$ )

Abbreviations: HIV = human immunodeficiency virus; ANCOVA = analysis of covariance

**Table 9.** Results of Logistic Regression for Serum Albumin (169)

<b>Variables entered</b>	<b>Significance (<i>p</i>)</b>	<b>Odds ratio (95% CI)</b>
Treatment Time > 4 hours	0.012	0.488 (0.280-0.851)
Ultrafiltration Rate	0.415	0.979 (0.929-1.031)
Age	0.144	1.011 (0.996-1.025)
Female Gender*	0.130	0.731 (0.487-1.097)
Ethnicity (Caucasian)†	0.000	3.386 (1.712-6.697)
Dialysis Vintage	0.078	0.996 (0.991-1.000)
Diabetes Mellitus	0.073	1.466 (0.964-2.229)
Acute Coronary Event	0.467	0.808 (0.455-1.435)
Congestive Heart Failure	0.590	1.119 (0.743-1.684)
HIV Infection	0.340	2.382 (0.401-14.163)
Dry Weight	0.016	0.985 (0.972-0.997)
KT/V	0.136	1.645 (0.855-3.166)
Vascular Access Type‡	0.659	
Tunneled Catheter	0.941	0.981 (0.595-1.619)
Temporary Catheter	0.224	1.640 (0.739-3.637)
Arteriovenous Graft	0.829	1.104 (0.448-2.721)
Acute Coronary Event	0.096	2.082 (0.879-4.932)
Acute Infectious Event	0.007	2.098 (1.219-3.609)

## Stepwise Selection for Serum Albumin

	<b>Variables selected</b>	<b>Significance (<i>p</i>)</b>	<b>Odds ratio (95% CI)</b>
Step 1	Treatment Time > 4 hour	0.001	0.432 (0.261-0.716)
Step 2	Treatment Time > 4 hour	0.001	0.406 (0.243-0.678)
	Ethnicity (Caucasian) †	0.001	2.113 (1.350-3.307)
Step 3	Treatment Time > 4 hours	0.000	0.380 (0.225-0.641)
	Ethnicity (Caucasian)†	0.000	2.266 (1.440-3.565)
	Acute Infectious Event	0.002	2.322 (1.379-3.910)
Step 4	Treatment Time > 4 hours	0.001	0.397 (0.235-0.672)
	Ethnicity (Caucasian) †	0.000	2.304 (1.462-3.630)
	Acute Infectious Event	0.003	2.240 (1.327-3.780)
	Dialysis Vintage	0.041	0.995 (0.991-1.000)

Symbols: \*reference: male; †reference: African American; ‡reference: native AV fistula access

Abbreviations: HIV = human immunodeficiency virus

**Table 10.** Results of logistic regression for C-reactive protein (169)

<b>Variables entered</b>	<b>Significance (<i>p</i>)</b>	<b>Odds ratio (95% CI)</b>
Treatment Time > 4 hours	0.965	1.010 (0.643-1.587)
Ultrafiltration Rate	0.333	1.022 (0.978-1.068)
Age	0.031	1.015 (1.001-1.028)
Gender*	0.085	0.726 (0.504-1.045)
Ethnicity (Caucasian)†	0.045	0.519 (0.274-0.984)
Dialysis Vintage	0.151	1.003 (0.999-1.007)
Diabetes Mellitus	0.465	1.155 (0.785-1.701)
Acute Coronary Event	0.926	1.025 (0.609-1.725)
Congestive Heart Failure	0.032	1.496 (1.035-2.162)
HIV Infection	0.697	1.379 (0.273-6.964)
Dry Weight	0.044	1.012 (1.000-1.024)
KT/V	0.590	1.166 (0.668-2.035)
Vascular Access Type‡	0.078	
Tunneled Catheter	0.059	1.589 (0.982-2.571)
Temporary Catheter	0.044	2.053 (1.018-4.141)
Arteriovenous Graft	0.426	1.427 (0.595-3.420)
Acute Coronary Event	0.735	1.161 (0.490-2.749)
Acute Infectious Event	0.091	1.601 (0.928-2.760)

## Stepwise Selection for C-reactive protein

	<b>Variables selected</b>	<b>Significance (<i>p</i>)</b>	<b>Odds ratio (95% CI)</b>
Step 1	Congestive Heart Failure	0.000	1.872 (1.341-2.613)
Step 2	Age	0.022	1.014 (1.002-1.026)
	Congestive Heart Failure	0.003	1.693 (1.199-2.390)
Step 3	Age	0.020	1.014 (1.002-1.026)
	Congestive Heart Failure	0.006	1.634 (1.154-2.312)
	Acute Infectious Event	0.030	1.799 (1.059-3.056)

Symbols: \*reference: male; †reference: African-American; ‡reference: native AV fistula access

Abbreviations: HIV = human immunodeficiency virus

The Mann-Whitney test demonstrated that treatment time lasting longer than 4 hours was associated with having significantly higher albumin (mean rank 322.63 vs. 248.42,  $p < 0.0001$ ), whereas its effect on CRP was not significant ( $p = 0.85$ ). UF rate had no significant effect on albumin or CRP levels ( $p = 0.326$  for albumin,  $p = 0.931$  for CRP ranks, respectively) (169)

### 4.3 Tunneled Dialysis Catheter removal success rate and biomarkers

#### 4.3.1 *Results of the Inpatient Cohort*

Our Study A population consisted of 55 hospitalized patients. All TDCs were removed at the bedside and most cases (50/55 or 90.9%) completed by nephrology fellows under attending physician's supervision. The rest of the catheters were removed by the attending physician alone with medical resident(s) observing the procedure. General cohort characteristics are shown in Table 11. (114). Most TDC removals took place in general wards (63.6%), while the rest of the removals were done either in the ED (12.7%) or one of the ICUs (23.6%) with a median time of 3 days [25-75% IQR 1-13] elapsing from admission with TDC in place or TDC placement. Of these, 36 (65.5%) TDCs were removed from the right internal jugular position, 14 (25.5%) from the left internal jugular position, and 5 (9.1%) from femoral veins. Most cases had urgent indication for TDC removal with potential for harm with delays. These included proven (culture-positive) bacteremia in 36.4% of the cases, otherwise unexplained fever in 41.8% of the cases or clinical signs of sepsis with hemodynamic instability or respiratory failure in 20% of the cases. Only three TDCs were removed in patients with recovering renal function, for the reason of being "no longer needed." At the time of TDC removal, four (7.2%) patients were hypothermic, 33 (60%) were febrile or subfebrile (temperature >37 C°) and 7 (12.7%) were on vasoactive supporting agents (norepinephrine or high dose dopamine). All removals were executed successfully without any retention of polyethylene ("Dacron") cuffs or catheter fracture observed. One patient had prolonged local bleeding which was controlled with extended local pressure. None of the cases required interventional radiology or general surgery consultation for assistance (114). Peak CRP (available in 63.6% of the cohort) was  $12.9 \pm 8.4$  mg/dL (reference range: <0.49 ml/dL), median troponin-I (34% available) was 0.127 ng/mL [25-75% IQR 0.03-0.9] (reference range: <0.034 ng/mL) and they did not correlate with each other (p=0.848). The associations of CRP and troponin-I with clinical indications for TDC removal and selected clinical parameters are shown in Table 12. (114). We did not observe any association between CRP and clinical indications for TDC removal. Additionally, clinical sepsis (as indication for TDC removal) correlated with systolic BP nadir (p<0.0001), temperature (p=0.002) and the lowest platelet count (p=0.016).

**Table 11.** Baseline Cohort Characteristics and Indications for Tunneled Dialysis Catheter Removal (N=55) (114)

Age (years)	53.9 (15.4)
Gender (% <i>female</i> )	54.5
Race (% <i>African-American</i> )	90.9
Heart Rate (/min) <sup>c</sup>	95.6 (20.6)
Systolic BP nadir (mmHg) <sup>c</sup>	116.5 (20.7)
Diastolic BP nadir (mmHg) <sup>c</sup>	64.9 (12.3)
Temperature (C°) <sup>b</sup>	37.6 (1.8)
Blood Urea Nitrogen (mg/dL) <sup>a</sup>	46.8 (23.6)
Creatinine (mg/dL) <sup>a</sup>	6.96 (3.37)
Platelet count, nadir (x10 <sup>3</sup> /mm <sup>3</sup> ) <sup>c</sup>	189.6 (114.8)
WBC count, peak (x10 <sup>3</sup> /mm <sup>3</sup> ) <sup>c</sup>	13.6 (8.7)
WBC count, nadir (x10 <sup>3</sup> /mm <sup>3</sup> ) <sup>c</sup>	7.9 (4.6)
Hemoglobin, nadir (gm/dL) <sup>c</sup>	9.4 (1.6)
<b>Biochemical Markers</b>	
CRP (mg/dL) <sup>b</sup> [ $<0.49$ ml/dL]	12.9 (8.4)
Troponin-I (ng/mL) <sup>b</sup> [ $<0.034$ ng/mL]	0.534 (0.708)
<b>Indication for TDC Removal</b>	
Bacteremia	36.4 %
Fever (temperature $>38$ C°)	41.8%
Clinical Sepsis	20%
Recovered Renal Function	5.5%

Abbreviations: BP, blood pressure; CRP, C-reactive protein; WBC, white blood cell  
 Obtained within 72 hours<sup>a</sup>, 48 hours<sup>b</sup> or 24 hours<sup>c</sup> of the procedure.  
 CRP values available for 63.6% of cohort; troponin-I for 34%.

Troponin-I had no association with systolic and diastolic BP or clinical sepsis as indication for TDC removal. However, troponin-I, as a continuous variable showed a trend with confirmed bacteremia ( $p=0.075$ ); furthermore, the association of troponin-I as a bivariate variable (abnormal/normal) with bacteremia was statistically significant (Pearson's chi-square=0.456,  $p=0.049$ ) [Table 2.; 3rd column] (114).

#### 4.3.2 Results of the Mixed Inpatient-Outpatient Cohort

For study B, we collected data on 138 subjects, where the mean age was  $50 \pm 15.9$  years, 49.3% being female, 88.2% African American and 41% diabetic. General cohort

**Table 12.** Associations of C-Reactive Protein and Troponin-I with Clinical Indications for TDC Removal and Selected Clinical Parameters (114)

	<b>CRP</b> (mg/dL) <sup>#</sup> <i>p</i> value	<b>Troponin-I</b> (ng/mL) <sup>#</sup> <i>p</i> value	<b>Troponin-I</b> (Bivariate: abnormal/normal) <i>p</i> value
<b>Indication for TDC Removal</b>			
Bacteremia	0.806	0.075	<b>0.049</b>
Fever (temperature >38 C°)	<b>0.005</b>	0.235	<b>0.018</b>
Clinical Sepsis	0.977	0.446	0.659
<b>Clinical Parameters</b>			
Systolic BP nadir (mmHg) <sup>c</sup>	0.690	0.561	0.254
Diastolic BP nadir (mmHg) <sup>c</sup>	0.526	0.288	0.945
Temperature (C°) <sup>b</sup>	<b>0.031</b>	0.941	0.256
Platelet count, nadir (x10 <sup>3</sup> /mm <sup>3</sup> ) <sup>c</sup>	0.292	0.745	0.912
WBC count, peak (x10 <sup>3</sup> /mm <sup>3</sup> ) <sup>c</sup>	0.225	0.383	0.594

Abbreviations: BP, blood pressure; CRP, C-reactive protein, TDC, tunneled dialysis catheter; WBC, white blood cell.

Obtained within 48 hours<sup>b</sup> or 72 hours<sup>a</sup> of the procedure; #considered as a continuous variable. CRP values available for 63.6% of cohort; troponin-I for 34%.

characteristics are shown in Table 13. The site of removal was the right internal jugular in 76.8% of the cases, the left internal jugular in 15.2% and one of the femoral vein in 8%; 44.9% of the cases took place in an outpatient setting. Main indications at the time of removal were proven bacteremia in 30.4% of the cases, clinical septic or infected state in 15.2%, along with “TDC no longer necessary” in 52.2% due to either recovery of renal function or maturation of permanent dialysis access [Table 13.]. Most of the outpatient removals took place due to access maturation ( $p < 0.0001$ ). Like in Study A, all removal procedures were successful and tolerated without tear of the catheter itself but, unlike in study A, we observed Dacron “cuff” separation and subcutaneous retention in 6.5% of cases, all in males. There was a significant association between cuff retention and outpatient removal ( $p = 0.007$ ) but not with the operators’ training level, or the site of



removal. Once again, similarly to study A, none of the patients required interventional radiology or general surgery consultation for assistance (170).

**Table 13.** Baseline Cohort Characteristics (N=138) (170)

Age (years)	50 (15.9)
Gender (% female)	49.3
Race (% African-American)	88.2
<b>Co-existing Medical Conditions (%)</b>	
Diabetes Mellitus	41
Systemic Lupus Erythematosus	6
Hypertension	85.1
Recent Renal Transplant	6.6
<b>Biochemical Parameters</b>	
Blood Urea Nitrogen, highest (mg/dL) <sup>a</sup> (n=109)	46.4 (18.9)
Creatinine, highest (mg/dL) <sup>a</sup> (n=109)	7.7 (3.9)
Platelet count, nadir (x10 <sup>3</sup> /mm <sup>3</sup> ) <sup>a</sup> (108)	223.4 (108.5)
PT International Normalized Ratio, highest <sup>a</sup> (n=56)	1.12 (0.31)
PTT, highest (sec) <sup>a</sup> (n=58)	33.1 (8.5)
WBC count, peak (x10 <sup>3</sup> /mm <sup>3</sup> ) <sup>a</sup> (n=108)	9 (4.7)
Hemoglobin, nadir (gm/dL) <sup>a</sup> (n=108)	10.2 (1.5)

<sup>a</sup>obtained within 72 hours (before or after procedure)

**Table 14.** Procedure Location and Indications for Tunneled Dialysis Catheter (TDC) Removal (N=138) (170)

<b>Location of TDC removed (%)</b>	
Femoral vein ( <i>left or right</i> )	8
Right Internal Jugular Vein	76.8
Left Internal Jugular Vein	15.2
Place of TDC Removal (% <i>outpatient services</i> )	44.9
<b>Indication for TDC Removal (%)</b>	
Bacteremia	30.4
Fever (temperature >38 C°), Sepsis or Clinical Concerns for Infection	15.2
Exit Site Infection (as sole indication)	1.4
TDC “no longer needed” (renal recovery or access maturation)	52.2

## 5. Discussion

### 5.1 Volume-related weight gains in critically ill patients with AKI

Volume management is very challenging even for stable, outpatient ESRD patients. Critically ill ICU patients with renal impairment and hemodynamic instability are the most vulnerable to adverse consequences of volume overload. Early publications on adult cohorts have been derived from the non-AKI surgical literature, noting increased morbidity and mortality in volume-overloaded patients with acute respiratory distress syndrome (153, 154), sepsis (155), and surgical ICU patients (156, 157). Quite on the reverse, lesser fluid gains were associated with better outcomes after colon resection (157) or in the case of abdominal compartment syndrome (158, 159). Subsequent studies and meta-analyses further corroborated these findings (174). Fluids are medication, not unlike antibiotics, glucocorticoids or blood pressure medication but an “ideal” fluid management in ICU settings remains insufficiently defined (175). In terms of the clinical significance of pre-CRRT fluid overload, pediatric literature predated material on adults, documenting the graded adverse impact of fluid overload in children (162, 163, 176). As surprisingly this may sound – pediatric cohorts are always smaller than adult ones – children are nonetheless less likely to be confounded by multiple comorbidities of aging and may demonstrate biomedical signals with less ambiguity. To state it differently, both surgical and pediatric cohorts with fluid overload may have represented a relatively “pure model” fluid overload in critical illnesses, leading to an earlier recognition of the phenomenon. Among adults, however, our group(167) was one of the first to describe the progressive risk of death with increasing fluid overload in critically ill renal-failure patients, as discussed earlier in the Results section of the present thesis. Our central finding was that patients with VRWG  $\geq 10\%$  had a markedly higher mortality than those who gained  $<10\%$  (63% vs. 39%), despite being reasonably similar with regard to demographics, severity of illness, sepsis or oliguria (167). Fluid (volume) overload may dilute the serum creatinine and result in a delay of recognizing AKI and the initiation of appropriate work-up and therapy for it (131-133). In keeping with such speculations, we detected lower creatinine with larger VRWG. We speculate that VRWG and fluid overload were, to a large degree, a surrogate for hypotension, labile hemodynamics or capillary leak, and overall severity of illness in our cohort. The kidneys are encapsulated organs, where a large degree of volume overload, especially in septic patients with

capillary leak may lead to compromised renal perfusion (177, 178). All our patients commenced on CRRT subsequently, further testifying to the severity of the illness of the cohort (166). The predominant local practice of the day of administering large amounts of IV fluids - rather than early vasoactive pressor administration - may have created some of the very large VRWG and may not be uniformly observed in all centers all over the world. If, however, the VRWG was simply a severity of the disease marker, one would have expected the impact on mortality to be diminished when adjusted for the severity of illness (e.g. Apache scores). Our multivariate analysis (which contained Apache II scores, diagnosis of sepsis, oliguria and VRWG) did not support this possibility, although “generic” illness severity scoring systems are known to have a relatively poor performance in similar cohorts (151, 179). Preceding our publication, findings from the Sepsis Occurrence in Acutely ill Patients multi-center database (165), observed larger fluid gains in non-survivors of AKI. The Program to Improve Care in Acute Renal Disease (PICARD) group (180) analyzed data from critically ill adult patients with AKI from multiple ICUs in the U.S. The same group of authors in 2009 observed the association of fluid overload with mortality, irrespective of the modality of RRT(181). Our 2010 study was the first to focus specifically on the impact of VRWG before CRRT in adult cohorts (167).

Oliguria is generally associated with worse outcomes in patients with AKI (151, 165, 182), which is in accordance with our findings as well; mortality was 60.4% in oliguric subjects compared to 39.8% in non-oliguric subjects. Oliguria was not defined based on weight (mL/kg/hour) and our definition of oliguria deviated from the current definition of the AKIN. Our study had several additional limitations evident even at the time of publication: lack of knowledge about weight changes before admission and the uncertainty about baseline creatinine in about one-fourth of the subjects. Additional methodological limitations (modest size, single-center design and lack of randomization) would have made our findings difficult to support without other studies reaching the same conclusion. Delays and individual practice patterns in obtaining renal consults may have influenced the timing of CRRT initiation, further questioning the external validity of our findings. Nevertheless, the subsequent years from 2010 on produced a flurry of supportive investigations on the subject as noted below.

### 5.1.1 *Literature on the importance of volume overload in critically ill patients with AKI*

Subsequent to our publication, Heung et al. documented that among patients surviving AKI, fluid overload at the beginning of RRT was associated with compromised renal recovery after recovery from critical illnesses (183). Pediatric studies continue to support the importance of VRWG even in very small-sized children (184). Most importantly, a number of other investigations of adult cohorts replicated our findings on the importance of VRWG in AKI. These include a Finnish trial of ICU patients, demonstrating higher 90-day mortality risk after adjusting for disease severity, RRT and sepsis (185); an Italian multicenter trial demonstrating that both fluid overload and oliguria were independent risk factors for 28-day mortality after adjustment for age, sex, diabetes, hypertension, diuretic use, non-renal Sequential Organ Failure Assessment (SOFA) and sepsis (186) (adjusted hazard ratio [aHR] 1.67 per L/day, 95% CI 1.33-2.09 for fluid overload,  $p < 0.001$ ); and aHR 0.47 per L/day per L of urine output, 95% CI 0.33-0.67 for oliguria,  $p < 0.001$  for both). On the other hand, diuretics use was associated with better survival in this population (aHR 0.25, 95% CI 0.12-0.52;  $p < 0.001$ ). In 2015 a very large, multicenter trial from Beijing, China once again confirmed that volume overload was an independent risk factor for new-onset AKI with OR 4.508 (95% CI 2.900-7.008;  $p < 0.001$ ) and increased the severity of AKI (187). Additionally, non-survivors with AKI had higher cumulative fluid balance during the first 3 days than survivors (2.77 [0.86-5.01] L versus 0.93 [-0.80 to 2.93] L;  $p < 0.001$ ). Multivariate analysis revealed that the cumulative fluid balance during the first 3 days was an independent risk factor for 28-day mortality (187). Most recently, the Dose Response Multicentre Investigation on Fluid Assessment (DoReMIFA) study demonstrated that volume overload was more harmful in the presence of AKI and preceded renal dysfunction. Both the severity and rapidity of fluid accumulation development were independent risk factors for ICU-associated mortality (188). A systematic review and meta-analysis also confirmed the associations between fluid overload and mortality in AKI patients but found only a non-significant trend for the association of fluid overload with renal recovery (189). Notwithstanding the limitations - as summed up in our review paper - "...these observations, however, have one major potential major error – confounding by indication, i.e., sicker patients were more likely to be hypotensive and received larger amount of fluids in an attempt to control hypotensive

tendency”(135), sufficient replications of our study findings in multiple settings provide external validity to support our initial findings.

### 5.1.2 *Fluid composition and AKI*

Attempts at modifying intravenous fluid composition used for volume resuscitation have not been successful so far. Literature emerging over the last decade attempted to support the use of colloid solutions over crystalloid solutions for volume resuscitation; however, concerns emerged about the association between hydroxyethyl starch and increased propensity for AKI in patients with sepsis (145). Similarly, albumin use failed to confer any survival benefits in controlled clinical trials (142, 143) and may have contributed to increased intracranial pressure in select individuals with brain trauma. Preventing metabolic acidosis with bicarbonate-enriched solutions may have an advantage over uncorrected metabolic acidosis (149, 175). In summary, it appears that the degree of net fluid gained (VRWG) is a stronger predictor of outcomes than the type of fluid administered during the early phase of treatment after admission.

### 5.1.3 *Renal replacement therapy choices – intermittent vs continuous*

The choice between intermittent vs continuous RRT remains a difficult one and published literature to date has not demonstrated the superiority of CRRT (190). Similarly, the recent (2012) reiteration of Surviving Sepsis Campaign did not specifically endorse CRRT over intermittent HD (191). The debate about this clinical conundrum continues among nephrologists, as summarized in our recent review:

“To address hypotension and volume overload in anuric subjects, CRRT is often preferred to intermittent hemodialysis to better control VRWG (190). Historically, the better tolerance of CRRT vs. conventional intermittent HD was attributed exclusively to the prolonged nature of the former enabling more fluid removal over an extended time period (192, 193). Nonetheless, at least clinical experience suggests that the true merit of RRT is not its ability to remove large amounts of fluid but in doing so while provoking less hemodynamic instability. Several mechanisms may contribute to decrease of hypotensive tendency during CRRT (in particular, during veno-venous hemofiltration) to afford net fluid removal (194). Early modalities of continuous therapies without built-in heater circuit likely provoked cooling with subsequent shivering and vasoconstriction, contributing to the improved BP on CRRT. Certainly, in this writer’s clinical experience, it appears that the ability of CRRT to decrease hemodynamic

instability is the primary process by which may improve outcomes. With successful source control, such as removing the source of infectious-inflammatory injury (e.g., abscess drained), we have observed many times gradual improvement of BP after 4-6 hours, enabling the clinicians to start net fluid removal. Nonetheless, individual responses are tremendous and calls for astute clinical re-evaluations in these patients. With regard to expected tolerated fluid removal, it appears the most obvious rule appears to be the lack of such. Accordingly, there is no apparent replacement for an astute clinician's daily assessment and judgement to estimate expected tolerance of fluid removal.”(135)

Time of initiation (195, 196), modality (193, 197), dose (198, 199), intensity and duration of CRRT (197, 200, 201), all of these remain argued in the literature without a clear preference of one over the other. Nonetheless, securing patency of the CRRT circuit remains a critical challenge in the ICU and multiple modalities, including regular heparin anticoagulation, regional citrate anticoagulation or the combination of both may fail in select patients to maintain circuit patency (202, 203). Our standard protocol of regional citrate anticoagulation at the University of Mississippi resulted in an overall mean filter life of ~45 hours and approximately 70% patency rate at 72 hours (unpublished observation of the author of this thesis).

#### 5.1.4 *Assessment of volume overload*

Multiple technologies are emerging to assist clinicians in this setting, including the assessment of inferior vena cava size, bioimpedance (6, 38, 204), the assessment of lung water content by ultrasound (205, 206) and biochemical markers for volume overload, such as elevated brain-type natriuretic peptide (BNP) (38, 207, 208). With regard to B-type natriuretic peptides, pro-atrial natriuretic peptid, BNP and N-terminal-pro-BNP all correlate independently with age, degree of systolic dysfunction and negatively with residual diuresis and 2-year survival, as well (209). Discordant results between BIA and BNP can be explained by capillary leaks during septic shock (210). Limited investigations explored the use of BIA-based vector analysis in assessing the degree of volume overload in ICU patients and potential associations with subsequent outcomes (208). On the other hand, multi-channel, total-body bioimpedance examinations remain severely underutilized and unexplored in critically ill, volume-overloaded ICU patients with AKI (135).

### 5.1.5 *Potential role of peritoneal dialysis in volume overloaded subjects*

One of the enigmas of clinical nephrology is the relatively good success rate of acute peritoneal dialysis (PD), practiced in resource-limited environments, comparing favorably to a much more resource-expensive technology, the slow continuous hemodialysis or hemodiafiltration (211-216). Acute abdominal compartment syndrome is an expected complication of over-aggressive volume resuscitation (174). Most importantly, as we pointed out in our recent review paper (135), the use of a temporary acute PD catheter virtually eliminates the possibility of abdominal compartment syndrome in severely volume-overloaded and critically ill medical ICU patients with acute ascites. In these subjects, the clinical success may be partially disconnected from the “clearance” provided by the acute PD and linked to improved perfusion of visceral organs in volume-overloaded subjects with acute ascites.

### 5.1.6 *Alternatives to serum creatinine to assess renal function; biomarkers in AKI?*

The Translational Research Investigating Biomarker Endpoints in AKI (TRIBE-AKI) Consortium has prospectively examined serial biomarker profiles in 1219 adults and 311 children scheduled for cardiac surgery in nine centers. They found that cystatin-C was superior to serum creatinine and serum creatinine-derived eGFR to predict AKI (217). An alternative strategy is to consider volume overload-adjusted changes in serum creatinine. To control for volume overload driven decrease of serum creatinine, literature has been published to predict the value of volume overload-corrected baseline serum creatinine (132, 133):  $\text{corrected Cr} = \text{baseline Cr} \times \text{correction factor}$  [Correction factor =  $\frac{\text{baseline water space} + \text{accumulated fluid balance}}{\text{baseline water space}}$  (baseline water space:  $\text{weight (kg)} \times 0.6$ )]. However, the practical value of the formula to improve survival predictions is not yet fully defined and understood. Our own results from the ICU cohort of us(167) certainly suggest that dilution of creatinine may have contributed to weakening of the effect of VRWG, but we have not specifically analyzed the data for this possibility. On the other hand, the literature on “biomarkers” of AKI is vast and ever-expanding (218). Our overall concerns with the existing approaches are summarized in our recent review paper, as well:

“Despite more than a decade of unfulfilled promises and spent efforts, we are yet to see a true disruptive technology to replace conventional markers or a seasoned clinicians’ experience.

Taking a prime example, newer biomarkers of AKI are yet to supersede a very imperfect but much simpler biochemical marker, the serum creatinine in clinical utility (219). The added costs of newer biomarkers for AKI are an additional concern, especially in resource-limited settings. The heterogeneity of clinical etiology for AKI is yet another challenge for biomarker-based diagnostic procedures. In many instances, the underlying etiology of AKI is unclear; in contrast, many biomarker-defined prognostic schemes have been derived from a specific disease cohort of patients. Only few studies used dedicated study adjudicators in attempt to develop rigorous, consensus-based clinical definitions to correlate the markers. Complexity is another problem. In a time-pressured busy environment any recommended prediction model has to be either very simple or it needs to be easily available via the healthcare system computer and bioinformatics network. There is also a major internal limitation for renal biomarkers. While most of the biomarker studies are focused on kidney-derived enzymes or products, AKI is in fact a systemic illness in many instances, being only one feature of multiple organ failure syndrome. Accordingly, there is a major conceptual difference between the so called “renal angina” (220, 221) and, for instance, the classic paradigm of myocardial infarction (MI). In MI, the prime cause of abnormality is the necrosis of myocardial tissues; in renal diseases, most commonly, AKI is a functional consequence of a systemic process.” (135)

To further support this viewpoint, in a recent series of limited autopsies by Takasu et al., only a limited degree of renal injury was detected in the examined tissues, markedly disconnected from the profound functional impairment taking place before death (222).

#### 5.1.7 *Oliguria*

In most clinical contexts, decreases in the urine output (oliguria) implies an acute hemodynamic process or an acute component of renal failure. Oliguria is an excellent independent risk factor predicting adverse renal outcomes (186, 223, 224) as it may be a sign of an overall clinical illness, such as an emerging sepsis. Accurate hourly urine output is difficult to obtain but can add to the assessment of these patients (225). Urine output, however, is not the same as creatinine excretion; only hourly monitoring of creatinine excretion would offer a fair chance of “real-time” monitoring of GFR. A major concern about using oliguria as an independent clinical parameter is, according to the author of the present thesis, the lack of adjustment for volume status. Often, fluid is given without a clear assessment of the underlying disease processes or the volume overload already taking place. Excessive volume resuscitation may be counterproductive in tissue hypoxia



with massive volume overload and in those with pulmonary edema and respiratory failure. As we pointed out in our very recent review:

“...the presence of low urine output cannot have the same meaning in an approximately euvoletic subject as opposed to one already markedly volume overloaded (>10 or 20% VRWG). In doing so, the scenario would be somewhat analogous for patients on mechanical ventilator support... [to] interpret an arterial blood gas panel and oxygenation without knowing the partial pressure or percent of O<sub>2</sub> on the inhaled gas.” (135). And “...before being lost in the plethora of various biomarkers or a myriad of derived hemodynamic parameters, clinical nephrologist should consider using and correctly interpreting basic parameters of critically ill patients with renal failure in ICU. Similar to urine output, VRWG should be considered as “renal vital sign,” incorporated into the rounding report and daily consideration of care decisions.” (135).

Indexing the urine output for the degree of volume overload is a completely unexplored area of biomedical research and another low-cost technology to potentially assess disease severity (135).

## **5.2 Time on hemodialysis**

To our knowledge, our publication (169) demonstrated for the first time a positive association between treatment time and albumin levels in chronic hemodialysis patients, with a significantly decreased risk (OR 0.397, 95% CI: 0.235-0.672;  $p < 0.001$ ) of hypoalbuminemia (<40 gm/L) in those dialyzing longer than 4 hours. Unlike time on dialysis, small solute clearance (Kt/V) was not associated with better albumin values in our study. Past studies of better survival with higher albumin levels (226) may have reflected a better-dialyzed state of patients due to longer treatments, better preserved RRF (227) or both. Longer treatment times achieve a better clearance of larger middle-molecular size substances (79) at a price of lesser hemodynamic fluctuations (228, 229). Volume removal and ultrafiltration rate are, nevertheless, closely integrated features with dialysis duration. Longer treatment time allows for slower fluid removal over a more prolonged period and thus, avoids repetitive episodes of intradialytic hypotension (228, 230), decreases hemodynamic fluctuations (228, 229) and may contribute to preservation of RRF (227). Low albumin is a risk factor for early readmission after hospital discharge

among the elderly (231). As most putative uremic toxins diffuse more slowly than urea (232), their removal will be largely a function of time spent on dialysis. Beside the longer treatment time, we also recorded lower UF rates and longer treatment than reported by the DOPPS from the US at that time (168).

Contrary to our expectations, unlike albumin, CRP showed no significant association with treatment time in our network. Nonetheless, our statistical model explained a remarkably little variation of CRP levels ( $R^2 = 0.127$ ) while several factors thought to influence CRP in a similar population without end-stage renal disease (233) did not appear significant in our cohort. While a statistically significant association has been observed between CRP and the choice of catheter for vascular access ( $p=0.002$ ), this was not maintained during stepwise regression. Although the hemodialysis procedure itself is known to potentially increase acute phase reactants levels (234, 235), more prolonged treatments may result in better clearance of larger middle-molecular size substances (79). With regard to congestive cardiomyopathy (OR 1.634, 95% CI: 1.154-2.312;  $p=0.006$ ), there have been reports documenting the association of congestive cardiomyopathy and CRP in non-renal patients (236, 237) and between CRP and volume overloaded state in both pre-dialysis (238) and peritoneal dialysis patients (239). Our study extended this potential association to the hemodialysis population. Anti-hypertensive agent class is known to exert some modest influence on CRP in hypertensive sibships (233), although such relationship is not well explored in ESRD.

In our study, the UF rate did not correlate with either inflammatory marker, which was not what we have expected. Possible explanations for the phenomenon are either a true lack of influence or a balance of competing influences. As most dialysis sessions last very close to the same duration (four hours), the UF rate will become largely a function of IDWG determined by appetite. Healthier patients may be less compliant with salt and water restrictions to accommodate an intact appetite. Accordingly, we speculated that some of the potential long-term harmful effects of increased UFR may be counterbalanced by a better appetite in healthier patients. (169) We also have observed remarkable similar biochemical outcomes (albumin, CRP) between the US and Hungarian arm of the cohort. We believe this observation demonstrates that good outcomes can be reached in disadvantaged and minority populations with attentive medical and dialysis care. (169)

### 5.2.1 *Recent literature of treatment time, survival and BP control*

Among DOPPS participants between 1996 to 2008, dialysis treatment time increases by 30 minutes was associated with a proportionate decline of all-cause mortality of 6% (130). Further, longer treatment times were associated with higher hemoglobin and albumin and lower WBC count and phosphorus concentrations (130). Shorter dialysis time (session length <240) was also shown to be associated with increased mortality in a large database of Fresenius Medical Care North America (aHR: 1.32, 95% CI: 1.03-1.69) (240). In a post hoc analysis of the 150 participants in the Dry-Weight Reduction in Hypertensive Hemodialysis Patients trial (N=150), fewer hours of dialysis treatment was associated with higher systolic BP, increased need for BP medications and a longer time to achieve a lower BP target (241). Similarly to past studies, in a subsequent study we demonstrated that post-dialytic (post-ultrafiltration) BPs had a better association with 48-hour BP burden during ABPM than predialysis BP (30). Additionally, we also demonstrated that by incorporating both pre- and post-dialysis BP values into linear regression modeling, pre-dialysis systolic BP readings lost significance entirely to predict ABPM-derived systolic BP (30). With the usual practice of three-times-a-week renal dialysis, BP variability is at the peak on the first dialysis of the week, when excess volume is likely to be the largest (126). Further, elevated systolic BP variability (defined as SBP variability above the medium) was associated with increased all-cause mortality (HR 1.51, 95% CI: 1.30-1.76;  $p < 0.001$ ) and cardiovascular mortality (HR 1.32, 95% CI, 1.01-1.71;  $p = 0.04$ ) in a cohort of 6393 prevalent adult HD patients (124). Paradoxical increases of blood pressure during treatments are associated with poor subjective symptoms and are indicative of increased future hospitalization rates, adverse cardiovascular outcomes and a rise of all-cause mortality (242, 243). The lowering of dialysis temperature may be poorly tolerated by patients, but leads to vasoconstriction and a relative rise of BP. Lowered counter-current temperature is associated with improved hemodynamic stability (244) and reduced white matter lesions in the brain (245). Clinical assessment can be incorrect in about 25-40% of patients to identify euvolemia correctly, at least in terms of overall body salt-water content (246). BIA-based assessment leads to less fluid overload (58) and improved left ventricular hypertrophy (53); further, prospective BIA-monitored EDW adjustments may be associated with decreased mortality in ESRD (58), though contrary evidence exists as well.

### 5.2.2 *Recent literature on interdialytic weight gain*

Greater IDWG has been linked to increased adverse outcomes in multiple studies since (46, 240, 247). In a study by Kalenter-Zadeh et al. in an analysis adjusted for demographics and markers of inflammation, a graded relationship was observed with IDWG: increased risk of CV death for  $\geq 4$  kg (aHR 1.25, 95% CI: 1.12-1.39) and decreased risk for  $< 1$  kg (aHR 0.67, 95% CI: 0.58-0.76), when compared to the reference group of 1.5-2 kg (46). A study by Flythe et al., from a cohort of over 14,000 prevalent HD patients, noted a 29% increase of mortality risk associated with higher ( $> 3$  kg) IDWG relative to lower ( $\leq 3$  kg) IDWG (240). At the same time, the authors also demonstrated that session length of  $< 240$  minutes had a similar negative impact on survival (aHR 1.32, 95% CI: 1.03-1.69). And, finally, a chronically volume-expanded state with missing EDW by  $> 2$  kg and  $> 30\%$  of the time was also associated with adverse CV and all-cause mortality (aHR 1.28, 95% CI: 1.15-1.43) (40). Similarly to the above, Cabrera et al., observed a stronger impact in terms of the relative change of weight; specifically, relative weight gain of  $> 3.5\%$  body weight was independently associated with multiple CV outcomes (CV mortality, myocardial infarction and heart failure) (248). Among other parameters, shorter treatment times with higher hourly UF rates may impact sudden cardiac death rates adversely (249). Some of the published literature debate the independent value of UF rate or volume when adjusting for the presence of volume-overloaded state at the beginning of renal dialysis (60). Dialysate sodium itself exerts an influence on both IDWG and BP control in ESRD. The most recent DOPPS data between phases 2 and 5 (2002 - 2014) indicated a modest decline of IDWG world-wide, probably mediated by a trend to use lower sodium concentrations and the avoidance of sodium-profiling during RRTs (250). For each 1 mEq/L rise of the dialysate sodium concentration, there was an associated rise of 0.13 kg (95% CI: 0.11-0.16) of IDWG. Among the participating regions, drops in IDWG were most evident in North America and Europe. Once again, mortality rate was higher for relative IDWG  $> 5.7\%$  (aHR: 1.23; 95% CI: 1.08-1.40) compared to the reference category of 2.5 - 3.99% weigh gain (250).

### 5.2.3 *Dialysis nonadherence*

Historically, restrictions on sodium and water have been advocated to curb IDWG. They are, however, conceptually not equivalent. A weight gain of free water would be

distributed through the entire water space (albeit at the price of decreasing serum sodium); on the other hand, the intake of salt would stimulate thirst and make the drive of fluid intake very hard to avoid (251). The resultant expansion would be effectively limited to the extracellular water space. All dialysis units should carefully consider the local cultural microenvironment to identify causes and patterns of nonadherence and barriers of effective healthcare delivery. Recent data from the Fresenius North America database (2005-2009) detected higher rates of treatment nonadherence among young and non-white subjects, with transportation issues, poor weather conditions, holidays, and non-renal illnesses identified as the underlying reasons (252). Missed treatments were associated with increased risk of ED visits, hospitalization and ICU admissions (252). In another study, non-white patients race and larger dialysis unit size was associated with increased nonadherence (missed and shortened treatments) and further confirmed large geographic variations across the US (253). Race and trust in the health care system may be an additional confounding factor impacting compliance (47, 119). In the U.S., African Americans known to have disproportionate trust towards providers from the same ethnic and cultural background, including physicians (254-256). Urban centers serving minority populations are known to miss various performance targets in general and have higher-than-expected mortality rates (257). As mentioned earlier, our own experiences from the Southeast US documented also remarkable nonadherence: in one cohort from Northern Louisiana 85.9% of patients shortened at least one HD session, and 29% did not attend at least one HD session per month (123). Quality improvement data from the UMMC Jackson Medical Mall Dialysis Unit (>85% of the patients were African American) have shown a similar magnitude of appointment nonadherence: 78.5% of the patients shortened treatment by at least 10 minutes and 31.2% missed at least one HD treatment during the index month (personal communication from Melissa Hubbard, R.D., UMMC Nephrology Unit; October 2009). This latter unit is in the center of the city of Jackson, Mississippi, and is well served by the public transportation system. One very little studied concept is the potential impact of overall climatic conditions on IDWG. The impact of sweating itself is likely to be minimal on IDWG and, in temperate climate at least, environmental conditions presumed not meaningfully impact the net result of session-session variations of fluid intake, sweating and residual urine output (24). Sweat has a relatively little sodium content in healthy subjects, when compared to other body fluids (258). On the

other hand, in a relatively small (N=100) cohort of Hungarian patients we have shown that hot-dry climatic condition resulted in the least weight gain, a difference which was statistically significant, when compared to warm-dry conditions (24).

#### 5.2.4 *Shortcomings of Kt/V based dialysis clearance*

Body surface area-based adjustment may be a more reliable expression of dialysis dosing than the classical approach which utilizes total body water (5). Examining a prevalent cohort of 7229 patients undergoing thrice-weekly hemodialysis Ramirez and coworkers (5) found that there was no associated survival benefit associated with a single-pool Kt/V >1.7, but the hazard ratio for mortality was progressively lower with higher Kt/Vs if the Kt/V was normalized for the body surface area. Thus, body surface area-based dialysis dose results in dose-mortality relationships are substantially different from those with volume-based dosing. This observation may be particularly relevant to women, who received proportionally smaller dialysis doses, when BSA was considered.

#### 5.2.5 *Overnight modalities – the future?*

In the future, expanding options of overnight dialysis may well address the time constraints of conventional dialysis and potential shortage of care staff. In one study obtained from the Fresenius North America database, comparing subjects with propensity-matched controls, overnight dialysis resulted in better clearances, improved control of biochemical parameters and an approximately one-fourth reduction of death for over a two-year period (HR 0.75, 95% CI: 0.61-0.91; p <0.004) (259). Enrollee retention was a major issue: in the latter study, after 2 years only 42% of the patients were adherent to the modality. Additionally, further investigation of the Frequent Hemodialysis Network Nocturnal Trial participants showed a yet unexplored paradoxical increase of mortality during the post-trial follow-up period (3.7 years): 3.88 (95% CI, 1.27-11.79; p=0.01) (260). Our own anecdotal experience with the University of Mississippi Nocturnal Shift (n=9) demonstrated good biochemical and BP control, along with excellent Kt/V values for this small cohort of very large or multiple co-morbid chronically ill subjects (unpublished observation of the author of the present thesis).

### 5.2.6 *The paradigm of pregnancy*

Pregnancy perhaps represents the ultimate model to define what the difference is between “minimum necessary” and an “optimal” dose of renal dialysis. It has been a time-honored observation by now that pregnant patients need more frequent or much longer sessions of renal dialysis, ultimately translating into a longer weekly total time on dialysis. Unlike in the past, when fetal survival was very rare, the more recent era is witnessing a marked improvement in successful pregnancy rate. One recent study has compared pregnancy success rates between the US and Canada, with a notable difference between practice patterns between the two countries. While in the US, the usual practice pattern dictated a daily dialysis of about 4 hours 6 days a week after the first trimester, in Canada, practitioners prescribe HD for 6-8 hours, 6-7 days per week as soon as pregnancy is recognized in a dialysis patients. This registry-based comparison observed a much higher successful live birth rate in Canada relative to that of the United States (86.4% vs 61.4%;  $p=0.03$ ) (261). Further review of the Canadian nocturnal program also suggests a graded dose-relationship between weekly hours of hemodialysis with live births, improving from 48% in women receiving <20 hours of therapy to 85% in those receiving  $\geq 37$  hours (261). Intensified therapy also decreased the number and severity of neonatal and maternal complications (261).

### **5.3 Transitioning between acute and chronic renal replacement therapy: the importance of access choice**

In our series entailing both inpatients (114, 170) and outpatients (170, 171), we have documented an excellent safety profile for bedside TDC removals, presumably contributing to the timely care of these patients. Vascular access catheter utilization remains a profound and escalating problem in the U.S., with >80% patients with no pre-ESRD nephrology care starting RRT with these devices (144), including those seeing a nephrologist in the preceding year (~40%). This situation has visibly worsened since the mid-nineties, when less than 20% of new hemodialysis patients utilized TDCs 60 days after the initiation of renal dialysis (262). It is ironic that the well-intentioned mandate of “Fistula First” initiative led to an escalated utilization of vascular access catheters (263) and replaced AV grafts with a much more morbid technology of TDCs, bringing about

the attendant risk of infection and death (99, 106, 114, 264) Access type (non-AV fistula) and elevated CRP are both risk factors for future infection and both are independently associated with increased infection-related hospitalization, along with other markers of fragility (old age >85, nursing home residence, poor mobility and chronic medical illnesses) (265). The lack of adequate pre-dialysis nephrology care is associated both with higher catheter utilization and mortality within one year after the start of dialysis, observed both in Canada (266) and the US (267). Long-term vascular access catheter use is associated with increased mortality (99, 101, 102) and every attempt should be made to minimize the duration of catheter-dependence. Alternative options to avoid temporary access should be considered, including acute start peritoneal dialysis (268, 269) or the initiation of deferred hemodialysis until chronic AV access have matured.

### 5.3.1 *Peritoneal dialysis*

Alternatively, peritoneal dialysis (PD) remains a viable option for effective renal replacement therapy and alleviate the need for indwelling vascular access catheters. PD remains a somewhat enigmatic modality which works clinically well despite the limited small solute clearance it provides. PD is cost-effective (23), avoids the need for temporary vascular access placement and may in fact have a survival advantage over hemodialysis (270), especially during first two or three years of RRT (271). Historically, the “slow but steady” nature of PD has been cited most often as the reason for its clinical efficacy. However, uremic toxins are generated disproportionately in various body compartments. While some tissues (muscles) are more active than others (fat tissue) to generate uremic toxins, in effect the largest generating compartment is the interface of human-bacteria in the gastrointestinal tract. In this regard, it would be perhaps most appropriate to view PD as a “compartment dialysis” (272), a modality delivering a disproportionately large clearance to the gastrointestinal tract, the very compartment generating most uremic toxins. It can be offered upon transition from renal transplantation to maintenance dialysis, a particularly vulnerable period to excess mortality (273). Survival advantages are also likely linked with the better preservation of residual renal function, improved hemodynamic stability, decreased need for human recombinant erythropoietin administration and a lesser risk of acquiring blood borne infections in PD (274-278). Nonetheless, with the exception of Hong Kong and Australia, PD remains severely underutilized all over the world. Obesity, commonly perceived as a



relative contraindication to PD is by itself not a limiting issue and most studies have reported a survival advantage of doing PD in obese patients (274, 279-281). Further, a recent systemic review and meta-analysis of more than 150,000 subjects also confirmed at least a neutrality of large body mass index (BMI) on survival (282). Fat tissue does not participate in urea distribution volume (water space) and relatively inert in terms of production of uremic toxins. Obesity and high BMI, however, do not always equal an excess of total body water space and therefore the feasibility of PD in large subjects without excess fat tissue is a different issue. In a single-center small cohort, we have documented relative success of PD in large subjects weighing  $>100$  kg (Kt/V:  $1.96 \pm 0.29$  vs.  $2.22 \pm 0.47$  in those weighing  $\leq 75$  kg) (283).

### **5.3.2 *Impact of access choice on morbidity and mortality***

Access-related infection is the single largest reason for admission in ESRD patients and a major cause of or contributor to mortality. The impact of access-related infection is probably under-appreciated in hemodialysis patients for the single reason that the definition is hinging on obtaining blood culture and clinical astuteness to seek infection in the background of confusing clinical presentations. It is critical to recognize infected TDCs and blood cultures should be obtained at a low clinical threshold of suspicion, preferably during dialysis (284, 285). This is highly important as uremia even under treatment and without blood stream access devices confirms an increased risk of bacteremia and fungemia (286). Our inpatient cohort was relatively ill with generally high CRP values. Herewith, the measurement of CRP was unlikely to contribute further to the clinical decision-making.

### **5.3.3 *Timely removal of vascular access devices***

An inordinate amount of clinical presentations may be ultimately attributed to access-related infections and patients with indwelling vascular access are at a particulate risk (287). *S. aureus* is a particularly common pathogen (288). Biofilms on the catheter may represent a sanctuary shielding bacteremia from the therapeutic level of antibiotics, making eradication difficult (103). An emerging treatment trend to address the issue of biofilm is the intraluminal antibiotic-enriched catheter “lock” solution which, in addition to systemic antibiotics (289), is cutting the need for catheter removals and recurrent bacteremia in half (289). Whether this strategy results in selecting out resistant bacteria

remains debated (289, 290). While some advocate guidewire-assisted catheter exchange (rather than utilizing a new puncture site), such approach is inevitably challenged by a higher rate of recurrence of infection. Low albumin, anemia or elevated CRP are known risk factors associated with adverse outcomes during TDC exchange (291, 292). As we summarized in our review paper on TDC removals:

“In our opinion, removal of TDC in the setting of endovascular infection and critical illness is an emergency and mandates immediate action (114, 293). Unlike renal dialysis catheter placement, it is not meaningful to entertain “simulation” training for TDC removal, *in lieu* of real-life, hands-on experience at bedside (294). Furthermore, unless a clear alternative source (e.g., pneumonia, infected decubitus ulcer) is present on presentation, it may be prudent to remove TDCs empirically in hemodynamically unstable patients, while awaiting the blood culture results (114).”(172) ... and: “Many of these patients presents with relatively non-specific or perplexing symptoms (e.g., chest pains, shortness of breath or only mild fever) (114, 273) and infection of TDC should be disproportionally high on the differential. Forming the appropriate clinical decision to remove the infected hardware is important part of clinical training. In addition to elevated white blood cell count, otherwise poorly explained rise of troponin-I (114) or CRP (169, 295) may provide useful clues early into the evaluation process.”(172)

#### **5.3.4 Complications during Tunneled Dialysis Catheter removal**

Bleedings, including major local bleedings do not appear to be a major concern during TDC removals. In a very recent paper by Dossabhoy et al., aspirin or clopidogrel therapy in roughly two-third of the cohort did not seem to increase bleeding risk (1/49 or 2% of the subjects with minor bleeding on these medications) (171). Another study conducted by Martinez et al. also found that anti-platelet therapy or anticoagulation was not associated with an increased risk of bleeding either (296). Checking of coagulation profile such as prothrombin time international normalized ratio (INR) can be generally reserved for patients on vitamin-K antagonist therapy or for those overtly ill and assumed to have consumptive coagulopathy. Only anecdotal experience exists with prolonged INR up until 3 (170, 171) and most of us would favor normalizing INR before catheter removal. Failed removal was generally rare in our experience; e.g., in the personal practice of the author of the present thesis (>400 removal over 15 years) this has happened in less than 1% of the cases. Based on our publications, it is probably expected to occur

no more than 1/50 – 1/200 (172). During graduate medical education training, hands-on assistance was needed from our faculty at a rate 6-10/100 (personal communications from Neville Dossabhoy, M.D., Shreveport, LA and Mihály Tapolyai, M.D., Budapest, Hungary). In our experience, it took approximately 5-8 supervised procedures for our first-year renal trainees to master the "learning curve" for the procedure and assimilate the skill to competency (172). In our own series, including the one by Dossabhoy et al., we have not encountered catheter body tears. On the other hand, single-lumen twin dialysis catheters (i.e., Tesio, MedComp) are reported to fracture very easily and are not suitable for traction removal (297, 298). Published literature has stated that immediate clamp compression of the proximal catheter fragment is to be executed to prevent air embolism or bleeding for these (297). Subcutaneous tunnels do collapse smoothly with external compression and hemostasis after removal and do not offer routes for air embolisms.

Retained cuffs do not seem to represent a problem. Surgical removal has been routinely offered for the affected patients but all patients deferred. We have not encountered subsequent local infections caused by the retained hardware. As we stated in our review paper:

"It appears these structures can be left in place, a scenario analogous to the clotted synthetic hemodialysis grafts (297). Alternatively, the retained cuffs can be removed later on, both for cause (e.g., migration) or aesthetic reasons via a direct skin excision above it (297). One unusual complication for retained cuffs is the potential misinterpretation as a mass on mammogram (299). Similar to our results, the published literature appears to quote a rate  $\leq 8\%$  of cuff retention (0-10 %) (126, 297). Additionally, cuff retention may be dependent on the catheter material, much less with polyurethane-based materials (297). In our inpatient series, we also have documented a 0% cuff retention rate (114), but many of those catheters were removed in clinically ill hospitalized patients for suspected or proven infections, had breakdown around the exit site, etc., thus making cuff retention less likely to occur."(172)

A separate issue is the embedded catheter proximal to the entry point in the internal jugular vein (300). As we summarized in our review paper:

"If catheter adherence to central veins or right atrium (301) is suspected, the bedside procedure should be aborted and care should be escalated with fluoroscopic guidance and surgical or interventional radiology consultation. Accordingly, it is a key for the operators to recognize the difficult to remove or ("stuck" or "embedded") catheter. A very large single-center database

spanning nearly a decade suggested this complication in about 1% of long-term dialysis catheters (302). Risk factors for catheter retention include cumulative indwelling time, female gender, small vessel caliber, past episodes of infection creating a prothrombotic state and repeated catheterizations in the same vessel (303). This situation also appears to occur more commonly with catheters implanted into the left internal jugular vein; likely due to the presence of more potential friction points associated with the longer catheters, as well as in those with ipsilateral intracardiac device wires or stents (304) [...] Accordingly, retained catheters fixated to the surrounding structures beyond the Dacron cuff may represent a distinct challenge and require endoluminal dilatation (305, 306), transcatheter extractor device (307) or laser sheath liberation (308), depending on institutional experience and are otherwise well summarized in recent reviews (170, 300).”(172)

## **5.4 Emerging concepts and future directions**

### **5.4.1 *Optimized start for renal replacement therapy***

Multiple studies argue against a preventive or “early” start of renal dialysis (309-311). In fact, in one of the studies, elderly subjects with early dialysis initiation were associated with greater all-cause mortality, cardiovascular mortality and all-cause hospitalizations (311). Rather, as stated by the National Kidney Foundation (NKF)-KDOQI Hemodialysis Adequacy Work Group, initiation maintenance dialysis therapy should be based on the presence of symptomatic uremia, protein energy wasting, metabolic abnormalities, or volume overload “rather than a specific level of kidney function” (312).

### **5.4.2 *Convective clearance.***

Current studies supporting the value of on-line hemodiafiltration represent almost all *post-hoc* analyses (313, 314), but one study (315), with variation of cut-offs representing “sufficient” or “ideal” convective clearance (i.e., the hemofiltration component of RRT): >22 L (313), >17.4 L (314) or >18 L (315) per session. A recent meta-analysis of 35 trials and more than 4000 patients suggested a lower cardiovascular (RR 0.75, 95% CI: 0.58-0.97), albeit not all-cause mortality (RR 0.87, 95% CI: 0.70-1.07) with HDF (316). Perhaps not unrelated, intra-dialytic hypotension was also reduced with HDF (RR 0.72, 95% CI: 0.66-0.80). None of these studies have been adjusted for the

body surface or calculated water space, when calculating the presumed survival effect of an achieved HF rate. Further, cost-effectiveness studies suggested quality-adjusted life year a cost of HDF vs. HD approximately €287,679 (or approximately 300,000 USD in June 2016), above the usually acceptable societal threshold (317). When HD and HDF were compared at different treatment times in a small, single-center trial (2x2 factorial design, HD vs HDF, 4-hour vs 8-hour treatment times), treatment times, but not modality conferred greater hemodynamic stability (9).

#### ***5.4.3 Frequency is not replacing effective time in renal replacement therapy***

Concerns exist with regard to the “stand-alone” frequent dialysis, that is more frequent dialysis (>three times a week) without meaningfully extending the weekly time spent on renal replacement (318). Commitment of time to travel, logistics of more frequent patients’ check-in and check-out procedures, increased utilization of medical supplies and increased access complications are additional concerns (319-321). In the pivotal Frequent Hemodialysis Network daily trial a statistically significant increase of “first access events” (repair, loss, and access-related hospitalizations) was observed among frequent dialysis enrollees, compared with a conventional HD group (HR 1.76, 95% CI: 1.11-2.79; p=0.02). To date, no prospective, randomized controlled trials of sufficient power are in existence to report on hard clinical outcomes. On the other hand, home dialysis remains a good choice to optimize weekly time on dialysis. Newer and simpler technologies (e.g., NxStage Home System, NxStage Medical Inc., Lawrence, MA, USA) have simplified the logistics of home dialysis and reduced the time-commitment for preparations. While most of the existing studies are likely to be contaminated by residual confounders, they all suggest survival advantage with more frequent standard 3-4-hour sessions (322, 323) or more prolonged (e.g., nocturnal) sessions of RRT.

#### ***5.4.4 Gradual escalation of treatment time***

According to current DOPPS data, roughly one-quarter of patients in China receive maintenance dialysis only twice a week (26% vs 5%, for the rest of the DOPPS regions) (324). Well-preserved RRF may enable such approach in subjects with well-preserved functional status and less comorbidity. On the other hand, less frequent and incrementally increased hemodialysis may preserve RRF longer (325). In a recent, single-

center Chinese study, independent predictors of RRF loss were thrice-weekly dialyses, larger urea reduction ratios and the presence of intradialytic hypotension (326).

#### ***5.4.5 Ensuring the lack of constipation and accelerating gastrointestinal transit time.***

Uremic toxins are generated disproportionately in various body compartments. While some tissues (muscles) are more active in that regard than others (fat tissue), the largest generating compartment is in fact the interface of human-bacteria in the GI tract. In this regard, it would be perhaps most appropriate to view PD as a “compartment dialysis” (272), a modality delivering disproportionately large clearance to the gut and liver, the very compartments generating most uremic toxins. Conceptually, this may be the largest contributor to the anti-uremic effect of PD, to explain the somewhat disconnected effectivity from removals of uremia markers, such as creatinine and blood urea nitrogen (BUN). While oral binders of uremic toxins failed to impact renal survival, the much simpler clinical question of frequent/loose bowel movements are in fact not studied in ESRD, including in anuric ESRD patients. Therefore, the scenario is somewhat analogous to end-stage liver disease: to reduce the generation and absorption of uremic toxins by inducing a mild state of diarrhea by laxatives. In a small, single-center trial (N=20), dietary fiber supplements lowered the level of non-dialyzable colon-derived uremic toxin (indoxyl sulfate and p-cresol sulfate) concentrations, presumably by binding in the GI tract (327). Similarly, pre- and probiotic supplements may also have the potential to lower effective uremic toxin generation and absorption (328).

## 6. Conclusions

In a single-center trial of eighty-one subjects, we found that fluid overload was common (46.9% had VRWG  $\geq 10\%$ ) and an important prognostic factor for survival in critically ill AKI patients treated with CRRT. Increasing VRWG had a graded adverse impact on 30-day survival, with mortality increasing by two and half times in those with VRWG  $\geq 10\%$  (OR 2.62, 95% CI: 1.07-6.44;  $p=0.046$ ) and almost four times with VRWG  $\geq 20\%$  (OR 3.98, 95% CI: 1.01-15.75;  $p=0.067$ ) in univariate analysis. Oliguria was also a strong predictor of death, with OR for mortality 3.22 (95% CI: 1.23-8.45;  $p=0.02$ ). Both oliguria (OR 3.04,  $p=0.032$ ) and VRWG  $\geq 10\%$  (OR 2.71,  $p=0.040$ ) maintained their statistically significant association with mortality in multivariate models that included sepsis and/or Apache II scoring. Therefore, among the first in adult medicine, we established fluid overload before CRRT to be an important prognostic factor for survival in critically ill patients with AKI. Further studies are needed to elicit mechanisms and develop effective preventive and therapeutic interventions for this very vulnerable group of patients.

We found that treatment time during conventional in-center HD had a significant cross-sectional association with serum albumin but not with CRP. In our study of  $>600$  participants, treatment time longer than four hours was associated with a decreased risk of having low ( $< 40$  gm/L) albumin levels with OR of 0.397 (95% CI: 0.235-0.672;  $p<0.001$ ). For elevated CRP, significant correlates were congestive heart failure (OR 1.634, 95% CI: 1.154-2.312;  $p=0.006$ ) and acute infection (OR 1.799, 95% CI: 1.059-3.056;  $p=0.03$ ). However, we have not observed an association between UFR and either CRP or albumin. To our knowledge, this constituted the first report demonstrating an association between treatment time and albumin levels in hemodialysis patients. A large number of our patients, both from the European and North American cohorts achieved serum albumin and CRP targets, albeit with relatively long treatment times ( $237.3 \pm 23.8$  minutes; approximately 16 minutes longer than the US average at that time). This study underlines and confirms the critical importance of time in good uremic control.

We have documented an excellent efficacy (100% success rate) and good safety profile during bedside removals of TDC from a combined cohort of two studies and 192 subjects. About one-third of the TDC removals took place urgently due to bacteremia,

and elevated troponin-I had statistically significant associations with catheter-induced bacteremia in inpatients ( $p < 0.05$ ). Most ( $>50\%$ ) of the outpatient removals took place due to access maturation or cessation of indication for renal dialysis ( $p < 0.0001$ ). During outpatient removals, we observed subcutaneous retainer cuff separation in 6.5% of cases, all in males. There was a significant association between cuff retention and outpatient removal ( $p = 0.007$ ) but not with the operators' level of training, or the site of removal. However, we have not observed catheter body tear or frank complications (major vascular damage or air embolism). To our knowledge, these results constituted the first reports demonstrating the feasibility and excellent success rate for bedside removal of tunneled-cuffed permanent hemodialysis catheters by nephrologists. Our results underscore the potential for this procedure to enrich clinical nephrology training and contribute to the clinical competency of practicing nephrologists.



## 7. Summary

Medicine is an ever-changing science. Not only our knowledge is changing but also the characteristics of the underlying populations. New methods and technology offer not only new avenues to address illnesses but new sources of morbidity and mortality as well. Volume overload is an emerging marker for the severity of illnesses in critically ill patients and a persisting problem in chronic dialysis patients. In critically ill patients with acute renal impairment, volume overload may partially mask the elevation of serum creatinine and appears to be contributing to adverse outcomes independently. Accordingly, volume-related weight gain should be viewed as a prognostic marker on its own during the daily evaluation of these patients and conventional indication of renal replacement therapy (RRT) may not apply in critically ill patients. In dialysis patients, clinical focus is shifting away from a purely biochemical and blood pressure-centered viewpoint to a much more patient-centered one, emphasizing effective volume control, reducing excess fluid gains and promoting hemodialytic stability during RRT. Time on renal replacement therapy is of paramount importance to deliver effective RRT and should not be compromised on the patients' and providers' convenience. Reduced treatment time of less than 4 hours three times a week is associated with likelihood of low albumin. Despite recommendations formed by professional societies, hemodialysis catheter use is still highly prevalent in end-stage renal disease patients and an ongoing source of morbidity and mortality. Every effort should be made to minimize the use and duration of indwelling artificial vascular access devices, including timely removal during catheter sepsis or after access maturation. Bedside removal of tunneled-cuffed hemodialysis catheters is a safe procedure with minimal complication rate, including during graduate medical education by nephrology trainees. New technologies and approaches need to be fostered to optimize the delivery of renal replacement therapy and to address emerging challenges.

## 8. Összefoglalás

Az orvostudomány folyamatosan változik. Nem csupán ismereteink bővülnek, hanem a vizsgált emberi populációk sajátosságai is változnak. Új módszerek és technológiák mindamelllett, hogy a gyógyításnak újabb perspektíváit nyitják meg, komplikációk és halálozások újabb forrásait is jelenthetik. A folyadék-túlterhelés mértéke - mely egy gyakori probléma a krónikus vesepótló terápiára szoruló betegeknél - egy viszonylag újonnan felismert jele lehet az általános állapot súlyosságának az intenzív osztályos kezelés során. Ezen betegeknél az akut vesekárosodás mellett, a folyadékterhelés mértéke részben elfedheti a szérum kreatinin emelkedését, és önmagában is hozzájárulhat a szövődmények kialakulásához. Ennek megfelelően a folyadékmennyiséggel összefüggő súlynövekedésnek kiemelt prognosztikai fontosságot kell tulajdonítani e betegek napi kiértékelése során, ahol a vesepótló terápia (VPT) hagyományos indikációi sem feltétlenül alkalmazhatóak. A krónikusan művese kezelésben részesülő betegeknél a tisztán biokémiai és vérnyomás-értékre koncentrált megközelítés egyre inkább átadja a helyét egy sokkal beteg centrikusabb megközelítésnek, amely a hatékony folyadékmennyiség-kontrollt hangsúlyozza, minimalizálva a felesleges folyadékbevitelt a kezelések között és hangsúlyozza a hemodinamikai stabilitás fontosságát a kezelések alatt. A VPT időtartama kritikus fontossággal bír a kezelés hatékonyságának szempontjából, így nem megengedhető, hogy csupán kényelmi szempontok alapján ezt csökkentjük. A heti háromszor kezelt művese betegek esetében, a négy óránál rövidebb ideig tartó kezelések az albumin szint csökkenésével járnak. A szakmai testületek által javasolt gyakorlat ellenére a hemodialízis katéter használata változatlanul rendkívül gyakori a dialízissel kezelt betegeknél, jóllehet a komplikációk és halálozás esélyét megnöveli. Mindent meg kell tenni hemodialízis kanülök használatának a minimalizálására, illetve fertőzés vagy fisztula beérés esetén amilyen hamar csak lehet, eltávolításukra. Az alagutas hemodialízis katéterek betegágy melletti eltávolítása minimális komplikációval terhelt orvosi beavatkozás, amely biztonságosan elvégezhető nefrológus szakorvos jelöltek által is a szakképzés során. Új technológiák és módszerek sikeres beépítése szükséges, hogy optimalizáljuk a meglévő VPT hatékonyságát, és sikerrel nézzünk szembe a reánk váró új kihívásokkal.

## 9. References

1. Sharif MU, Elsayed ME, Stack AG. (2016) The global nephrology workforce: emerging threats and potential solutions! *Clin Kidney J*, 9: 11-22.
2. Berns JS, Ellison DH, Linas SL, Rosner MH. (2014) Training the next generation's nephrology workforce. *Clin J Am Soc Nephrol*, 9: 1639-1644.
3. Scribner BH, Buri R, Caner JE, Hegstrom R, Burnell JM. (1960) The treatment of chronic uremia by means of intermittent hemodialysis: a preliminary report. *Trans Am Soc Artif Intern Organs*, 6: 114-122.
4. Mc Causland FR, Brunelli SM, Waikar SS. (2013) Dialysis dose and intradialytic hypotension: results from the HEMO study. *Am J Nephrol*, 38: 388-396.
5. Ramirez SP, Kapke A, Port FK, Wolfe RA, Saran R, Pearson J, Hirth RA, Messana JM, Daugirdas JT. (2012) Dialysis dose scaled to body surface area and size-adjusted, sex-specific patient mortality. *Clin J Am Soc Nephrol*, 7: 1977-1987.
6. Tapolyai M, Faludi M, Reti V, Lengvarszky Z, Szarvas T, Berta K. (2011) Dialysis patients' fluid overload, antihypertensive medications, and obesity. *ASAIO J*, 57: 511-515.
7. Vanholder R, Smet RD, Glorieux G, Dhondt A. (2003) Survival of hemodialysis patients and uremic toxin removal. *Artif Organs*, 27: 218-223.
8. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W, European Uremic Toxin Work Group. (2003) Review on uremic toxins: classification, concentration, and interindividual variability. *Kidney Int*, 63: 1934-1943.
9. Cornelis T, van der Sande FM, Eloot S, Cardinaels E, Bekers O, Damoiseaux J, Leunissen KM, Kooman JP. (2014) Acute hemodynamic response and uremic toxin removal in conventional and extended hemodialysis and hemodiafiltration: a randomized crossover study. *Am J Kidney Dis*, 64: 247-256.
10. Eloot S, Vanholder R, Dequidt C, Van Biesen W. (2015) Removal of different classes of uremic toxins in APD vs CAPD: a randomized cross-over study. *Perit Dial Int*, 35: 436-442.

11. Hai X, Landeras V, Dobre MA, DeOreo P, Meyer TW, Hostetter TH. (2015) Mechanism of prominent trimethylamine oxide (TMAO) accumulation in hemodialysis patients. *PLoS One*, 10: e0143731.
12. Shafi T, Meyer TW, Hostetter TH, Melamed ML, Parekh RS, Hwang S, Banerjee T, Coresh J, Powe NR. (2015) Free levels of selected organic solutes and cardiovascular morbidity and mortality in hemodialysis patients: results from the retained organic solutes and clinical outcomes (ROSCO) investigators. *PLoS One*, 10: e0126048.
13. Zsom L, Zsom M, Fulop T, Flessner MF. (2008) Treatment time, chronic inflammation, and hemodynamic stability: the overlooked parameters in hemodialysis quantification. *Semin Dial*, 21: 395-400.
14. Lehrich RW, Middleton JP. (2016) NephSAP: End-Stage Renal Disease and Dialysis, 15: 413-419.
15. Rahman M, Griffin V, Kumar A, Manzoor F, Wright JT, Jr., Smith MC. (2002) A comparison of standardized versus "usual" blood pressure measurements in hemodialysis patients. *Am J Kidney Dis*, 39: 1226-1230.
16. Georgianos PI, Agarwal R. (2017) Blood pressure and mortality in long-term hemodialysis-time to move forward. *Am J Hypertens*, 30: 211-222.
17. O'Hare A, Johansen K. (2001) Lower-extremity peripheral arterial disease among patients with end-stage renal disease. *J Am Soc Nephrol*, 12: 2838-2847.
18. O'Hare AM, Glidden DV, Fox CS, Hsu CY. (2004) High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999-2000. *Circulation*, 109: 320-323.
19. Rajagopalan S, DelleGrottaglie S, Furniss AL, Gillespie BW, Satayathum S, Lameire N, Saito A, Akiba T, Jadoul M, Ginsberg N, Keen M, Port FK, Mukherjee D, Saran R. (2006) Peripheral arterial disease in patients with end-stage renal disease: observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Circulation*, 114: 1914-1922.
20. McKay DW, Campbell NR, Parab LS, Chockalingam A, Fodor JG. (1990) Clinical assessment of blood pressure. *J Hum Hypertens*, 4: 639-645.

21. Mitra S, Chandna SM, Farrington K. (1999) What is hypertension in chronic haemodialysis? The role of interdialytic blood pressure monitoring. *Nephrol Dial Transplant*, 14: 2915-2921.
22. Raimann JG, Usvyat LA, Thijssen S, Kotanko P, Rogus J, Lacson E, Jr., Levin NW. (2012) Blood pressure stability in hemodialysis patients confers a survival advantage: results from a large retrospective cohort study. *Kidney Int*, 81: 548-558.
23. Usvyat LA, Carter M, Thijssen S, Kooman JP, van der Sande FM, Zabetakis P, Balter P, Levin NW, Kotanko P. (2012) Seasonal variations in mortality, clinical, and laboratory parameters in hemodialysis patients: a 5-year cohort study. *Clin J Am Soc Nephrol*, 7: 108-115.
24. Tapolyai MB, Faludi M, Berta K, Szarvas T, Lengvarszky Z, Molnar MZ, Dossabhoy NR, Fulop T. (2016) The effect of ambient temperature and humidity on interdialytic weight gains in end-stage renal disease patients on maintenance hemodialysis. *Int Urol Nephrol*, 48: 1171-1176.
25. Agarwal R, Peixoto AJ, Santos SF, Zoccali C. (2006) Pre- and postdialysis blood pressures are imprecise estimates of interdialytic ambulatory blood pressure. *Clin J Am Soc Nephrol*, 1: 389-398.
26. Tapolyai M, Udvari-Nagy S, Schede-Don K. (2001) The rate of complications of 24-hour ambulatory blood pressure monitoring (ABPM) is low. *Am J Hypertens*, 14: 487.
27. Peixoto AJ, Santos SF, Mendes RB, Crowley ST, Maldonado R, Orias M, Mansoor GA, White WB. (2000) Reproducibility of ambulatory blood pressure monitoring in hemodialysis patients. *Am J Kidney Dis*, 36: 983-990.
28. Agarwal R, Satyan S, Alborzi P, Light RP, Tegegne GG, Mazengia HS, Yigazu PM. (2009) Home blood pressure measurements for managing hypertension in hemodialysis patients. *Am J Nephrol*, 30: 126-134.
29. Agarwal R, Andersen MJ, Light RP. (2008) Location not quantity of blood pressure measurements predicts mortality in hemodialysis patients. *Am J Nephrol*, 28: 210-217.
30. Fulop T, Schmidt DW, Cosmin A, Islam N, Wells C, Lengvarszky Z, Bilbrew DM, Zsom L. (2012) Ambulatory blood pressure monitoring and peri-hemodialysis blood pressures in a Southeast US hemodialysis unit. *Clin Nephrol*, 77: 383-391.

31. Agarwal R, Metiku T, Tegegne GG, Light RP, Bunaye Z, Bekele DM, Kelley K. (2008) Diagnosing hypertension by intradialytic blood pressure recordings. *Clin J Am Soc Nephrol*, 3: 1364-1372.
32. Fulop T, Zsom L. (2015) On poor agreement between dialysis unit and ambulatory blood pressures. *J Clin Hypertens*, 17: 244-244.
33. Wizemann V, Wabel P, Chamney P, Zaluska W, Moissl U, Rode C, Malecka-Masalska T, Marcelli D. (2009) The mortality risk of overhydration in haemodialysis patients. *Nephrol Dial Transplant*, 24: 1574-1579.
34. Sivalingam M, Suresh M, Farrington K. (2011) Comparison of B-type natriuretic peptide and NT proBNP as predictors of survival in patients on high-flux hemodialysis and hemodiafiltration. *Hemodial Int*, 15: 359-365.
35. Charra B. (2007) Fluid balance, dry weight, and blood pressure in dialysis. *Hemodial Int*, 11: 21-31.
36. Raimann J, Liu L, Tyagi S, Levin NW, Kotanko P. (2008) A fresh look at dry weight. *Hemodial Int*, 12: 395-405.
37. Thomson GE, Waterhouse K, McDonald HP, Jr., Friedman EA. (1967) Hemodialysis for chronic renal failure. Clinical observations. *Arch Intern Med*, 120: 153-167.
38. Tapolyai M, Faludi M, Réti V, Lengvárszky Z, Szarvas T, Fülöp T, Bekő G, Berta K. (2013) Volume estimation in dialysis patients: the concordance of brain-type natriuretic peptide measurements and bioimpedance values. *Hemodial Int*, 17: 406-412.
39. Curatola G, Bolignano D, Rastelli S, Caridi G, Tripepi R, Tripepi G, Politi R, Catalano F, Delfino D, Ciccarelli M, Mallamaci F, Zoccali C. (2011) Ultrafiltration intensification in hemodialysis patients improves hypertension but increases AV fistula complications and cardiovascular events. *J Nephrol*, 24: 465-473.
40. Flythe JE, Kshirsagar AV, Falk RJ, Brunelli SM. (2015) Associations of posthemodialysis weights above and below target weight with all-cause and cardiovascular mortality. *Clin J Am Soc Nephrol*, 10: 808-816.
41. Ori Y, Chagnac A, Schwartz A, Herman M, Weinstein T, Zevin D, Gafter U, Korzets A. (2005) Non-occlusive mesenteric ischemia in chronically dialyzed patients: a disease with multiple risk factors. *Nephron Clin Pract*, 101: c87-93.

42. London GM. (2011) Ultrafiltration intensification for achievement of dry weight and hypertension control is not always the therapeutic gold standard. *J Nephrol*, 24: 395.
43. Agarwal R, Andersen MJ, Pratt JH. (2008) On the importance of pedal edema in hemodialysis patients. *Clin J Am Soc Nephrol*, 3: 153-158.
44. Weiner DE, Brunelli SM, Hunt A, Schiller B, Glassock R, Maddux FW, Johnson D, Parker T, Nissenson A. (2014) Improving clinical outcomes among hemodialysis patients: a proposal for a “volume first” approach from the chief medical officers of US dialysis providers. *Am J Kidney Dis*, 64: 685-695.
45. Moissl U, Arias-Guillen M, Wabel P, Fontsero N, Carrera M, Campistol JM, Maduell F. (2013) Bioimpedance-guided fluid management in hemodialysis patients. *Clin J Am Soc Nephrol*, 8: 1575-1582.
46. Kalantar-Zadeh K, Regidor DL, Kovesdy CP, Van Wyck D, Bunnapradist S, Horwich TB, Fonarow GC. (2009) Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. *Circulation*, 119: 671-679.
47. Kimmel PL, Peterson RA, Weihs KL, Simmens SJ, Alleyne S, Cruz I, Veis JH. (1998) Psychosocial factors, behavioral compliance and survival in urban hemodialysis patients. *Kidney Int*, 54: 245-254.
48. Salem MM. (1995) Hypertension in the hemodialysis population: a survey of 649 patients. *Am J Kidney Dis*, 26: 461-468.
49. Tapolyai M, Jariatul K, Atif F. (2008) Escalating antihypertensive medications in end-stage renal disease patients does not improve blood pressure control. *J Clin Hyperts*, 10: 215.
50. Salem MM. (2000) Treatment of hypertension in the hemodialysis patient : beneficial or not. *Curr Hypertens Reports*, 2: 441-444.
51. Lins RL, Elseviers M, Rogiers P, Van Hoeyweghen RJ, De Raedt H, Zachee P, Daelemans RA. (1997) Importance of volume factors in dialysis related hypertension. *Clin Nephrol*, 48: 29-33.
52. Agarwal R, Alborzi P, Satyan S, Light RP. (2009) Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. *Hypertension*, 53: 500 - 507.
53. Hur E, Usta M, Toz H, Asci G, Wabel P, Kahvecioglu S, Kayikcioglu M, Demirci MS, Ozkahya M, Duman S, Ok E. (2013) Effect of fluid management guided

by bioimpedance spectroscopy on cardiovascular parameters in hemodialysis patients: a randomized controlled trial. *Am J Kidney Dis*, 61: 957-965.

54. Agarwal R, Weir MR. (2010) Dry-weight: a concept revisited in an effort to avoid medication-directed approaches for blood pressure control in hemodialysis patients. *Clin J Am Soc Nephrol*, 5: 1255-1260.
55. Sinha AD, Agarwal R. Setting the dry weight and its cardiovascular implications. (2017) *Semin Dial*, DOI: 10.1111/sdi.12624 (E-pub date: 30 June 2017)
56. Zalozyc A, Schaefer B, Schaefer F, Krid S, Salomon R, Niaudet P, Schmitt CP, Fischbach M. (2013) Hydration measurement by bioimpedance spectroscopy and blood pressure management in children on hemodialysis. *Pediatr Nephrol*, 28: 2169-2177.
57. Tapolyai MB, Faludi M, Fülöp T, Dossabhoy NR, Szombathelyi A, Berta K. (2014) Which fluid space is affected by ultrafiltration during hemodiafiltration? *Hemodial Int*, 18: 384-390.
58. Onofriescu M, Hogas S, Voroneanu L, Apetrii M, Nistor I, Kanbay M, Covic AC. (2014) Bioimpedance-guided fluid management in maintenance hemodialysis: a pilot randomized controlled trial. *Am J Kidney Dis*, 64: 111-118.
59. Reddan DN, Szczech LA, Hasselblad V, Lowrie EG, Lindsay RM, Himmelfarb J, Toto RD, Stivelman J, Winchester JF, Zillman LA, Califf RM, Owen WF, Jr. (2005) Intradialytic blood volume monitoring in ambulatory hemodialysis patients: a randomized trial. *J Am Soc Nephrol*, 16: 2162-2169.
60. Agarwal R. (2010) Hypervolemia is associated with increased mortality among hemodialysis patients. *Hypertension*, 56: 512-517.
61. Black S, Kushner I, Samols D. (2004) C-reactive protein. *J Biol Chem*, 279: 48487-48490.
62. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, Bleyer A, Newman A, Siscovick D, Psaty B. (2005) Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. *JAMA*, 293: 1737-1745.
63. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB, Vasan RS. (2006) Multiple biomarkers for the prediction of first major cardiovascular events and death. *N Engl J Med*, 355: 2631-2639.



64. Bellelli G, Rozzini R, Frisoni GB, Trabucchi M. (2001) Is C-reactive protein an independent risk factor for essential hypertension? *J Hypertens*, 19: 2107-2107.
65. Howard DS. (2003) C-reactive protein and the risk of developing hypertension. *JAMA*, 290: 2945.
66. Ridker PM, Hennekens CH, Buring JE, Rifai N. (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N Engl J Med*, 342: 836-843.
67. Christine MA. (2002) Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. *Circulation*, 105: 2595.
68. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB. (2004) Inflammatory markers and the risk of coronary heart disease in men and women. *N Engl J Med*, 351: 2599-2610.
69. Ford ES, Giles WH. (2000) Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey. *Arterioscler Thromb Vasc Biol*, 20: 1052-1056.
70. Kullo IJ, Seward JB, Bailey KR, Bielak LF, Grossardt BR, Sheedy PF, Peyser PA, Turner ST. (2005) C-reactive protein is related to arterial wave reflection and stiffness in asymptomatic subjects from the community. *American J Hypertens*, 18: 1123-1129.
71. Schillaci G, Pirro M, Gemelli F, Pasqualini L, Vaudo G, Marchesi S, Siepi D, Bagaglia F, Mannarino E. (2003) Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. *J Hypertens*, 21: 1841-1846.
72. Banerjee T, Kim SJ, Astor B, Shafi T, Coresh J, Powe NR. (2014) Vascular access type, inflammatory markers, and mortality in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. *Am J Kidney Dis*, 64: 954-961.
73. Lee CT, Lee CH, Su Y, Chuang YC, Tsai TL, Chen JB. (2004) The relationship between inflammatory markers, leptin and adiponectin in chronic hemodialysis patients. *Int J Artif Organs*, 27: 835-841.

74. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL. (1998) Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. *Am J Kidney Dis*, 32: 107-114.
75. Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Pecoits-Filho R, Stenvinkel P, Lindholm B. (2006) Serum albumin, C-reactive protein, interleukin 6, and fetuin A as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. *Am J Kidney Dis*, 47: 139-148.
76. Qureshi AR, Alvestrand A, Danielsson A, Divino-Filho JC, Gutierrez A, Lindholm B, Bergstrom J. (1998) Factors predicting malnutrition in hemodialysis patients: a cross-sectional study. *Kidney Int*, 53: 773-782.
77. Kaysen GA, Chertow GM, Adhikarla R, Young B, Ronco C, Levin NW. (2001) Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. *Kidney Int*, 60: 333-340.
78. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, McAllister CJ, Alcorn H, Jr., Kopple JD, Greenland S. (2005) Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. *Nephrol Dial Transplant*, 20: 1880-1888.
79. Kaysen GA, Rathore V, Shearer GC, Depner TA. (1995) Mechanisms of hypoalbuminemia in hemodialysis patients. *Kidney Int*, 48: 510-516.
80. Kaysen GA, Don BR. (2003) Factors that affect albumin concentration in dialysis patients and their relationship to vascular disease. *Kidney Int*, 63: S94-S97.
81. Kalantar-Zadeh K. (2007) Inflammatory marker mania in chronic kidney disease: pentraxins at the crossroad of universal soldiers of inflammation. *Clin J Am Soc Nephrol*, 2: 872-875.
82. Iseki K, Kawazoe N, Fukiyama K. (1993) Serum albumin is a strong predictor of death in chronic dialysis patients. *Kidney Int*, 44: 115-119.
83. Fung F, Sherrard DJ, Gillen DL, Wong C, Kestenbaum B, Seliger S, Ball A, Stehman-Breen C. (2002) Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients. *Am J Kidney Dis*, 40: 307-314.
84. Cooper BA, Penne EL, Bartlett LH, Pollock CA. (2004) Protein malnutrition and hypoalbuminemia as predictors of vascular events and mortality in ESRD. *Am J Kidney Dis*, 43: 61-66.

85. Lowrie EG, Lew NL. (1990) Death risk in hemodialysis patients - the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. *Am J Kidney Dis*, 15: 458-482.
86. Beddhu S, Cheung AK, Larive B, Greene T, Kaysen GA, Levey AS, Rocco M, Sarnak M, Toto R, Eknoyan G, Hemodialysis Study Group. (2007) Inflammation and inverse associations of body mass index and serum creatinine with mortality in hemodialysis patients. *J Ren Nutr*, 17: 372-380.
87. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. (2000) C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. *Am J Kidney Dis*, 35: 469-476.
88. Apple FS, Murakami MM, Pearce LA, Herzog CA. (2004) Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. *Clin Chem*, 50: 2279-2285.
89. Usvyat LA, Barth C, Bayh I, Etter M, von Gersdorff GD, Grassmann A, Guinsburg AM, Lam M, Marcelli D, Marelli C, Scatizzi L, Schaller M, Tashman A, Toffelmire T, Thijssen S, Kooman JP, van der Sande FM, Levin NW, Wang Y, Kotanko P. (2013) Interdialytic weight gain, systolic blood pressure, serum albumin, and C-reactive protein levels change in chronic dialysis patients prior to death. *Kidney Int*, 84: 149-157.
90. Desmeules S, Canaud B. (2004) Venous access for chronic hemodialysis: "Undesirable yet unavoidable". *Artif Organs*, 28: 611-616.
91. Weijmer MC, Vervloet MG, ter Wee PM. (2004) Compared to tunnelled cuffed haemodialysis catheters, temporary untunnelled catheters are associated with more complications already within 2 weeks of use. *Nephrol Dial Transplant*, 19: 670-677.
92. Schwab SJ, Buller GL, McCann RL, Bollinger RR, Stickel DL. (1988) Prospective evaluation of a Dacron cuffed hemodialysis catheter for prolonged use. *Am J Kidney Dis*, 11: 166.
93. Xue JL, Dahl D, Ebben JP, Collins AJ. (2003) The association of initial hemodialysis access type with mortality outcomes in elderly Medicare ESRD patients. *Am J Kidney Dis*, 42: 1013-1019.

94. Rayner HC, Besarab A, Brown WW, Disney A, Saito A, Pisoni RL. (2004) Vascular access results from the Dialysis Outcomes and Practice Patterns Study (DOPPS): performance against Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines. *Am J Kidney Dis*, 44: 22-26.
95. Xue H, Ix JH, Wang W, Brunelli SM, Lazarus M, Hakim R, Lacson E, Jr. (2013) Hemodialysis access usage patterns in the incident dialysis year and associated catheter-related complications. *Am J Kidney Dis*, 61: 123-130.
96. Roca-Tey R, Arcos E, Comas J, Cao H, Tort J, Catalan Renal Registry Committee. (2016) Starting hemodialysis with catheter and mortality risk: persistent association in a competing risk analysis. *J Vasc Access*, 17: 20-28.
97. Raithatha A, McKane W, Kendray D, Evans C. (2010) Catheter access for hemodialysis defines higher mortality in late-presenting dialysis patients. *Ren Fail*, 32: 1183-1188.
98. Pantelias K, Grapsa E. (2012) Vascular access today. *World J Nephrol*, 1: 69-78.
99. Donati G, Cianciolo G, Mauro R, Rucci P, Scrivo A, Marchetti A, Giampalma E, Golfieri R, Panicali L, Iorio M, Stella A, La Manna G, Stefoni S. (2015) PTFE grafts versus tunneled cuffed catheters for hemodialysis: which is the second choice when arteriovenous fistula is not feasible? *Artif Organs*, 39: 134-141.
100. Dhingra RK, Young EW, Hulbert-Shearon T, Leavey SF, Port FK. (2001) Type of vascular access and mortality in US hemodialysis patients. *Kidney Int*, 60: 1443-1451.
101. Pisoni RL, Young EW, Mapes DL, Keen ML, Port FK. (2003) Vascular access use and outcomes in the US, Europe, and Japan: results from the Dialysis Outcomes and Practice Patterns Study. *Nephrol News Issues*, 17: 38.
102. Pisoni RL, Arrington CJ, Albert JM, Ethier J, Kimata N, Krishnan M, Rayner HC, Saito A, JJ S, Saran R. (2009) Facility hemodialysis vascular access use and mortality in countries participating in DOPPS: an instrumental variable analysis. *Am J Kidney Dis*, 53: 475.
103. Ramanathan V, Riosa S, Al-Sharif AH, Mansouri MD, Tranchina A, Kayyal T, Abreo AP, Aslam S, Nassar G, Darouiche RO. (2012) Characteristics of biofilm on tunneled cuffed hemodialysis catheters in the presence and absence of clinical infection. *Am J Kidney Dis*, 60: 976-982.

104. Kang JS, Jang HR, Lee JE, Park YJ, Rhee H, Seong EY, Kwak IS, Kim IY, Lee DW, Lee SB, Song SH. (2016) The bacterial colonization in tunneled cuffed dialysis catheter and its effects on residual renal function in incident hemodialysis patients. *Clin Exp Nephrol*, 20: 294-301.
105. Alomari AI, Falk A. (2007) The natural history of tunneled hemodialysis catheters removed or exchanged: a single-institution experience. *J Vasc Interv Radiol*, 18: 227-235.
106. Little MA, O'Riordan A, Lucey B, Farrell M, Lee M, Conlon PJ, Walshe JJ. (2001) A prospective study of complications associated with cuffed, tunneled haemodialysis catheters. *Nephrol Dial Transplant*, 16: 2194-2200.
107. Ponce D, Mendes M, Silva T, Oliveira R. (2015) Occluded tunneled venous catheter in hemodialysis patients: risk factors and efficacy of alteplase. *Artif Organs*, 39: 741-747.
108. Oliver MJ, Callery SM, Thorpe KE, Schwab SJ, Churchill DN. (2000) Risk of bacteremia from temporary hemodialysis catheters by site of insertion and duration of use: a prospective study. *Kidney Int*, 58: 2543-2545.
109. Kairaitis LK, Gottlieb T. (1999) Outcome and complications of temporary haemodialysis catheters. *Nephrol Dial Transplant*, 14: 1710-1714.
110. Falk A, Prabhuram N, Parthasarathy S. (2005) Conversion of temporary hemodialysis catheters to permanent hemodialysis catheters: a retrospective study of catheter exchange versus classic de novo placement. *Semin Dial*, 18: 425-430.
111. Schwab SJ, Beathard G. (1999) The hemodialysis catheter conundrum: hate living with them, but can't live without them. *Kidney Int* 56: 1-17.
112. Trerotola SO, Johnson MS, Harris VJ, Shah H, Ambrosius WT, McKusky MA, Kraus MA. (1997) Outcome of tunneled hemodialysis catheters placed via the right internal jugular vein by interventional radiologists. *Radiology*, 203: 489-495.
113. Beathard GA. (1999) Management of bacteremia associated with tunneled-cuffed hemodialysis catheters. *J Am Soc Nephrol*, 10: 1045-1049.
114. Fülöp T, Tapolyai M, Qureshi NA, Beemidi VR, Gharaibeh KA, Hamrahan SM, Szarvas T, Kovcsdy CP, Csongrádi É. (2013) The safety and efficacy of bedside removal of tunneled hemodialysis catheters by nephrology trainees. *Ren Fail*, 35: 1264-1268.

115. Yahav D, Rozen-Zvi B, Gafter-Gvili A, Leibovici L, Gafter U, Paul M. (2008) Antimicrobial lock solutions for the prevention of infections associated with intravascular catheters in patients undergoing hemodialysis: systematic review and meta-analysis of randomized, controlled trials. *Clin Infect Dis*, 47: 83-93.
116. Jamey MT, Cooley J, Tonelli M, Manus BJ, MacRae J, Hemmelgarn BR. (2008) Alberta Kidney Disease Network. Meta-analysis: Antibiotics for prophylaxis against hemodialysis catheter-related infections. *Ann Intern Med*, 148: 596-605.
117. Suhocki PV, Conlon PJ, Jr., Knelson MH, Harland R, Schwab SJ. (1996) Silastic cuffed catheters for hemodialysis vascular access: thrombolytic and mechanical correction of malfunction. *Am J Kidney Dis*, 28: 379-386.
118. Richardson IP, Sturtevant R, Heung M, Solomon MJ, Younger JG, VanEpps JS. (2016) Hemodialysis catheter heat transfer for biofilm prevention and treatment. *ASAIO J*, 62: 92-99.
119. Saran R, Bragg-Gresham JL, Rayner HC, Goodkin DA, Keen ML, Van Dijk PC, Kurokawa K, Piera L, Saito A, Fukuhara S, Young EW, Held PJ, Port FK. (2003) Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. *Kidney Int*, 64: 254-262.
120. Leggat JE, Jr., Orzol SM, Hulbert-Shearon TE, Golper TA, Jones CA, Held PJ, Port FK. (1998) Noncompliance in hemodialysis: predictors and survival analysis. *Am J Kidney Dis*, 32: 139-145.
121. Unruh ML, Evans IV, Fink NE, Powe NR, Meyer KB, Choices for Healthy Outcomes in Caring for End-Stage Renal Disease Study. (2005) Skipped treatments, markers of nutritional nonadherence, and survival among incident hemodialysis patients. *Am J Kidney Dis*, 46: 1107-1116.
122. Held PJ, Port FK, Wolfe RA, Stannard DC, Carroll CE, Daugirdas JT, Bloembergen WE, Greer JW, Hakim RM. (1996) The dose of hemodialysis and patient mortality. *Kidney Int*, 50: 550-556.
123. Tapolyai M, Fülöp T, Uysal A, Lengvárszky Z, Szarvas T, Ballard K, Dossabhoy NR. (2010) Regional differences in nonadherence to dialysis among southern dialysis patients: a comparative cross-sectional study to the dialysis outcomes and practice patterns study. *Am J Med Sci*, 339: 516-518.

124. Flythe JE, Inrig JK, Shafi T, Chang TI, Cape K, Dinesh K, Kunaparaju S, Brunelli SM. (2013) Association of intradialytic blood pressure variability with increased all-cause and cardiovascular mortality in patients treated with long-term hemodialysis. *Am J Kidney Dis*, 61: 966-974.
125. Park J, Rhee CM, Sim JJ, Kim YL, Ricks J, Streja E, Vashistha T, Tolouian R, Kovesdy CP, Kalantar-Zadeh K. (2013) A comparative effectiveness research study of the change in blood pressure during hemodialysis treatment and survival. *Kidney Int*, 84: 795-802.
126. Kuipers J, Usvyat LA, Oosterhuis JK, Dasselaar JJ, de Jong PE, Westerhuis R, Sands JJ, Wang Y, Kotanko P, Franssen CF. (2013) Variability of predialytic, intradialytic, and postdialytic blood pressures in the course of a week: a study of Dutch and US maintenance hemodialysis patients. *Am J Kidney Dis*, 62: 779-788.
127. Bragg-Gresham JL, Fissell RB, Mason NA, Bailie GR, Gillespie BW, Wizemann V, Cruz JM, Akiba T, Kurokawa K, Ramirez S. (2007) Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). *Am J Kidney Dis*, 49: 426-431.
128. Trinh E, Bargman JM. (2016) Are diuretics underutilized in dialysis patients? *Semin Dial*, 29: 338-341.
129. Jost CM, Agarwal R, Khair-el-Din T, Grayburn PA, Victor RG, Henrich WL. (1993) Effects of cooler temperature dialysate on hemodynamic stability in "problem" dialysis patients. *Kidney Int*, 44: 606-612.
130. Tentori F, Zhang J, Li Y, Karaboyas A, Kerr P, Saran R, Bommer J, Port F, Akiba T, Pisoni R, Robinson B. (2012) Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Nephrol Dial Transplant*, 27: 4180-4188.
131. Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W, Bauer P, Hiesmayr M. (2004) Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. *J Am Soc Nephrol*, 15: 1597-1605.
132. Macedo E, Bouchard J, Soroko SH, Chertow GM, Himmelfarb J, Ikizler TA, Paganini EP, Mehta RL, Program to Improve Care in Acute Renal Disease Study.

(2010) Fluid accumulation, recognition and staging of acute kidney injury in critically-ill patients. *Crit Care*, 14: R82.

133. Liu KD, Thompson BT, Ancukiewicz M, Steingrub JS, Douglas IS, Matthay MA, Wright P, Peterson MW, Rock P, Hyzy RC, Anzueto A, Truitt JD, National Institutes of Health National Heart, Lung Blood Institute Acute Respiratory Distress Syndrome Network. (2011) Acute kidney injury in patients with acute lung injury: impact of fluid accumulation on classification of acute kidney injury and associated outcomes. *Crit Care Med*, 39: 2665-2671.

134. Moçin ÖY, Karakurt Z, Şen E, Güngör G, Altınöz H, Ersava BE, Yalçınsoy M, Yalçın A, Adıgüzel N, Akın Kaya A. (2013) Serum creatinine and weaning in patients with chronic obstructive pulmonary disease: multicenter pilot study. *J Pall Care Med*, 3: 143.

135. Fülöp T, Zsom L, Tapolyai MB, Molnar MZ, Rosiváll L. (2017) Volume-related weight gain as an independent indication for renal replacement therapy in the intensive care units. *J Renal Inj Prev*, 6: 35-42.

136. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM. (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. *Intensive Care Med*, 30: 536-555.

137. Kelm DJ, Perrin JT, Cartin-Ceba R, Gajic O, Schenck L, Kennedy CC. (2015) Fluid overload in patients with severe sepsis and septic shock treated with early goal-directed therapy is associated with increased acute need for fluid-related medical interventions and hospital death. *Shock*, 43: 68-73.

138. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M, Early Goal-Directed Therapy Collaborative Group. (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med*, 345: 1368-1377.

139. Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA, Pike F, Terndrup T, Wang HE, Hou PC, LoVecchio F, Filbin MR, Shapiro NI, Angus DC, ProCESS Investigators. (2014) A randomized trial of protocol-based care for early septic shock. *N Engl J Med*, 370: 1683-1693.



140. Peake SL, Delaney A, Bailey M, Bellomo R, Cameron PA, Cooper DJ, Higgins AM, Holdgate A, Howe BD, Webb SA, Williams P, ARISE Investigators and the ANZICS Clinical Trials Group. (2014) Goal-directed resuscitation for patients with early septic shock. *N Engl J Med*, 371: 1496-1506.
141. Gunnerson KJ, Saul M, He S, Kellum JA. (2006) Lactate versus non-lactate metabolic acidosis: a retrospective outcome evaluation of critically ill patients. *Crit Care*, 10: R22.
142. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R, Safe Study Investigators. (2004) A comparison of albumin and saline for fluid resuscitation in the intensive care unit. *N Engl J Med*, 350: 2247-2256.
143. Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, Fanizza C, Caspani L, Faenza S, Grasselli G, Iapichino G, Antonelli M, Parrini V, Fiore G, Latini R, Gattinoni L, ALBIOS Study Investigators. (2014) Albumin replacement in patients with severe sepsis or septic shock. *N Engl J Med*, 370: 1412-1421.
144. Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C, McGuinness S, Rajbhandari D, Taylor CB, Webb SA; Australian Chest Investigators, New Zealand Intensive Care Society Clinical Trials Group. (2012) Hydroxyethyl starch or saline for fluid resuscitation in intensive care. *N Engl J Med*, 367: 1901-1911.
145. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Aneman A, Madsen KR, Moller MH, Elkjaer JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Soe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjaeldgaard AL, Fabritius ML, Mondrup F, Pott FC, Moller TP, Winkel P, Wetterslev J, Scandinavian Critical Care Trials Group. (2012) Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. *N Engl J Med*, 367: 124-134.
146. Annane D, Siami S, Jaber S, Martin C, Elatrous S, Declere AD, Preiser JC, Outin H, Troche G, Charpentier C, Trouillet JL, Kimmoun A, Forceville X, Darmon M, Lesur O, Reignier J, Abroug F, Berger P, Clec'h C, Cousson J, Thibault L, Chevret S, CRISTAL Investigators. (2013) Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial. *JAMA*, 310: 1809-1817.

147. Haase N, Perner A, Hennings LI, Siegemund M, Lauridsen B, Wetterslev M, Wetterslev J. (2013) Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. *BMJ*, 346: f839.
148. Zarychanski R, Abou-Setta AM, Turgeon AF, Houston BL, McIntyre L, Marshall JC, Fergusson DA. (2013) Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. *JAMA*, 309: 678-688.
149. Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M. (2012) Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. *JAMA*, 308: 1566-1572.
150. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, Kurella Tamura M, Feldman HI. (2014) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. *Am J Kidney Dis*, 63: 713-735.
151. Mehta RL, Pascual MT, Gruta CG, Zhuang S, Chertow GM. (2002) Refining predictive models in critically ill patients with acute renal failure. *J Am Soc Nephrol*, 13: 1350-1357.
152. Ostermann M, Chang RW. (2007) Acute kidney injury in the intensive care unit according to RIFLE. *Crit Care Med*, 35: 1837-1843; quiz 1852.
153. Sakr Y, Vincent JL, Reinhart K, Groeneveld J, Michalopoulos A, Sprung CL, Artigas A, Ranieri VM, Sepsis Occurrence in Acutely Ill Patients I. (2005) High tidal volume and positive fluid balance are associated with worse outcome in acute lung injury. *Chest*, 128: 3098-3108.
154. Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, Connors AF, Jr., Hite RD, Harabin AL. The National Heart, Lung and Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. (2006) Comparison of two fluid-management strategies in acute lung injury. *N Engl J Med*, 354: 2564-2575.
155. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D, Sepsis Occurrence in Acutely Ill Patients Investigators. (2006) Sepsis in European intensive care units: results of the SOAP study. *Crit Care Med*, 34: 344-353.

156. Lowell JA, Schiffdecker C, Driscoll DF, Benotti PN, Bistrain BR. (1990) Postoperative fluid overload: not a benign problem. *Crit Care Med*, 18: 728.
157. Brandstrup B, Tonnesen H, Beier-Holgersen R, Hjortso E, Ording H, Lindorff-Larsen K, Rasmussen MS, Lannig C, Wallin L, Iversen LH, Gramkow CS, Okholm M, Blemmer T, Svendsen PE, Rottensten HH, Thage B, Riis J, Jeppesen IS, Teilum D, Christensen AM, Graungaard B, Pott F, Danish Study Group on Perioperative Fluid Therapy. (2003) Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens: a randomized assessor-blinded multicenter trial. *Ann Surg*, 238: 641-648.
158. Dalfino L, Tullo L, Donadio I, Malcangi V, Brienza N. (2008) Intra-abdominal hypertension and acute renal failure in critically ill patients. *Intensive Care Med*, 34: 707-713.
159. McNelis J, Marini CP, Jurkiewicz A, Fields S, Caplin D, Stein D, Ritter G, Nathan I, Simms HH. (2002) Predictive factors associated with the development of abdominal compartment syndrome in the surgical intensive care unit. *Arch Surg*, 137: 133-136.
160. RENAL Replacement Therapy Study Investigators. (2012) An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. *Critical Care Med*, 40: 1753-1760.
161. Foland JA, Fortenberry JD, Warshaw BL, Pettignano R, Merritt RK, Heard ML, Rogers K, Reid C, Tanner AJ, Easley KA. (2004) Fluid overload before continuous hemofiltration and survival in critically ill children: A retrospective analysis. *Crit Care Med*, 32: 1771-1776.
162. Gillespie RS, Seidel K, Symons JM. (2004) Effect of fluid overload and dose of replacement fluid on survival in hemofiltration. *Pediatr Nephrol*, 19: 1394-1399.
163. Symons JM, Chua AN, Somers MJ, Baum MA, Bunchman TE, Benfield MR, Brophy PD, Blowey D, Fortenberry JD, Chand D, Flores FX, Hackbarth R, Alexander SR, Mahan J, McBryde KD, Goldstein SL. (2007) Demographic characteristics of pediatric continuous renal replacement therapy: a report of the prospective pediatric continuous renal replacement therapy registry. *Clin J Am Soc Nephrol*, 2: 732-738.
164. Mehta RL, Pascual MT, Soroko S, Savage BR, Himmelfarb J, Ikizler TA, Paganini EP, Chertow GM, Program to Improve Care in Acute Renal Disease. (2004)

Spectrum of acute renal failure in the intensive care unit: the PICARD experience. *Kidney Int*, 66: 1613-1621.

165. Payen D, de Pont AC, Sakr Y, Spies C, Reinhart K, Vincent JL, Sepsis Occurrence in Acutely Ill Patients Investigators. (2008) A positive fluid balance is associated with a worse outcome in patients with acute renal failure. *Crit Care*, 12: R74.

166. Brar H, Olivier J, Lebrun C, Gabbard W, Fulop T, Schmidt D. (2008) Predictors of mortality in a cohort of intensive care unit patients with acute renal failure receiving continuous renal replacement therapy. *Am J Med Sci*, 335: 342-347.

167. Fulop T, Pathak MB, Schmidt DW, Lengvarszky Z, Juncos JP, Lebrun CJ, Brar H, Juncos LA. (2010) Volume-related weight gain and subsequent mortality in acute renal failure patients treated with continuous renal replacement therapy. *ASAIO J*, 56: 333-337.

168. Saran R, Bragg-Gresham JL, Levin NW, Twardowski ZJ, Wizemann V, Saito A, Kimata N, Gillespie BW, Combe C, Bommer J, Akiba T, Mapes DL, Young EW, Port FK. (2006) Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. *Kidney Int*, 69: 1222-1228.

169. Zsom L, Zsom M, Fulop T, Wells C, Flessner MF, Eller J, Wollheim C, Hegbrant J, Strippoli GF. (2010) Correlation of treatment time and ultrafiltration rate with serum albumin and C-reactive protein levels in patients with end-stage kidney disease receiving chronic maintenance hemodialysis: a cross-sectional study. *Blood Purif*, 30: 8-15.

170. Fulop T, Rodriguez B, Kosztaczky BA, Gharaibeh KA, Lengvarszky Z, Dossabhoy NR, Tapolyai MB. (2015) Tunneled hemodialysis catheter removals by non-interventional nephrologists: the University of Mississippi experience. *Semin Dial*, 28: E48-52.

171. Dossabhoy NR, Sangha B, Tapolyai MB, Fulop T. (2016) Outpatient removal of tunneled dialysis catheters by nephrology fellows in training at a Veterans Affairs Medical Center. *J Vasc Access*, 17: 340-344.

172. Fulop T, Tapolyai MB, Agarwal M, Lopez-Ruiz A, Molnar MZ, Dossabhoy NR. (2016) Bedside tunneled dialysis catheter removal - A lesson learned from nephrology trainees. *Artif Organs*, DOI: 10.1111/aor.12869. (E-pub date: 26 December 2016)

173. Removal of Tunneled Dialysis Catheters (on-line U-tube video) [Internet]. [cited October 20, 2016]. Available from: [https://www.youtube.com/watch?v=DGya15H\\_Jfw](https://www.youtube.com/watch?v=DGya15H_Jfw).
174. Malbrain ML, Marik PE, Witters I, Cordemans C, Kirkpatrick AW, Roberts DJ, Van Regenmortel N. (2014) Fluid overload, de-resuscitation, and outcomes in critically ill or injured patients: a systematic review with suggestions for clinical practice. *Anaesthesiol Intensive Ther*, 46: 361-380.
175. Raghunathan K, Shaw AD, Bagshaw SM. (2013) Fluids are drugs: type, dose and toxicity. *Curr Opin Crit Care*, 19: 290-298.
176. Foland JA, Fortenberry JD, Warshaw BL, Pettignano R, Merritt RK, Heard ML, Rogers K, Reid C, Tanner AJ, Easley KA. (2004) Fluid overload before continuous hemofiltration and survival in critically ill children: A retrospective analysis. *Critical Care Medicine*, 32: 1771-1776.
177. Prowle JR, Echeverri JE, Ligabo EV, Ronco C, Bellomo R. (2010) Fluid balance and acute kidney injury. *Nat Rev Nephrol*, 6: 107-115.
178. Sanchez M, Jimenez-Lendinez M, Cidoncha M, Asensio MJ, Herrerot E, Collado A, Santacruz M. (2011) Comparison of fluid compartments and fluid responsiveness in septic and non-septic patients. *Anaesth Intensive Care*, 39: 1022-1029.
179. Fiaccadori E, Maggiore U, Lombardi M, Leonardi S, Rotelli C, Borghetti A. (2000) Predicting patient outcome from acute renal failure comparing three general severity of illness scoring systems. *Kidney Int*, 58: 283-292.
180. Mehta RL, Pascual MT, Soroko S, Savage BR, Himmelfarb J, Ikizler TA, Paganini EP, Chertow GM, Program to Improve Care in Acute Renal Disease. (2004) Spectrum of acute renal failure in the intensive care unit: The PICARD experience. *Kidney Int*, 66: 1613-1621.
181. Bouchard J, Soroko SB, Chertow GM, Himmelfarb J, Ikizler TA, Paganini EP, Mehta RL, Program to Improve Care in Acute Renal Disease Study Group. (2009) Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. *Kidney Int*, 76: 422-427.
182. Cruz DN, Bolgan I, Perazella MA, Bonello M, de Cal M, Corradi V, Polanco N, Ocampo C, Nalesso F, Piccinni P, Ronco C, North East Italian Prospective Hospital

Renal Outcome Survey on Acute Kidney Injury Investigators. (2007) North East Italian Prospective Hospital Renal Outcome Survey on Acute Kidney Injury (NEiPHROS-AKI): targeting the problem with the RIFLE Criteria. *Clin J Am Soc Nephrol*, 2: 418-425.

183. Heung M, Wolfgram DF, Kommareddi M, Hu Y, Song PX, Ojo AO. (2011) Fluid overload at initiation of renal replacement therapy is associated with lack of renal recovery in patients with acute kidney injury. *Nephrol Dial Transplant: gfr*470.

184. Askenazi DJ, Goldstein SL, Koralkar R, Fortenberry J, Baum M, Hackbarth R, Blowey D, Bunchman TE, Brophy PD, Symons J. (2013) Continuous renal replacement therapy for children  $\leq 10$  kg: a report from the prospective pediatric continuous renal replacement therapy registry. *J Pediatrics*, 162: 587-592. e583.

185. Vaara ST, Korhonen AM, Kaukonen KM, Nisula S, Inkinen O, Hoppu S, Laurila JJ, Mildh L, Reinikainen M, Lund V, Parviainen I, Pettila V, Finnaki Study Group. (2012) Fluid overload is associated with an increased risk for 90-day mortality in critically ill patients with renal replacement therapy: data from the prospective FINNAKI study. *Critical Care*, 16: R197.

186. Teixeira C, Garzotto F, Piccinni P, Brienza N, Iannuzzi M, Gramaticopolo S, Forfori F, Pelaia P, Rocco M, Ronco C, Anello CB, Bove T, Carlini M, Michetti V, Cruz DN, NEFROlogia e Cura INTensiva investigators. (2013) Fluid balance and urine volume are independent predictors of mortality in acute kidney injury. *Crit Care*, 17: R14.

187. Wang N, Jiang L, Zhu B, Wen Y, Xi XM, Beijing Acute Kidney Injury Trial Workgroup. (2015) Fluid balance and mortality in critically ill patients with acute kidney injury: a multicenter prospective epidemiological study. *Crit Care*, 19: 371.

188. Garzotto F, Ostermann M, Martin-Langerwerf D, Sanchez-Sanchez M, Teng J, Robert R, Marinho A, Herrera-Gutierrez ME, Mao HJ, Benavente D, Kipnis E, Lorenzin A, Marcelli D, Tetta C, Ronco C, DoReMIFA Study Group. (2016) The Dose Response Multicentre Investigation on Fluid Assessment (DoReMIFA) in critically ill patients. *Crit Care*, 20: 196.

189. Zhang L, Chen Z, Diao Y, Yang Y, Fu P. (2015) Associations of fluid overload with mortality and kidney recovery in patients with acute kidney injury: A systematic review and meta-analysis. *J Crit Care*, 30: 860 e867-813.

190. Uchino S, Bellomo R, Kellum JA, Morimatsu H, Morgera S, Schetz MR, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-Van Straaten HM, Ronco C, Beginning, Ending Supportive Therapy for the Kidney Investigators Writing Committee. (2007) Patient and kidney survival by dialysis modality in critically ill patients with acute kidney injury. *Int J Artif Organs*, 30: 281-292.
191. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R. (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. *Intensiv Care Med*, 39: 165-228.
192. Mehta RL, McDonald B, Gabbai FB, Pahl M, Pascual MT, Farkas A, Kaplan RM, Collaborative Group for Treatment of ARF in the ICU. (2001) A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. *Kidney Int*, 60: 1154-1163.
193. Vinsonneau C, Camus C, Combes A, Costa de Beauregard MA, Klouche K, Boulain T, Pallot JL, Chiche JD, Taupin P, Landais P, Dhainaut JF, Hemodiafe Study Group. (2006) Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome: a multicentre randomised trial. *Lancet*, 368: 379-385.
194. Yagi N, Leblanc M, Sakai K, Wright EJ, Paganini EP. (1998) Cooling effect of continuous renal replacement therapy in critically ill patients. *Am J Kidney Dis*, 32: 1023-1030.
195. Vaara ST, Reinikainen M, Wald R, Bagshaw SM, Pettila V, Finnaki Study Group. (2014) Timing of RRT based on the presence of conventional indications. *Clin J Am Soc Nephrol*, 9: 1577-1585.
196. Gaudry S, Hajage D, Schortgen F, Martin-Lefevre L, Pons B, Boulet E, Boyer A, Chevrel G, Lerolle N, Carpentier D, de Prost N, Lautrette A, Bretagnol A, Mayaux J, Nseir S, Megarbane B, Thirion M, Forel JM, Maizel J, Yonis H, Markowicz P, Thiery G, Tubach F, Ricard JD, Dreyfuss D, AKIKI Study Group. (2016) Initiation strategies for renal-replacement therapy in the Intensive Care Unit. *N Engl J Med*, 375: 122-133.
197. VA/NIH Acute Renal Failure Trial Network. (2008) Intensity of renal support in critically ill patients with acute kidney injury. *N Engl J Med*, 2008: 7-20.

198. Saudan P, Niederberger M, De Seigneux S, Romand J, Pugin J, Perneger T, Martin PY. (2006) Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. *Kidney Int*, 70: 1312-1317.
199. Tolwani AJ, Campbell RC, Stofan BS, Lai KR, Oster RA, Wille KM. (2008) Standard versus high-dose CVVHDF for ICU-related acute renal failure. *J Am Soc Nephrol*, 19: 1233.
200. Schiffh H, Lang SM, Fischer R. (2002) Daily hemodialysis and the outcome of acute renal failure. *N Engl J Med*, 346: 305-310.
201. RENAL Replacement Therapy Study Investigators. (2009) Intensity of continuous renal-replacement therapy in critically ill patients. *N Engl J Med*, 2009: 1627-1638.
202. Ferguson LM, Dreisbach AW, Csongradi E, Juncos LA, Fulop T. (2013) Recurring extracorporeal circuit clotting during continuous renal replacement therapy in fungal sepsis: successful treatment with argatroban. *Am J Med Sci*, 345: 256-258.
203. Fulop T, Cosmin A, Juncos LA. (2011) Recurring extracorporeal circuit clotting during continuous renal replacement therapy resolved after single-session therapeutic plasma exchange. *J Clin Apher*, 26: 214-215.
204. Malbrain ML, Huygh J, Dabrowski W, De Waele JJ, Staelens A, Wauters J. (2014) The use of bio-electrical impedance analysis (BIA) to guide fluid management, resuscitation and deresuscitation in critically ill patients: a bench-to-bedside review. *Anaesthesiol Int Ther*, 46: 381-391.
205. Agricola E, Bove T, Oppizzi M, Marino G, Zangrillo A, Margonato A, Picano E. (2005) "Ultrasound comet-tail images": a marker of pulmonary edema - a comparative study with wedge pressure and extravascular lung water. *Chest*, 127: 1690-1695.
206. Noble VE, Murray AF, Capp R, Sylvia-Reardon MH, Steele DJ, Liteplo A. (2009) Ultrasound assessment for extravascular lung water in patients undergoing hemodialysis: time course for resolution. *Chest*, 135: 1433-1439.
207. Tapolyai M, Uysal A, Maeweathers G, Bahta E, Dossabhoy NR. (2009) B-type natriuretic peptide-directed ultrafiltration improves care in acutely hospitalized dialysis patients. *Congest Heart Fail*, 15: 131-135.
208. Chen H, Wu B, Gong D, Liu Z. (2015) Fluid overload at start of continuous renal replacement therapy is associated with poorer clinical condition and outcome: a



- prospective observational study on the combined use of bioimpedance vector analysis and serum N-terminal pro-B-type natriuretic peptide measurement. *Crit Care*, 19: 1.
209. Artunc F, Mueller C, Breidthardt T, Twerenbold R, Rettig I, Usta E, Häring H-U, Friedrich B. (2012) Comparison of the diagnostic performance of three natriuretic peptides in hemodialysis patients: which is the appropriate biomarker? *Kidney Blood Press Res*, 36: 172-181.
210. Papanikolaou J, Makris D, Mpaka M, Palli E, Zygoulis P, Zakynthinos E. (2014) New insights into the mechanisms involved in B-type natriuretic peptide elevation and its prognostic value in septic patients. *Crit Care*, 18: 1.
211. George J, Varma S, Kumar S, Thomas J, Gopi S, Pisharody R. (2011) Comparing continuous venovenous hemodiafiltration and peritoneal dialysis in critically ill patients with acute kidney injury: a pilot study. *Perit Dial Int*, 31: 422-429.
212. Ponce D, Berbel MN, Regina de Goes C, Almeida CT, Balbi AL. (2012) High-volume peritoneal dialysis in acute kidney injury: indications and limitations. *Clin J Am Soc Nephrol*, 7: 887-894.
213. Ponce D, Berbel MN, Abrao JM, Goes CR, Balbi AL. (2013) A randomized clinical trial of high volume peritoneal dialysis versus extended daily hemodialysis for acute kidney injury patients. *Int Urol Nephrol*, 45: 869-878.
214. Cullis B, Abdelraheem M, Abrahams G, Balbi A, Cruz DN, Frishberg Y, Koch V, McCulloch M, Numanoglu A, Nourse P, Pecoits-Filho R, Ponce D, Warady B, Yeates K, Finkelstein FO. (2014) Peritoneal dialysis for acute kidney injury. *Perit Dial Int*, 34: 494-517.
215. Liborio AB, Leite TT, Neves FM, Teles F, Bezerra CT. (2015) AKI complications in critically ill patients: association with mortality rates and RRT. *Clin J Am Soc Nephrol*, 10: 21-28.
216. Parapiboon W, Chamradpan T. (2017) Intensive versus standard dosage for peritoneal dialysis in acute kidney injury: a randomized pilot study. *Perit Dial Int*, doi: 10.3747/pdi.2016.00260 (E-pub date: 25 May 2017).
217. Shlipak MG, Coca SG, Wang Z, Devarajan P, Koyner JL, Patel UD, Thiessen-Philbrook H, Garg AX, Parikh CR, TRIBE-AKI Consortium. (2011) Presurgical serum cystatin C and risk of acute kidney injury after cardiac surgery. *Am J Kidney Dis*, 58: 366-373.

218. Vanmassenhove J, Vanholder R, Nagler E, Van Biesen W. (2013) Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. *Nephrol Dial Transplant*, 28: 254-273.
219. Devarajan P, Murray P. (2014) Biomarkers in acute kidney injury: are we ready for prime time? *Nephron Clin Pract*, 127: 176-179.
220. Goldstein SL, Chawla LS. (2010) Renal angina. *Clin J Am Soc Nephrol*, 5: 943-949.
221. Gheissari A. (2013) Acute kidney injury and renal angina. *J Renal Inj Prev*, 2: 33-34.
222. Takasu O, Gaut JP, Watanabe E, To K, Fagley RE, Sato B, Jarman S, Efimov IR, Janks DL, Srivastava A, Bhayani SB, Drewry A, Swanson PE, Hotchkiss RS. (2013) Mechanisms of cardiac and renal dysfunction in patients dying of sepsis. *Am J Respir Crit Care Med*, 187: 509-517.
223. Ralib AM, Pickering JW, Shaw GM, Endre ZH. (2013) The urine output definition of acute kidney injury is too liberal. *Critical Care*, 17: R112.
224. Kellum JA, Sileanu FE, Murugan R, Lucko N, Shaw AD, Clermont G. (2015) Classifying AKI by urine output versus serum creatinine level. *J Am Soc Nephrol*, 26: 2231-2238.
225. Macedo E, Malhotra R, Bouchard J, Wynn SK, Mehta RL. (2011) Oliguria is an early predictor of higher mortality in critically ill patients. *Kidney Int*, 80: 760-767.
226. Chazot C, Vo VC, Blanc C, Hurot JM, Jean G, Vanel T, Terrat JC, Charra B. (2006) Stability of nutritional parameters during a 5-year follow-up in patients treated with sequential long-hour hemodialysis. *Hemodial Int*, 10: 389-393.
227. Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT, NECOSAD Study Group. (2004) Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. *J Am Soc Nephrol*, 15: 1061-1070.
228. Zhou YL, Liu HL, Duan XF, Yao Y, Sun Y, Liu Q. (2006) Impact of sodium and ultrafiltration profiling on haemodialysis-related hypotension. *Nephrol Dial Transplant*, 21: 3231-3237.

229. Selby NM, McIntyre CW. (2007) The acute cardiac effects of dialysis. *Semin Dial*, 20: 220-228.
230. Shoji T, Tsubakihara Y, Fujii M, Imai E. (2004) Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. *Kidney Int*, 66: 1212-1220.
231. Dalrymple LS, Mu Y, Romano PS, Nguyen DV, Chertow GM, Delgado C, Grimes B, Kaysen GA, Johansen KL. (2015) Outcomes of infection-related hospitalization in Medicare beneficiaries receiving in-center hemodialysis. *Am J Kidney Dis*, 65: 754-762.
232. Dhondt A, Vanholder R, Van Biesen W, Lameire N. (2000) The removal of uremic toxins. *Kidney Int Suppl*, 76: S47-59.
233. Fulop T, Rule AD, Schmidt DW, Wiste HJ, Bailey KR, Kullo IJ, Schwartz GL, Mosley TH, Boerwinkle E, Turner ST. (2009) C-reactive protein among community-dwelling hypertensives on single-agent antihypertensive treatment. *J Am Soc Hypertens*, 3: 260-266.
234. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimbürger O, Cederholm T, Girndt M. (2005) IL-10, IL-6, and TNF-alpha: Central factors in the altered cytokine network of uremia - the good, the bad, and the ugly. *Kidney Int*, 67: 1216-1233.
235. Caglar K, Peng Y, Pupim LB, Flakoll PJ, Levenhagen D, Hakim RM, Ikizler TA. (2002) Inflammatory signals associated with hemodialysis. *Kidney Int*, 62: 1408-1416.
236. Windram JD, Loh PH, Rigby AS, Hanning I, Clark AL, Cleland JG. (2007) Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. *Am Heart J*, 153: 1048-1055.
237. Bahrami H, Bluemke DA, Kronmal R, Bertoni AG, Lloyd-Jones DM, Shahar E, Szklo M, Lima JA. (2008) Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. *J Am Coll Cardiol*, 51: 1775-1783.
238. Ortega O, Gallar P, Munoz M, Rodriguez I, Carreno A, Ortiz M, Molina A, Olié A, Lozano L, Vigil A. (2004) Association between C-reactive protein levels and

N-terminal pro-B-type natriuretic peptide in pre-dialysis patients. *Nephron Clin Pract*, 97: c125-130.

239. Avila-Diaz M, Ventura MD, Valle D, Vicente-Martinez M, Garcia-Gonzalez Z, Cisneros A, Furlong MD, Gomez AM, Prado-Urbe MD, Amato D, Paniagua R. (2006)

Inflammation and extracellular volume expansion are related to sodium and water removal in patients on peritoneal dialysis. *Perit Dial Int*, 26: 574-580.

240. Flythe JE, Curhan GC, Brunelli SM. (2013) Disentangling the ultrafiltration rate-mortality association: the respective roles of session length and weight gain. *Clin J Am Soc Nephrol*, 8: 1151-1161.

241. Tandon T, Sinha AD, Agarwal R. (2013) Shorter delivered dialysis times associate with a higher and more difficult to treat blood pressure. *Nephrol Dial Transplant*, 28: 1562-1568.

242. Movilli E, Camerini C, Gaggia P, Zubani R, Feller P, Poiatti P, Pola A, Carli O, Valzorio B, Cancarini G. (2013) Role of dialysis sodium gradient on intradialytic hypertension: an observational study. *Am J Nephrol*, 38: 413-419.

243. Inrig JK, Van Buren P, Kim C, Vongpatanasin W, Povsic TJ, Toto R. (2012) Probing the mechanisms of intradialytic hypertension: a pilot study targeting endothelial cell dysfunction. *Clin J Am Soc Nephrol*, 7: 1300-1309.

244. Odudu A, Eldehni MT, McCann GP, McIntyre CW. (2015) Randomized controlled trial of individualized dialysate cooling for cardiac protection in hemodialysis patients. *Clin J Am Soc Nephrol*, 10: 1408-1417.

245. Eldehni MT, Odudu A, McIntyre CW. (2015) Randomized clinical trial of dialysate cooling and effects on brain white matter. *J Am Soc Nephrol*, 26: 957-965.

246. Passauer J, Petrov H, Schleser A, Leicht J, Pucalka K. (2010) Evaluation of clinical dry weight assessment in haemodialysis patients using bioimpedance spectroscopy: a cross-sectional study. *Nephrol Dial Transplant*, 25: 545-551.

247. Kimmel PL, Varela MP, Peterson RA, Weihs KL, Simmens SJ, Alleyne S, Amarashinge A, Mishkin GJ, Cruz I, Veis JH. (2000) Interdialytic weight gain and survival in hemodialysis patients: effects of duration of ESRD and diabetes mellitus. *Kidney Int*, 57: 1141-1151.

248. Cabrera C, Brunelli SM, Rosenbaum D, Anum E, Ramakrishnan K, Jensen DE, Stålhammar N-O, Stefánsson BV. (2015) A retrospective, longitudinal study estimating

the association between interdialytic weight gain and cardiovascular events and death in hemodialysis patients. *BMC Nephrol*, 16: 1.

249. Jadoul M, Thumma J, Fuller DS, Tentori F, Li Y, Morgenstern H, Mendelssohn D, Tomo T, Ethier J, Port F, Robinson BM. (2012) Modifiable practices associated with sudden death among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. *Clin J Am Soc Nephrol*, 7: 765-774.

250. Wong MM, McCullough KP, Bieber BA, Bommer J, Hecking M, Levin NW, McClellan WM, Pisoni RL, Saran R, Tentori F, Tomo T, Port FK, Robinson BM. (2017) Interdialytic weight gain: trends, predictors, and associated outcomes in the international Dialysis Outcomes and Practice Patterns Study (DOPPS). *Am J Kidney Dis*, 69: 367-379.

251. Rigby A, Scribner B, Ahmad S. (2000) Sodium, not fluid, controls interdialytic weight gain. *Nephrol News Issues*, 14: 21.

252. Chan KE, Thadhani RI, Maddux FW. (2014) Adherence barriers to chronic dialysis in the United States. *J Am Soc Nephrol*, 25: 2642-2648.

253. Obialo C, Zager PG, Myers OB, Hunt WC. (2014) Relationships of clinic size, geographic region, and race/ethnicity to the frequency of missed/shortened dialysis treatments. *J Nephrol*, 27: 425-430.

254. Armstrong K, McMurphy S, Dean LT, Micco E, Putt M, Halbert CH, Schwartz JS, Sankar P, Pyeritz RE, Bernhardt B, Shea JA. (2008) Differences in the patterns of health care system distrust between blacks and whites. *J Gen Intern Med*, 23: 827-833.

255. Braunstein JB, Sherber NS, Schulman SP, Ding EL, Powe NR. (2008) Race, medical researcher distrust, perceived harm, and willingness to participate in cardiovascular prevention trials. *Medicine (Baltimore)*, 87: 1-9.

256. Armstrong K, Ravenell KL, McMurphy S, Putt M. (2007) Racial/ethnic differences in physician distrust in the United States. *Am J Public Health*, 97: 1283-1289.

257. Rodriguez RA, Sen S, Mehta K, Moody-Ayers S, Bacchetti P, O'Hare AM. (2007) Geography matters: relationships among urban residential segregation, dialysis facilities, and patient outcomes. *Ann Internal Med*, 146: 493-501.

258. Kaptein EM, Sreeramoju D, Kaptein JM, Kaptein MJ. (2016) A systematic literature search and review of sodium concentrations of body fluids. *Clin Nephrol*, 86: 203-228.
259. Lacson E, Jr., Xu J, Suri RS, Nesrallah G, Lindsay R, Garg AX, Lester K, Ofsthun N, Lazarus M, Hakim RM. (2012) Survival with three-times weekly in-center nocturnal versus conventional hemodialysis. *J Am Soc Nephrol*, 23: 687-695.
260. Rocco MV, Daugirdas JT, Greene T, Lockridge RS, Chan C, Pierratos A, Lindsay R, Larive B, Chertow GM, Beck GJ, Eggers PW, Klinger AS, FHN Trial Group. (2015) Long-term effects of frequent nocturnal hemodialysis on mortality: The Frequent Hemodialysis Network (FHN) nocturnal trial. *Am J Kidney Dis*, 66: 459-468.
261. Hladunewich MA, Hou S, Odutayo A, Cornelis T, Pierratos A, Goldstein M, Tennankore K, Keunen J, Hui D, Chan CT. (2014) Intensive hemodialysis associates with improved pregnancy outcomes: a Canadian and United States cohort comparison. *J Am Soc Nephrol*, 25: 1103-1109.
262. (1997) Excerpts from the *USRDS: Annual Report. IV. The USRDS dialysis morbidity and mortality study: Wave 2*. *Am J Kidney Dis*, 30: S67-S85
263. Lacson E, Jr., Lazarus JM, Himmelfarb J, Ikizler TA, Hakim RM. (2007) Balancing fistula first with catheters last. *Am J Kidney Dis*, 50: 379-395.
264. Mokrzycki MH, Zhang M, Cohen H, Golestaneh L, Laut JM, Rosenberg SO. (2006) Tunnelled haemodialysis catheter bacteraemia: risk factors for bacteraemia recurrence, infectious complications and mortality. *Nephrol Dial Transplant*, 21: 1024-1031.
265. Dalrymple LS, Mu Y, Nguyen DV, Romano PS, Chertow GM, Grimes B, Kaysen GA, Johansen KL. (2015) Risk factors for infection-related hospitalization in in-center hemodialysis. *Clin J Am Soc Nephrol*, 10: 2170-2180.
266. Singhal R, Hux JE, Alibhai SM, Oliver MJ. (2014) Inadequate predialysis care and mortality after initiation of renal replacement therapy. *Kidney Int*, 86: 399-406.
267. Foley RN, Chen SC, Solid CA, Gilbertson DT, Collins AJ. (2014) Early mortality in patients starting dialysis appears to go unregistered. *Kidney Int*, 86: 392-398.
268. Povlsen JV, Ivarsen P. (2006) How to start the late referred ESRD patient urgently on chronic APD. *Nephrol Dial Transplant*, 21: ii56-ii59.

269. Ghaffari A. (2012) Urgent-start peritoneal dialysis: a quality improvement report. *Am J Kidney Dis*, 59: 400-408.
270. Mehrotra R, Chiu YW, Kalantar-Zadeh K, Bargman J, Vonesh E. (2011) Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. *Arch Intern Med*, 171: 110-118.
271. Saxena R. (2014) Peritoneal dialysis: misperceptions and reality. *Am J Med Sci*, 348: 250-261.
272. Schmidt DS, Salahudeen AK. (2007) Cardiovascular and survival paradoxes in dialysis patients: obesity-survival paradox - still a controversy? *Semin Dial*, 20: 486-492.
273. Elmahi N, Csongradi E, Kokko K, Lewin JR, Davison J, Fulop T. (2013) Residual renal function in peritoneal dialysis with failed allograft and minimum immunosuppression. *World J Transplant*, 3: 26-29.
274. Afthentopoulos I, Oreopoulos D. (1997) Is CAPD an effective treatment for ESRD patients with a weight over 80 kg? *Clin Nephrol*, 47: 389-393.
275. Johnson DW, Herzig KA, Purdie DM, Chang W, Brown AM, Rigby RJ, Campbell SB, Nicol DL, Hawley CM. (2000) Is obesity a favorable prognostic factor in peritoneal dialysis patients? *Perit Dial Int*, 20: 715-721.
276. Wang AY, Lai KN. (2006) The importance of residual renal function in dialysis patients. *Kidney Int*, 69: 1726-1732.
277. Khawar O, Kalantar-Zadeh K, Lo WK, Johnson D, Mehrotra R. (2007) Is the declining use of long-term peritoneal dialysis justified by outcome data? *Clin J Am Soc Nephrol*, 2: 1317-1328.
278. Liao CT, Chen YM, Shiao CC, Hu FC, Huang JW, Kao TW, Chuang HF, Hung KY, Wu KD, Tsai TJ. (2009) Rate of decline of residual renal function is associated with all-cause mortality and technique failure in patients on long-term peritoneal dialysis. *Nephrol Dial Transplant*, 24: 2909-2914.
279. Tzamaloukas AH, Murata GH, Piraino B, Malhotra D, Bernardini J, Rao P, Oreopoulos DG. (1999) The relation between body size and normalized small solute clearances in continuous ambulatory peritoneal dialysis. *J Am Soc Nephrol*, 10: 1575-1581.

280. Heaf JG, Lokkegaard H, Madsen M. (2002) Initial survival advantage of peritoneal dialysis relative to haemodialysis. *Nephrol Dial Transplant*, 17: 112-117.
281. McDonald SP, Marshall MR, Johnson DW, Polkinghorne KR. (2009) Relationship between dialysis modality and mortality. *J Am Soc Nephrol*, 20: 155-163.
282. Ahmadi SF, Zahmatkesh G, Streja E, Mehrotra R, Rhee CM, Kovesdy CP, Gillen DL, Ahmadi E, Fonarow GC, Kalantar-Zadeh K. (2016) Association of body mass index with mortality in peritoneal dialysis patients: a systematic review and meta-analysis. *Perit Dial Int*, 36: 315-325.
283. Abdul Salim S, Akula Y, Kandhuri S, Afshan S, Zsom L, Dixit MP, Fülöp T. (2016) Successful peritoneal dialysis in relatively large subjects ( $\geq 100$  kg): clinical features and comparison with normal weight ( $\leq 75$  kg) individuals. *Adv Perit Dial*, 32: 61-67.
284. Quittnat Pelletier F, Joarder M, Poutanen SM, Lok CE. (2016) Evaluating approaches for the diagnosis of hemodialysis catheter-related bloodstream infections. *Clin J Am Soc Nephrol*, 11: 847-854.
285. Johns TS, Mokrzycki MH. (2016) Optimal approach for the diagnosis of hemodialysis catheter-related bacteremia. *Clin J Am Soc Nephrol*, 11: 756-758.
286. Dalgaard LS, Nørgaard M, Povlsen JV, Jespersen B, Jensen-Fangel S, Ellermann-Eriksen S, Østergaard L, Schønheyder HC, Søgaaard OS. (2016) Risk and prognosis of bacteremia and fungemia among peritoneal dialysis patients: a population-based cohort study. *Perit Dial Int*, 36: 647-654.
287. Ravani P, Gillespie BW, Quinn RR, MacRae J, Manns B, Mendelssohn D, Tonelli M, Hemmelgarn B, James M, Pannu N, Robinson BM, Zhang X, Pisoni R. (2013) Temporal risk profile for infectious and noninfectious complications of hemodialysis access. *J Am Soc Nephrol*, 24: 1668-1677.
288. Chan KE, Warren HS, Thadhani RI, Steele DJ, Hymes JL, Maddux FW, Hakim RM. (2012) Prevalence and outcomes of antimicrobial treatment for *Staphylococcus aureus* bacteremia in outpatients with ESRD. *J Am Soc Nephrol*, 23: 1551-1559.
289. Dixon JJ, Steele M, Mankanjuola AD. (2012) Anti-microbial locks increase the prevalence of *Staphylococcus aureus* and antibiotic-resistant *Enterobacter*: observational retrospective cohort study. *Nephrol Dial Transplant*, 27: 3575-3581.



290. Moran J, Sun S, Khababa I, Pedan A, Doss S, Schiller B. (2012) A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients. *Am J Kidney Dis*, 59: 102-107.
291. Tapping CR, Scott PM, Lakshminarayan R, Ettles DF, Robinson GJ. (2012) Replacement tunneled dialysis catheters for haemodialysis access: same site, new site, or exchange - a multivariate analysis and risk score. *Clin Radiol*, 67: 960-965.
292. Tanriover B, Carlton D, Saddekni S, Hamrick K, Oser R, Westfall AO, Allon M. (2000) Bacteremia associated with tunneled dialysis catheters: comparison of two treatment strategies. *Kidney Int*, 57: 2151-2155.
293. Gharaibeh KA, Csongrádi É, Shoemaker-Moyle M, Lerant A, Tapolyai MI, Fülöp T. (2012) Pulmonary embolization with tunneled hemodialysis catheter-associated blood stream infection: the perils of systemic anticoagulation. *Nephrol Rev*, 4: e17.
294. McQuillan RF, Clark E, Zahirieh A, Cohen ER, Paparello JJ, Wayne DB, Barsuk JH. (2015) Performance of temporary hemodialysis catheter insertion by nephrology fellows and attending nephrologists. *Clin J Am Soc Nephrol*, 10: 1767-1772.
295. Hung A, Pupim L, Yu C, Shintani A, Siew E, Ayus C, Hakim RM, Ikizler TA. (2008) Determinants of C-reactive protein in chronic hemodialysis patients: relevance of dialysis catheter utilization. *Hemodial Int*, 12: 236-243.
296. Martinez SG, Tan CS, Spearman K, Wicky S, Wu S. (2013) Safety of percutaneous tunneled hemodialysis catheter procedures in patients receiving concurrent clopidogrel therapy. *J Vasc Access*, 15: 33-37.
297. Kohli MD, Tretotola SO, Namyslowski J, Stecker MS, McLennan G, Patel NH, Johnson MS, Shah H, Seshadri R. (2001) Outcome of polyester cuff retention following traction removal of tunneled central venous catheters. *Radiology*, 219: 651-654.
298. Kelly MJ, Anwar S, Vachharajani T, Karasek M, Ahmed S. (2016) Learning From Images: fundamental mistake during tunneled hemodialysis catheter (TDC) removal. *Open Urol Nephrol J*, 9.
299. Ellis RL, Dempsey PJ, Rubin E, Pile NS, Bernreuter WK. (1997) Mammography of breasts in which catheter cuffs have been retained: normal, infected, and postoperative appearances. *Am J Roentgenol*, 169: 713-715.

300. Forneris G, Savio D, Quaretti P, Fiorina I, Cecere P, Pozzato M, Trogolo M, Roccatello D. (2014) Dealing with stuck hemodialysis catheter: state of the art and tips for the nephrologist. *J Nephrol*, 27: 619-625.
301. Akbar Beigi A, Yaribakht M, Sehat S. (2013) Four cases of adhered permanent double lumen hemodialysis catheters (Permcath). *Arch Iranian Med*, 16: 243.
302. Vellanki VS, Watson D, Rajan DK, Bhola CB, Lok CE. (2015) The stuck catheter: a hazardous twist to the meaning of permanent catheters. *J Vasc Access*, 16: 289-293.
303. Hassan A, Khalifa M, Al-Akraa M, Lord R, Davenport A. (2006) Six cases of retained central venous haemodialysis access catheters. *Nephrol Dial Transplant*, 21: 2005-2008.
304. Drew DA, Meyer KB, Weiner DE. (2011) Transvenous cardiac device wires and vascular access in hemodialysis patients. *Am J Kidney Dis*, 58: 494-496.
305. Garcarek J, Golebiowski T, Letachowicz K, Kusztal M, Szymczak M, Madziarska K, Jakuszko K, Zmonarski S, Guzinski M, Weyde W, Klinger M. (2016) Balloon dilatation for removal of an irretrievable permanent hemodialysis catheter: the safest approach. *Artif Organs*, 40: E84-88.
306. Ryan SE, Hadziomerovic A, Aquino J, Cunningham I, O'Kelly K, Rasuli P. (2012) Endoluminal dilation technique to remove "stuck" tunneled hemodialysis catheters. *J Vasc Interv Radiol*, 23: 1089-1093.
307. Niyyar VD, Work J. (2011) Avoiding a cutdown--use of the transcatheter extractor in removal of tunneled dialysis catheters. *Semin Dial*, 24: 115-117.
308. Carrillo RG, Garisto JD, Salman L, Merrill D, Asif A. (2009) A novel technique for tethered dialysis catheter removal using the laser sheath. *Semin Dial*, 22: 688-691.
309. Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, Harris A, Johnson DW, Kesselhut J, Li JJ, Luxton G, Pilmore A, Tiller DJ, Harris DC, Pollock CA. (2010) A randomized, controlled trial of early versus late initiation of dialysis. *N Engl J Med*, 363: 609-619.
310. Crews DC, Scialla JJ, Boulware LE, Navaneethan SD, Nally JV, Jr., Liu X, Arrigain S, Schold JD, Ephraim PL, Jolly SE, Sozio SM, Michels WM, Miskulin DC, Tangri N, Shafi T, Wu AW, Bandeen-Roche K, DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators. (2014) Comparative effectiveness of early

versus conventional timing of dialysis initiation in advanced CKD. *Am J Kidney Dis*, 63: 806-815.

311. Crews DC, Scialla JJ, Liu J, Guo H, Bandeen-Roche K, Ephraim PL, Jaar BG, Sozio SM, Miskulin DC, Tangri N, Shafi T, Meyer KB, Wu AW, Powe NR, Boulware LE, Developing Evidence to Inform Decisions about Effectiveness Patient Outcomes in End Stage Renal Disease Study Investigators. (2014) Predialysis health, dialysis timing, and outcomes among older United States adults. *J Am Soc Nephrol*, 25: 370-379.

312. National Kidney Foundation. (2015) KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update. *Am J Kidney Dis*, 66: 884-930.

313. Grooteman MP, van den Dorpel MA, Bots ML, Penne EL, van der Weerd NC, Mazairac AH, den Hoedt CH, van der Tweel I, Levesque R, Nube MJ, ter Wee PM, Blankestijn PJ. (2012) Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. *J Am Soc Nephrol*, 23: 1087-1096.

314. Ok E, Asci G, Toz H, Ok ES, Kircelli F, Yilmaz M, Hur E, Demirci MS, Demirci C, Duman S, Basci A, Adam SM, Isik IO, Zengin M, Suleymanlar G, Yilmaz ME, Ozkahya M, Turkish Online Haemodiafiltration Study. (2013) Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. *Nephrol Dial Transplant*, 28: 192-202.

315. Maduell F, Moreso F, Pons M, Ramos R, Mora-Macia J, Carreras J, Soler J, Torres F, Campistol JM, Martinez-Castelao A, ESHOL Study Group. (2013) High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. *J Am Soc Nephrol*, 24: 487-497.

316. Nistor I, Palmer SC, Craig JC, Saglimbene V, Vecchio M, Covic A, Strippoli GF. (2014) Convective versus diffusive dialysis therapies for chronic kidney failure: an updated systematic review of randomized controlled trials. *Am J Kidney Dis*, 63: 954-967.

317. Mazairac AH, Blankestijn PJ, Grooteman MP, Penne EL, van der Weerd NC, den Hoedt CH, Buskens E, van den Dorpel MA, ter Wee PM, Nube MJ, Bots ML, de Wit GA. (2013) The cost-utility of haemodiafiltration versus haemodialysis in the Convective Transport Study. *Nephrol Dial Transplant*, 28: 1865-1873.

318. Suri RS, Lindsay RM, Bieber BA, Pisoni RL, Garg AX, Austin PC, Moist LM, Robinson BM, Gillespie BW, Couchoud CG, Galland R, Lacson EK, Jr., Zimmerman DL, Li Y, Nesrallah GE. (2013) A multinational cohort study of in-center daily hemodialysis and patient survival. *Kidney Int*, 83: 300-307.
319. Suri RS, Larive B, Sherer S, Eggers P, Gassman J, James SH, Lindsay RM, Lockridge RS, Ornt DB, Rocco MV, Ting GO, Klinger AS, Frequent Hemodialysis Network Trial Group. (2013) Risk of vascular access complications with frequent hemodialysis. *J Am Soc Nephrol*, 24: 498-505.
320. Suri RS, Garg AX, Chertow GM, Levin NW, Rocco MV, Greene T, Beck GJ, Gassman JJ, Eggers PW, Star RA, Ornt DB, Klinger AS, Frequent Hemodialysis Network Trial Group. (2007) Frequent Hemodialysis Network (FHN) randomized trials: study design. *Kidney Int*, 71: 349-359.
321. Weinhandl ED, Nieman KM, Gilbertson DT, Collins AJ. (2015) Hospitalization in daily home hemodialysis and matched thrice-weekly in-center hemodialysis patients. *Am J Kidney Dis*, 65: 98-108.
322. Weinhandl ED, Liu J, Gilbertson DT, Arneson TJ, Collins AJ. (2012) Survival in daily home hemodialysis and matched thrice-weekly in-center hemodialysis patients. *J Am Soc Nephrol*, 23: 895-904.
323. Nesrallah GE, Lindsay RM, Cuerden MS, Garg AX, Port F, Austin PC, Moist LM, Pierratos A, Chan CT, Zimmerman D, Lockridge RS, Couchoud C, Chazot C, Ofsthun N, Levin A, Copland M, Courtney M, Steele A, McFarlane PA, Geary DF, Pauly RP, Komenda P, Suri RS. (2012) Intensive hemodialysis associates with improved survival compared with conventional hemodialysis. *J Am Soc Nephrol*, 23: 696-705.
324. Bieber B, Qian J, Anand S, Yan Y, Chen N, Wang M, Wang M, Zuo L, Hou FF, Pisoni RL, Robinson BM, Ramirez SP. (2014) Two-times weekly hemodialysis in China: frequency, associated patient and treatment characteristics and Quality of Life in the China Dialysis Outcomes and Practice Patterns Study. *Nephrol Dial Transplant*, 29: 1770-1777.
325. Kalantar-Zadeh K, Unruh M, Zager PG, Kovesdy CP, Bargman JM, Chen J, Sankarasubbaiyan S, Shah G, Golper T, Sherman RA, Goldfarb DS. (2014) Twice-

weekly and incremental hemodialysis treatment for initiation of kidney replacement therapy. *Am J Kidney Dis*, 64: 181-186.

326. Zhang M, Wang M, Li H, Yu P, Yuan L, Hao C, Chen J, Kalantar-Zadeh K. (2014) Association of initial twice-weekly hemodialysis treatment with preservation of residual kidney function in ESRD patients. *Am J Nephrol*, 40: 140-150.

327. Sirich TL, Plummer NS, Gardner CD, Hostetter TH, Meyer TW. (2014) Effect of increasing dietary fiber on plasma levels of colon-derived solutes in hemodialysis patients. *Clin J Am Soc Nephrol*, 9: 1603-1610.

328. Rossi M, Johnson DW, Morrison M, Pascoe EM, Coombes JS, Forbes JM, Szeto CC, McWhinney BC, Ungerer JP, Campbell KL. (2016) Synbiotics easing renal failure by improving gut microbiology (SYNERGY): A Randomized Trial. *Clin J Am Soc Nephrol*, 11: 223-231.

## 10. Bibliography of the candidate's publications

### 10.1 Original publications utilized to develop the Thesis

Fülöp T, Pathak MB, Schmidt DW, Lengvárszky Z, Juncos JP, Lebrun CJ, Brar H, Juncos LA. (2010) *Volume-Related Weight Gain and Subsequent Mortality in Acute Renal Failure Patients Treated with Continuous Renal Replacement Therapy*. *ASAIO J*, 56: 333-337. (Impact Factor: 1.221)

\*Zsom L, Zsom M, \*Fülöp T, Wells C, Flessner MF, Eller J, Wollheim C, Hegbrant J, Strippoli FMG. (2010) *Correlation of Treatment Time and Ultrafiltration Rate with Serum Albumin and C-reactive Protein Levels in Patients with End Stage Kidney Disease Receiving Chronic Maintenance Hemodialysis: A Cross-Sectional Study*. *Blood Purif*, 30: 8-15. (Impact Factor: 1.521)

\*Authors contributed to the article equally; Dr. Fülöp corresponding Author

Fülöp T, Tapolyai M, Qureshi NA, Beemidi VR, Gharaibeh KA, Szarvas T, Hamrahian SM, Csongrádi É. (2013) *The Safety and Efficacy of Bedside Removal of Tunneled Hemodialysis Catheters by Nephrology Trainees*. *Ren Fail*, 35: 1264-1268. (Impact Factor: 0.775)

Fülöp T, Rodríguez B, Kosztaczký BA, Gharaibeh KA, Lengvárszky Z, Dossabhoy NR, Tapolyai MB. (2015) *Tunneled Hemodialysis Catheter Removals by Non-Interventional Nephrologists: the University of Mississippi Experience*. *Semin Dial*, 28: E48–E52. (Impact Factor: 1.912)

### 10.2 Additional publications

Fülöp T, Tapolyai M, Agarwal M, Lopez-Ruiz A, Dossabhoy NR. (2016) *Tunneled Dialysis Catheter Removal by Nephrologists - A Lesson Learned from Nephrology Trainees*. *Artif Organs*, DOI: 10.1111/aor.12869 (E-pub date: 26 December 2016)

Fülöp T, Zsom L, Tapolyai MB, Molnar MZ, Rosiváll L. (2017) *Volume-related Weight Gain as an Independent Indication for Renal Replacement Therapy in the Intensive Care Units*. J Renal Inj Prev, 6: 35-42.

Akula YV, Fülöp T\*, Dixit MP. (2017) *Peritoneal Dialysis in Class 2-3 Obesity – A Single-Center Experience*. Am J Med Sci, 353: 70-75.

\*Dr. Fülöp corresponding Author

Fülöp T, Zsom L, Rodríguez B, Afshan S, Davidson JV, Szarvas T, Dixit MP, Tapolyai MB, Rosiváll L. (2016) *Clinical Utility of Potassium-Sparing Diuretics in Peritoneal Dialysis Patients to Maintain Normal Serum Potassium*. Perit Dial Int, 37: 63-69.

Molnar MZ, Nagy K, Rempfort A, Gaipov A, Fülöp T, Czira ME, Kovesdy CP, Mucsi I, Mathe Z. (2017) *Association between Serum Leptin Level and Mortality in Kidney Transplant Recipients*. J Ren Nutr, 27: 53-61.

Tapolyai MB, Pethő Á, Fülöp T. (2017) *Whole-Body Imaging Procedures in Resistant Hypertension: Evaluating for Secondary Causes or to Define End-Organ Damages?* J Clin Hypertens, 19: 23-25.

Afshan S, Farah Musa AR, Lerant AA, Echols V, Fülöp T. (2017) *Persisting Hypocalcemia after Surgical Parathyroidectomy: The Differential Effectiveness of Calcium-Citrate vs. Calcium-Carbonate with Acid Suppression*. Am J Med Sci, 353: 82-86.

Li M, Li Y, Weeks O, Mijatovic V, Teumer A, Huffman JE, Tromp G, Fuchsberger C, Gorski M, Lyytikäinen LP, Nutile T, Sedaghat S, Sorice R, Tin A, Yang Q, Ahluwalia TS, Arking DE, Bihlmeyer NA, Böger CA, Carroll RJ, Chasman DI, Cornelis MC, Dehghan A, Faul JD, Feitosa MF, Gambaro G, Gasparini P, Giulianini F, Heid I, Huang J, Imboden M, Jackson AU, Jeff J, Jhun MA, Katz R, Kifley A, Kilpeläinen TO, Kumar A, Laakso M, Li-Gao R, Lohman K, Lu Y, Mägi R, Malerba G, Mihailov E, Mohlke KL,

Mook-Kanamori DO, Robino A, Ruderfer D, Salvi E, Schick UM, Schulz CA, Smith AV, Smith JA, Traglia M, Yerges-Armstrong LM, Zhao W, Goodarzi MO, Kraja AT, Liu C, Wessel J; CHARGE Glycemic-T2D Working Group,.; CHARGE Blood Pressure Working Group,., Boerwinkle E, Borecki IB, Bork-Jensen J, Bottinger EP, Braga D, Brandslund I, Brody JA, Campbell A, Carey DJ, Christensen C, Coresh J, Crook E, Curhan GC, Cusi D, de Boer IH, de Vries AP, Denny JC, Devuyst O, Dreisbach AW, Endlich K, Esko T, Franco OH, Fulop T, Gerhard GS, Glümer C, Gottesman O, Grarup N, Gudnason V, Harris TB, Hayward C, Hocking L, Hofman A, Hu FB, Husemoen LL, Jackson RD, Jørgensen T, Jørgensen ME, Kähönen M, Kardia SL, König W, Kooperberg C, Kriebel J, Launer LJ, Lauritzen T, Lehtimäki T, Levy D, Linksted P, Linneberg A, Liu Y, Loos RJ, Lupo A, Meisinger C, Melander O, Metspalu A, Mitchell P, Nauck M, Nürnberg P, Orho-Melander M, Parsa A, Pedersen O, Peters A, Peters U, Polasek O, Porteous D, Probst-Hensch NM, Psaty BM, Qi L, Raitakari OT, Reiner AP, Rettig R, Ridker PM, Rivadeneira F, Rossouw JE, Schmidt F, Siscovick D, Soranzo N, Strauch K, Toniolo D, Turner ST, Uitterlinden AG, Ulivi S, Velayutham D, Völker U, Völzke H, Waldenberger M, Wang JJ, Weir DR, Witte D, Kuivaniemi H, Fox CS, Franceschini N, Goessling W, Köttgen A, Chu AY. (2017) *Two Loci Identified through Large-Scale Exome Chip Meta-Analysis, SOS2 and ACPI, Show Evidence for Altered Kidney Development*. *J Am Soc Nephrol*, 28: 981-994.

Abdul Salim S, Yougandhar A, Kandhuri S, Afshan S, Zsom L, Dixit MP, Fülöp T. (2016) *Successful Peritoneal Dialysis in Relatively Large Subjects ( $\geq 100$  kg): Clinical Features and Comparison with Normal Weight ( $\leq 75$  kg) Individuals*. *Adv Perit Dial*, 32: 61-67.

Arany I, Carter A, Hall S, Fulop T, Dixit MP. (2016) *Coenzyme Q10 Protects Renal Proximal Tubule Cells against Nicotine-induced Apoptosis through Induction of p66shc-Dependent Antioxidant Responses*. *Apoptosis*, 22: 220-228.

Cade BE, Gottlieb DJ, Lauderdale DS, Bennett DA, Buchman AS, Buxbaum SG, DeJager PL, Evans DS, Fülöp T, Gharib SA, Johnson WC, Larkin EK, Lim AS, Punjabi NM, Saxena R, Tranah GJ, Weng J, Zee PC, Patel SR, Zhu X, Redline S. (2016) *DRD2 is Associated with Sleep Duration: The CARE Consortium*. *Hum Mol Genet*, 25: 167-79.



Dossabhoy NR, Sangha B, Tapolyai MB, Fülöp T. (2016) *Outpatient Removal of Tunneled Dialysis Catheters by Nephrology Fellows in Training at a Veteran Administration Medical Center*. J Vasc Access 17: 340-344.

Molnar MZ, Nagy K, Remport A, Tapolyai MB, Fülöp T, Kama F, Kovesdy CP, Mucsi I, Mathe Z. (2016) *Inflammatory Markers and Outcomes in Kidney Transplant Recipients*. Transplantation, DOI: 10.1097/TP.0000000000001548 (E-pub date: Oct 28, 2016)

Tapolyai MB, Faludi M, Berta K, Szarvas T, Lengvárszky Z, Molnar MZ, Dossabhoy NR, Fülöp T. (2016) *The Effect of Ambient Temperature and Humidity on Inter-Dialytic Weight Gains in End-Stage Renal Disease Patients*. Int Urol Nephrol, 48: 1171-1176.

Young BA, Katz R, Boulware E, Kestenbaum B, de Boer I, Wang W, Fülöp T, Bansal N, Robinson-Cohen C, Griswold M, Correa A. (2016) *Risk Factors for Rapid Renal Function Decline and Incident Chronic Kidney Disease (CKD) among African Americans: The Jackson Heart Study (JHS)*. Am J Kidney Dis, 68: 229-239.

Henson ZK, Fülöp T. (2016) *Dietary Salt Restriction: How Much Education Is Enough?* J Clin Hypertens, 18: 383-384.

Humayun Y, Ball KC, Lerant AA, Lewin JR, Fülöp T. (2015) *Acute Oxalate Nephropathy Associated with Orlistat*. J Nephrothol, 5: 79-83.

Farah Musa AR, Fülöp T, Kokko K, Kanyicska B, Lewin JR, Csongrádi É. (2015) *Cytomegalovirus Colitis in a Critically Ill, Dialysis-dependent Acute Kidney Injury Patient without Immunosuppressive Therapy*. Clin Nephrol, 84: 44-49.

Fülöp T, Dixit MP. (2015) *Hypertension and End-Organ Damage in Children—Is the Picture Less Fuzzy Now?* J Clin Hypertens, 17: 767-769.

Fülöp T, Tapolyai M. (2015) *Beauty in Simplicity: Abnormal Neutrophil to Lymphocyte Ratio in Resistant Hypertension*. J Clin Hypertens, 17: 538-540.

Humayun Y, Sanchez P, Norris LT, Monga D, Lewin J, Fülöp T. (2015) *Kidney Biopsy for Renal Tubular Acidosis: When Tissue Diagnosis Makes a Difference*. Clin Nephrol – Case Studies, 5: 79–83.

Wang W, Young BA, Fülöp T, de Boer IH, Boulware LE, Katz R, Correa A, Griswold ME. (2015) *Effects of Serum Creatinine Calibration on Estimated Renal Function in African Americans: the Jackson Heart Study*. Am J Med Sci, 349: 379-384.

Fülöp T, Csongrádi É, Lerant AA, Lewin M, Lewin JR. J Nephropathol. (2015) *Resolution of C1q Deposition but not of the Clinical Nephrotic Syndrome after Immunomodulating Therapy in Focal Sclerosis*. J Nephropathol, 4: 54-58.

Fülöp T, Zsom L. (2015) *On Poor Agreement between Dialysis Unit and Ambulatory Blood Pressures*. J Clin Hypertens, 17: 244.

Gharaibeh KA, Brewer JM, Agarwal M, Fülöp T. (2015) *Risk Factors, Complications and Measures to Prevent or Reverse Catastrophic Sodium Overcorrection in Chronic Hyponatremia*. Am J Med Sci, 2015, 349: 170-175.

Gottlieb DJ, Hek K, Chen Th, Watson NF, Eiriksdottir G, Byrne EM, Cornelis M, Warby SC, Bandinelli S, Cherkas L, Evans DS, Grabe HJ, Lahti J, Li M, Lehtimäki T, Lumley T, Marciano KD, Perusse L, Psaty BM, Robbins J, Tranah GJ, Vink JM, Wilk JB, Stafford JM, Bellis C, Biffar R, Bouchard C, Cade B, Curhan GC, Eriksson JG, Ewert R, Ferrucci L, Fulop T, Gehrman PR, Goodloe R, Harris TB, Heath AC, Hernandez D, Hofman A, Hottenga JJ, Hunter DJ, Jensen MK, Johnson AD, Kahonen M, Kao L, Kraft P, Larkin EK, Lauderdale DS, Luik AI, Medici M, Montgomery GW, Palotie A, Patel SR, Pistis G, Porcu E, Quaye L, Raitakari O, Redline S, Rimm EB, Rotter JI, Smith AV, Spector TD, Teumer A, Uitterlinden AG, Vohl MC, Widen E, Willemsen G, Young T, Zhang X, Liu Y, Blangero J, Boomsma DI, Gudnason V, Hu F, Mangino M, Martin NG,

O'Connor GT, Stone KL, Tanaka T, Viikari J, Gharib SA, Punjabi NM, Raikonen K, Volzke H, Mignot E, Tiemeier H. (2014) *Novel Loci Associated With Usual Sleep Duration: the CHARGE Consortium Genome-Wide Association Study*. *Mol Psychiatry*, 20: 1232–1239.

Zsom L, Wagner L, Fülöp T. (2015) *Minimization vs. Tailoring - Where Do We Stand with Personalized Immunosuppression during Renal Transplantation in 2015?* *World J Transplant*, 5: 73-80.

Fülöp T, Alemu B, Dossabhoy NR, Bain JH, Pruett DE, Szombathelyi A, Dreisbach AW, Tapolyai, M. (2014) *The Safety and Efficacy of Percutaneous Renal Biopsy by Physician-in-Training in an Academic Teaching Setting*. *South Med J*, 107: 520-525.

Tapolyai M, Faludi M, Barna I, Dossabhoy NR, Lengvárszky Z, Szarvas T, Berta K, Fülöp T. (2014) *Diuretics and Bioimpedance-measured Fluid Spaces in Hypertensive Patients*. *J Clin Hypertens*, 16: 895–899.

Csongrádi É, Shoemaker-Moyle M, Zsom L, Wells C, Lengvárszky Z, Tapolyai M, Fülöp T. (2014) *Investigation of the Efficacy of Intravenous versus Subcutaneous Recombinant Erythropoietin in Obese African-American Patients in a Southeast U.S. Dialysis Cohort*. *Br J Med Medic Res*, 4: 184-193.

Tapolyai MB, Faludi M, Fülöp T, Dossabhoy NR, Szombathelyi A, Berta K. (2014) *Which Fluid Space is Affected by Ultrafiltration During Hemodiafiltration?* *Hemodial Int*, 18: 384-390.

Agarwal M, Csongrádi É, Koch CA, Juncos LA, Echols V, Tapolyai M, Fülöp T. (2013) *Severe Symptomatic Hypocalcemia after Denosumab Administration in an End-Stage Renal Disease Patient on Peritoneal Dialysis with Controlled Secondary Hyperparathyroidism*. *Br J Med Medical Res*, 3: 1398-1406.

Avusula R, Shoemaker-Moyle M, Pathak MB, Csongrádi É, Fülöp T. (2013) *Bacterial Peritonitis Following Esophagogastro-duodenoscopy in a Patient on Peritoneal Dialysis*. Br J Med Medical Res, 3: 784-789.

Chandrashekar KB, Fulop T., Juncos LA. (2015) *The Reply*. Am J Med, 126: e27.

Elmahi N, Csongradi E, Kokko K, Lewin JR, Davison J, Fulop T. (2013) *Residual Renal Function in Deritoneal Dialysis with Failed Allograft and Minimum Immunosuppression*. World J Transplant, 3: 26-29.

Ferguson LM, Dreisbach AW, Csongrádi É, Juncos LA, Fulop T. (2013) *Recurring Extracorporeal Circuit Clotting during Continuous Renal Replacement Therapy in a Patient with Scedosporium prolificans Induced Fungal Sepsis: Successful Treatment with Argatroban*. Am J Med Sci, 345: 256-258.

Fülöp T., Tapolyai M, Dossabhoy NR. (2013) *Timing of Continuous Renal Replacement Therapy Initiation in Septic Shock and Acute Kidney Injury*. Ther Apher Dial, 17: 642-643.

Fülöp T., Iboaya BU, Avusula R, Csongrádi É, Juncos LA. (2013) *Recalcitrant Hypoglycemia Resolved with 2.5% Dextrose Containing Replacement Fluid during Hemodiafiltration*. Ren Fail, 35: 1035–1037.

Gharaibeh KA, Craig MJ, Koch CA, Lerant AA, Fülöp T., Csongrádi É. (2013) *Desmopressin is an Effective Adjunct Treatment for Reversing Excessive Hyponatremia Overcorrection*. World J Clin Cases, 1: 155-158.

Hui X, Matsushita K, Sang Y, Ballew SH, Fülöp T., Coresh J. (2013) *CKD and Cardiovascular Disease in the Atherosclerosis Risk in Communities (ARIC) Study: Interactions with Age, Sex, and Race*. Am J Kidney Dis, 62: 691-702.

Tapolyai M, Faludi M, Réti V, Lengvárszky Z, Szarvas T, Fülöp T, Bekő G, Berta K. (2013) *Volume estimation in Dialysis Patients: the Concordance of Brain-type Natriuretic Peptide Measurements and Bioimpedence Values*. Hemodial Int, 17: 406-412.

Chandrashekar KB, Fulop T, Juncos LA. (2012) *Medical Prevention of Nephrolithiasis*. Am J Med, 125: 344-347. Erratum in: Am J Med (2012) 125: e27.

Fülöp T, Schmidt DW, Cosmin A, Islam N, Wells C, Lengvárszky Z, Bilbrew D, Zsom L. (2012) *Ambulatory Blood Pressure Monitoring and Peri-hemodialysis Blood Pressures in a Southeast U.S. Hemodialysis Unit*. Clin Nephrol, 77: 383-391.

\*Fülöp T, \*Hickson DM, Wyatt SB, Bhagat R, Rack N, Gowdy O, Jr., Flessner MF, Taylor HA. (2012) *Sleep-Disordered Breathing Symptoms among African-Americans in the Jackson Heart Study*. Sleep Med, 13: 1039-1049.

\*Authors contributed to the article equally; Dr. Fülöp corresponding Author

Gharaibeh KA, Csongrádi É, Shoemaker-Moyle M, Lerant AA, Tapolyai M, Fülöp T. (2012) *Pulmonary Embolization in Face of Tunneled Catheter-Associated Blood Stream Infection; the Perils of Systemic Anticoagulation*. Nephrol Rev, 4: e17.

Hamrahian M, Pitman KT, Csongrádi É, Bain J, Kanyicska B, Fülöp T. (2012) *Symmetrical Craniofacial Hypertrophy in Patients with Tertiary Hyperparathyroidism and High-dose Cinacalcet Exposure*. Hemodial Int, 16: 571-576.

Patel SR, Goodloe R, De G, Kowgier M, Larkin E, Young T, Buxbaum S, Fulop T, Gharib S, Gottlieb DJ, Johnson C, Lauderdale D, Punjabi NM, Zee P, Cade B, Laird N, Mukherjee S, Palmer L, Zhu X, Redline S. (2012) *Association of Genomic Loci with Sleep Apnea in European Americans and African-Americans: The Candidate Gene Association Resource (CARE)*. PLoS ONE, 7: e48836.

Csongrádi É, Nagy B, Jr, Fulop T, Varga Z, Karányi Z, Magyar MT, Oláh L, Papp M, Facskó A, Kappelmayer J, Paragh G, Káplár M. (2011) *Increased Level of Platelet Activation Markers is Positively Associated with Carotid Wall Thickness in Obese Patients*. *Thromb Haemost*, 106: 567–752.

Fülöp T, Cosmin A, Juncos LA. (2011) *Recurring Extracorporeal Circuit Clotting During Continuous Renal Replacement Therapy Resolved after Single-Session Therapeutic Plasma Exchange*. *J Clin Apheresis*, 26: 214-215.

Zsom M, Fülöp T\*, Zsom L, Baráth Á, Maróti Z, Endreffy E. (2011) *Genetic Polymorphisms and the Risk of Progressive Renal Failure in Elderly Hungarian Patients*. *Hemodial Int*, 15: 501-8.

\*Dr. Fülöp corresponding Author

Akoudad S, Szklo M, McAdams MA, Fulop T, Hong W, Kao L, Coresh J, Köttgen A. (2010) *Correlates of Kidney Stone Disease in a Multi-Ethnic Middle-Aged Population: The ARIC Study*. *Preventive Med*, 51: 416-420.

\*Islam N, \*Fulop T, Zsom L, Miller E, Mire CD, Lebrun CJ, Schmidt DW. (2010) *Do Platelet Function Analyser-100 Testing Results Correlate with Bleeding Events after Percutaneous Renal Biopsy?* *Clin Nephrol*, 73: 229-237.

\*Authors contributed to the article equally; Dr. Fülöp corresponding Author

Fulop T, Olivier J, Meador RS, Hall J, Islam N, Mena L, Henderson H, Schmidt DW. (2010) *Screening for Chronic Kidney Disease in the Ambulatory HIV Population*. *Clin Nephrol*, 73: 190-196.

Tapolyai M, Uysal A, Dossabhoy NR, Zsom L, Szarvas T, Lengvárszky Z, Fülöp T. (2010) *High Prevalence of Liddle's Syndrome Phenotype Among Hypertensive U.S. Veterans in Northwest Louisiana*. *J Clin Hypertens*, 12: 856-860.

Tapolyai M, Fülöp T, Uysal A, Lengvárszki Z, Szarvas T, Karim J, Ballard K, Dossabhoy NR. (2010) *Regional Differences in Nonadherence to Dialysis Among Southern Dialysis Patients; A Comparative Cross-Sectional Study to the DOPPS Study*. Am J Med Sci, 339: 516-518.

Tapolyai M, Fülöp T. (2010) *Hypervolemic Hemorrhage after Dialysis Catheter Placement*. J Vasc Access, 11: 173-174.

Bash LD, Coresh J, Köttgen A, Parekh RS, Fulop T, Wang Y, Astor BC. (2009) *Defining Incident Chronic Kidney Disease in the Research Setting: The ARIC Study*. Am J Epidemiol, 170: 414-424.

Flessner MF, Wyatt SB, Akylbekova EL, Coady S, Fulop T, Lee F, Taylor HA, Crook E. (2009) *Prevalence and awareness of CKD among African Americans: the Jackson Heart Study*. Am J Kidney Dis, 53: 238-247. Erratum in: Am J Kidney Dis (2009) 53: 721.

Fulop T, Rule AD, Schmidt DW, Wiste HJ, Bailey KR, Kullo IJ, Schwartz GL, Mosley TH, Boerwinkle E, Turner ST. (2009) *C-reactive Protein among Community-Dwelling Hypertensives on Single-agent Antihypertensive Treatment*. J Am Soc Hypertens, 3: 260-266.

Brar H, Olivier J, Lebrun CJ, Gabbard W, Fulop T, Schmidt DW. (2008) *Predictors of Mortality in a Cohort of Intensive Care Unit Patients with Acute Renal Failure Receiving Continuous Renal Replacement Therapy*. Am J Med Sci, 335: 342-347.

Zsom L, Zsom M, Fulop T, Flessner MF. (2008) *Treatment Time, Chronic Inflammation, and Hemodynamic Stability: The Overlooked Parameters in Hemodialysis Quantification*. Sem Dial 21: 395-400.

## **Acknowledgements**

My first thanks go to my Consulting Advisor, **Prof. Dr. László Rosivall**, Director of the Basic Medicine Doctoral School, for providing me the venue and support to develop this Thesis. He has been a tremendous source of inspiration for generations of basic scientists and clinical nephrologists and I am proud to be one of them. Similarly, I am thankful to the **Institute of Pathophysiology, Semmelweis University**, where I have started my career as a young physician-scientist, more than two decades ago.

Second, would also like to thank to my previous supervisors and mentors: **Dr. Michael F. Flessner, Dr. Richard DeShazo, Dr. Darren W. Schmidt** and **Dr. Mihály B. Tapolyai**, who initiating me in biomedical research and provided support, inspirations and critical review during the writing process of many of my papers.

I am very grateful for the relentless support of **my beloved wife**, for without her unyielding support I could not have survived the daily chores, less to speak to have this work done. I remain thankful for **my parents** and **my brother**, who have supported with a commitment all my life I can only hope one I can do myself for upcoming generations. And for **my daughter**, Anna, for being here. Not until one looks into the eyes of the first-born child, to understand while humans are on Earth. It made all the journey well worthy.

The research forming the basis of this thesis received partial support from the John Bower Foundation of Mississippi and the clinical revenue support from the Division of Nephrology, University of Mississippi Medical Center. All permissions to republish relevant materials for this Thesis, in parts or whole (text, figures) – when relevant - have been obtained from the Journals and Publishers: Elsevier (©2008 Southern Society for Clinical Investigation); John Wiley and Sons; Wolters Kluwer Health Lippincott Williams & Wilkins©, ASAIO J: July-Aug 2010 - Volume 56 - Issue 4 - p 333-337 (©2010 by the American Society for Artificial Internal Organs), Karger Publishers (©2010, Karger Publishers) and Taylor & Francis.